

GENERAL INDEX

(A1 and A2 = Abstracts Supplements 1 and 2, S1 = Supplement 1, E = Editorial,
L = Letter to the Editor, CC = Clinical Conundrum)

- ABBOT SE *See* Stevens CR
- ABDEL-HAMID OSMAN A, BASSIOUNI H, NIJS J, DEQUEKER J. ROC analysis of vertebral morphometry in osteoarthritis and osteoporosis, (A2) 118
- ABDEL-SALAM A, EYRES KS, CLEARY J. Paradiscal injection technique, new, for relief of back spasm after chemonucleolysis, 491
- ABDUL-WAHAB RA *See* Lim KL
- ABNEY E *See* Chu CO
- ABRAHAM DJ, KHURANA K, OLSEN I. Sex hormones in autoimmune disease, (A2) 196
- ABRAHAM DJ *See also* Tulip GR
- Academic rheumatology and the Arthritis and Rheumatism Council, (E) 650
- ACCARDO S *See* Cimmino MA: Cutolo M
- Acemetacin
safety: analysis of spontaneously reported gastrointestinal adverse drug reactions, (A2) 176
therapy of inflammatory rheumatic joint diseases, (A2) 176
a well tolerated NSAID with minor irritation of the gastric mucosal membrane, (A2) 177
- ACKMAN RG. Snake oil, (L) 788
- Actively-passive prolong pathogenetic hypnosis in rheumatology, (A2) 231
- Acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in patient with polymyalgia rheumatica, 277
- Acute phase protein
DMARDs, steroids and NSAIDs affecting, (A2) 257
inhibition of production by tenidap - new antirheumatic agent, (A2) 257
modulation by tenidap, (A2) 175
production, clinical measures of disease activity and progression of radiological damage in early rheumatoid arthritis. Analysis of the global and individual value for prognostic purposes, (A2) 256
- ADEBAJO AO *See* Birrell F
- ADEBAJO AO, CHARLES P, HAZLEMAN BL, MAINI RN. Anti-neutrophil cytoplasmic antibodies (ANCA), false positive in infections, (A1) 9
- ADEBAJO AO, CHARLES P, MAINI RN, HAZLEMAN BL. Anti cardiolipin antibodies in association with chronic infections, (A2) 45
- ADEBAJO AO, HAZLEMAN BL. Soft tissue shoulder lesions in the African, 275
- ADEBAJO AO, WILLIAMS RO, WILLIAMS DG, HAZLEMAN BL, MAINI RN. Anti-type II collagen and anti-keratin antibodies in the rheumatoid arthritis population of West Africa, 8(A1)
- ADEBAJO AO *See also* Vecchio P
- ADERKA D *See* Cope AP
- Adhesion molecules
can we stop cells getting into joints, (A2) 235
immunolocalisation in synovium and skin in psoriatic arthritis, (A2) 89
- Adjuvant arthritis, human recombinant manganese superoxide dismutase suppresses disease activity, (A2) 99
- Adjuvant treatment of recent onset rheumatoid arthritis by selenium supplementation: preliminary observations, (L) 281
- Adrenal infarction, hypoadrenalism and splinter haemorrhages in the primary antiphospholipid syndrome, 117
- Adult dermatomyositis treated with cyclosporin A, (L) 855
- Adult fibromyalgia: causative and modulating factors and forms of onset, (A2) 228
- Adult onset Still's disease
diagnosis and therapy, (A2) 194
in India, 417
- Adult respiratory distress syndrome in systemic lupus erythematosus, (L) 647
- ADYA CM *See* Singh YN
- AFONSO C *See* Costa L
- AGAMBAR L, HERBERT KE, SCOTT DL. Low powered laser therapy for rheumatoid arthritis, (A2) 81
- AHMED K, SAFIEH-GARABEDIAN B, KHAMASHTA MA, REILLY KM, HUGHES GRV. Cytokine modulation by Tenidap in systemic lupus erythematosus, (A2) 25
- AHMED T *See* D'Cruz D
- AJLUS K. IgM-rheumatoid factors measured by ELISA in non-rheumatoid sera: comparison of human and rabbit Fc fragments as antigens, (L) 141
- AKGÜN K *See* Onel D
- AKHTAR N *See* Deodhar AA
- AL-BALAA SR *See* Al-Dalaan AN
- AL-BALAA S *See* Al-Dalaan AN
- AL-DALAAN AN, AL-BALAA SR, AL-JANADI MA, BOHLEGA S, BAHABRI S. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behçet's disease, (A2) 185
- AL-DALAAN AN, BAHABRI S, AL-BALAA S, SHEIKH A, AL-SUDAIRI SN. Abnormalities of T-cell subsets in Behçet's disease, (A2) 185
- AL-HAMAMI FA *See* Jalal MZ
- AL-JANADI MA *See* Al-Dalaan AN
- AL-SUDAIRI SN *See* Al-Dalaan AN
- ALAVI A, AXFORD JS.
Anti-galactosyltransferase antibody: an integral part of a glycosylation control system in rheumatoid arthritis, (A2) 115
Anti-galactosyltransferase antibody: a potential glycosylation control mechanism in health and rheumatic disease, (A2) 193
- ALAVI A *See also* Axford JS
- ALBERT K *See* Saal JG
- ALCINO S *See* Costa L: Quevedo V
- ALDERSON DM *See* McKenna F
- ALDWINCKLE TJ, DONOVAN S. Circadian rhythms and sustained-release flurbiprofen (Froben SR, Flugal SR) in the treatment of ankylosing spondylitis, (A2) 161
- ALDWINCKLE TJ *See also* Kool J
- ALEVIZAKI C *See* Kaskani E
- Algodystrophy, use of intranasal calcitonin in treatment, 567
- ALLARD S *See* Chu CO
- ALLARD SA *See* Hughes RA
- ALLEGRA A *See* Coaccioli S
- ALLEGREZZA-GIULIETTI A, SERRETTI R, PERONI M, CERVINI C. In vitro effects of 6-methoxy-2-naphthylacetic acid, major active metabolite of nabumetone, on polymorphonuclear leukocyte functions, (A2) 170
- ALMEIDA G *See* Quevedo V
- ALONSO F *See* Lima J
- ALPASLAN B *See* Dilşen G
- Alpha interferon-2a (Roferon-A) in treatment of diffuse cutaneous systemic sclerosis: a pilot study, 683
- Alpha-interferon treatment, preliminary study on effect on joint inflammation and serum calcium in rheumatoid arthritis, 405
- Alpha-1-antitrypsinase in patients with rheumatoid arthritis: is all API in these patients functionally active, (A1) 10
- Alternative care, rheumatologists and their patients who seek alternative care: an agreement to disagree, 485
- AMES DE, ASHERSON RA, AYRES B, CASSAR J, HUGHES GRV. Adrenal infarction, hypoadrenalism and splinter haemorrhages in the primary antiphospholipid syndrome, 117
- 5-Amino-salicylic acid, sulphasalazine and sulphapyridine comparison on the humoral response to antigen in-vivo, (A2) 39
- 3-Aminohydroxypropylidene-1,1-bisphosphonate (ADP), weekly infusions in treatment of Paget's disease, 97
- Aminopeptidase M in normal and diseased human synovium, (A2) 18
- Aminopropylidene diphosphonate, intravenous effects in patients with refractory Paget's disease, (A2) 65
- Aminoterminal propeptide of collagen type III in rheumatoid arthritis. Pulse treatment with methylprednisolone, (A2) 129
- AMOS M *See* Pimm TJ
- AMOS R *See* Donnelly S: Griffiths ID
- Amyloid, looking at in patients, (A2) 244
- Amyloid arthropathy complicating myelomatosis: successful treatment with radiosynovectomy, (L) 718
- Anaemia in rheumatoid arthritis: evaluation of marrow iron stores, serum ferritin and disease activity, (A2) 34
- ANCA in rheumatoid arthritis, (A2) 206
- ANDERSEN L *See* Beier JM
- ANDERSEN V *See* Lyngberg K: Pødenphant J
- ANDERSON A, HARKISS G, WATT N. Immunohistological investigation of maedi-visna virus-associated synovitis in sheep, (A2) 5
- ANDREOTTI F *See* Mackworth-Young CG
- ANDREU G *See* Menkes CJ
- ANDREW E *See* Sadigh S
- Androgen receptor identification in synovial macrophage-like cells: significance in rheumatoid arthritis, (A2) 16
- ANGELINI M *See* Carraba M
- Angiogenesis factor activity, increased levels correlate with inflammatory index in ankylosing spondylitis, (A2) 12
- Angiotensin converting enzyme activity is lower in rheumatoid arthritis patients than age and sex matched controls, (A2) 110
- Anionic phospholipid of the erythrocyte membrane-phosphatidyl serine in collagen disorders, (L) 644

- Ankle dislocations, topical treatment with an etofenamate containing gel.
Results of a randomized, placebo-controlled double-blind study, (A2) 157
- Ankylosing spondylitis
assessment, (L) 143
cardiovascular disorders in, (A2) 219
cervical and lumbar spine disease correlation, (A2) 73
circadian rhythms and sustained-release flurbiprofen (Froben SR, Flugal SR), (A2) 161
clinical measurements suitable to follow-up, (A2) 72
a comparison of clinical and radiographic features in men and women, (A1) 1
costovertebral joint changes with thoracic pain, 413
course of established and effects of sulphasalazine over 3 years, (A2) 82
debrisoquine genotype as a marker of susceptibility, (A2) 9
endothelial cell stimulating angiogenesis factor (ESAF) in, (A2) 15
immunoglobulin E levels, (A2) 198
increased levels of angiogenesis factor activity correlate with inflammatory index, (A2) 12
left ventricular diastolic dysfunction: correlation with disease severity, (A2) 74
long-term efficacy and safety of arthrotec, (A2) 179
social status impact on outcome and employability, (A1) 1
total immunoglobulins and specific antibodies to self gut bacteria, (A2) 48
- Anorexia nervosa, osteoporosis in, (A2) 140
- Anti-cardiolipin antibodies
in association with chronic infections, (A2) 45
association with vascular thrombosis and neurological manifestation of Behçet's disease, (A2) 185
haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus, 453
and a severe subset of systemic lupus erythematosus, (L) 567
- Anti-CD4 chimeric monoclonal antibody in rheumatoid arthritis, (A2) 102
- Anti-collagen antibodies in connective tissue disorders, (A2) 199
- Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS), (A1) 5
- Anti-DNAase autoantibodies, pathogenetic and diagnostic role at diffuse diseases of connective tissue, (A2) 182
- Anti-galactosyltransferase antibody
an integral part of a glycosylation control system in rheumatoid arthritis, (A2) 115
a potential glycosylation control mechanism in health and rheumatic disease, (A2) 193
- Anti-hnRNP A1 protein antibodies, Raynaud's phenomenon and esophageal dysmotility, association in SLE patients, (A2) 191
- Anti-inflammatory drugs, *Helicobacter pylori* infection and gastric damage in arthritic patients, (A2) 204
- Anti-intrinsic factor antibodies in systemic lupus erythematosus, (A2) 49
- Anti-keratin antibodies in the rheumatoid arthritis population of West Africa, 8(A1)
- Anti-myeloperoxidase human monoclonal antibodies derived from peripheral blood, (A2) 48
- Anti-neutrophil cytoplasmic antibodies (ANCA)
false positive in infections, (A1) 9
positive titre in patients with recent infection, 8(A1)
in rheumatoid arthritis, (L) 859
in sera of patients with Felty's syndrome, 185
and vasculitis, (A2) 255
- Anti-*Proteus* antibodies
failure to detect urinary more frequently in rheumatoid arthritis patients compared with controls, (A1) 4
patient medication does not explain elevated levels in rheumatoid arthritis, (A1) 3
response specificity in rheumatoid arthritis, (A1) 3
in rheumatoid arthritis same-sexed sibships, 241
- Anti-SSA autoimmune response characterization by Western immunoblotting with HELA cell cytoplasmic extract, (A2) 212
- Anti-streptococcal antibody titres in inflammatory joint disease, prospective study, (A2) 190
- Anti-topoisomerase-1-antibodies and complement, rapid resynthesis after plasma exchange in a patient with systemic sclerosis, (A2) 50
- Anti-topoisomerase-I antibodies, familial clustering, (A2) 87
- Anti-type II collagen and anti-keratin antibodies in the rheumatoid arthritis population of West Africa, 8(A1)
- Anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients, 811
- Anticentromere antibody and calcinosis: its clinical, radiological and immunogenetic aspects, 9
- α -1-Antichymotrypsin levels in polymyalgia rheumatica and giant cell arteritis (PMR/GCA), (A2) 38
- Antigen induced immunoglobulin isotype switch and somatic mutation in the variable region genes of CD5+ B-lymphocytes, (A2) 187
- Antigens, (A2) 253
- Antilactoferrin antibody in systemic lupus erythematosus, 669
- Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in sera of patients with Felty's syndrome, 185
- Antiphospholipid syndrome, endothelium-derived haemostatic factors, (A2) 189
- Antiphospholipid syndrome, primary
adrenal infarction, hypoadrenalism and splinter haemorrhages in, 117
anti DNA antibodies in, (A1) 5
- Antirheumatic drugs and chondroprotective drugs effects on experimental papain arthropathy, (A2) 131
- alpha, -Antitrypsin, determination of cleaved in arthritic synovial fluids and sera by an enzyme-linked immunosorbent assay (ELISA), (A2) 230
- Antiviral antibodies in rheumatoid arthritis discordant HLA- identical same-sexed sibling pairs, (L) 357
- ANTONENKO VT See Lysenko GI
- ANTOVA D See Grlićkov M
- APÁTHY Á See Bély M
- Apoprotein C in hyperuricemic patients, (A2) 21
- Applications of the new genetics to the investigation of the rheumatic diseases, (A2) 104
- APRIL PA See Tindall EA
- ARA classification criteria modification for rheumatoid arthritis for use in population surveys, (A2) 37
- ARAGÓN A. Confusional syndrome as presenting form of calcium pyrophosphate dihydrate deposition disease, (L) 144
- ARAL O See Dilşen N; Konice M
- ARASIL T See Kinikli G
- ARASIL TK See Tuncer S
- ARAUJO D See Costa L; Quevedo V
- ARC family material repository, 207
- ARCHER JR See Asmar G
- ARMAN MI, BUTUN B, DOSEYEN A, BIRCAN I, GUVEN A. Rheumatic findings in thalassaemia minor, frequency and features: a blind controlled study, 197
- ARMENGOL P See Cañete JD
- ARMSTRONG M See Beyeler C
- ARMSTRONG RD See Smith RW
- ARNALICH F, BENTO-ÚRBINA S, GONZALEZ-GANCEDO P, IGLESIAS E, DE MIGUEL E, GJON-BAÑOS J. Progesterone inadequate production in women with systemic lupus erythematosus, 247
- ARNER E See Venn G
- ARNOLD MM, LEE RD, HAMID BNA, McKENNA F. Tissue microdissection and quantification of epithelial cell proliferation applied to duodenal mucosa in patients taking NSAIDs, (A2) 174
- ARNOLD MM, McKENNA F. Incidence of NSAID induced gastropathy in unselected patients, (A2) 173
- Arthritis
chronic, synovial lining cells, (E) 433
cytokine inter-relationships and their association with disease activity, 725
early, genetic factors influencing the outcome - role of sulphoxidation status, 449
of familial Mediterranean fever and Behçet's disease: two further members of seronegative arthritis, (A2) 184
following immunisation: a report of 21 cases, (A2) 116
and HIV infection in Kigali, Rwanda, (A2) 200
infectious, transdermal fungal implantation causing, (L) 715
models, 13
mutilans, pseudoarthroplastic hand, 559
and Rheumatism Council fellowships, 797
seronegative, 771
- Arthritis impact measurement scales, comparison with patient satisfaction index, (A2) 75, (A2) 94
- Arthritogenic nonapeptide, cartilage link protein and HSP65, cellular immunity to in patients with inflammatory and non inflammatory arthritis, (A2) 44
- Arthroscopy seminar, 125
- Arthrosis, primary and secondary, efficacy and tolerability of nabumetone in. A 12-week open evaluation, (A2) 163
- Arthrotec
antiarthritis efficacy in rheumatoid arthritis patients: subgroup analysis of the effects of disease duration and functional capacity, (A2) 179
gastroduodenal safety in osteoarthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
gastroduodenal safety in rheumatoid arthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
long-term efficacy and safety in patients with rheumatoid arthritis, osteoarthritis or ankylosing spondylitis, (A2) 179
- ARTHUR V See Emery P
- Articular cartilage

- mechanical properties: do they adapt to the prevalent stress, (A2) 100
- proteoglycan core protein, autoimmune responses to in patients with inflammatory and non-inflammatory arthritis, (A2) 44
- susceptibility of normal and arthritic human to degradative stimuli, 369
- Articular chondrocytes, human, integrin expression, 231
- Articular indices
- comparison of two in rheumatoid arthritis, (A2) 229
 - in rheumatoid arthritis - the Trafford index correlates with the acute phase response, (A2) 76
- ASCHERSON R *See* Ehrenstein MR
- Ascorbic acid, plasma concentrations in osteoporotic outpatients, (L) 142
- ASHERSON R *See* D'Cruz D
- ASHERSON RA *See* Ames DE; D'Cruz DP
- ASHTON BA *See* Ashton IK; Hobbs RN
- ASHTON IK, ASHTON BA, MARSHALL MJ, BUTLER RC. Trap activity and vitronectin receptor immunostaining in synovium, (A1) 11
- ASMAR G, CHIDWICK K, SMITH EC, ZHANG Z, ARCHER JR, BLAKE DR, WINYARD PG. Determination of cleaved alpha₁-antitrypsin in arthritic synovial fluids and sera by an enzyme-linked immunosorbent assay (ELISA), (A2) 230
- ASTALDI-RICOTTI GCB *See* Caporali R
- ASTBURY C, HILL J, BIRD HA. Phthalylsulphathiazole in rheumatoid arthritis, 461
- ASTBURY C, MCLAREN AM, ROBINS SP, BIRD HA. Effect of sulphasalazine on urinary excretion of pyridinium cross-links in patients with rheumatoid arthritis, (A1) 26
- ASTBURY C *See also* Beyeler C
- ATKINS CJ, ZIELINSKI A, KLINCKHOFF A, CHALMERS A, WADE J, WILLIAMS D, SCHULZER M, DELLA CIOPPA G. Validation of electronic method for measuring joint tenderness in rheumatoid arthritis, (A2) 76
- ATKINS RM *See* Ismail S; Majkowski RS
- ATP
- cartilage resorption induction, interleukin 1beta, tumour necrosis factor alpha and transforming growth factor-beta effects, (A2) 22
 - extracellular, and tumour necrosis factor alpha interact in stimulating the production of prostaglandin E by human articular chondrocytes, (A2) 22
- AUCKEN H *See* Salih H
- Audit
- computers in: experience with NE Thames RHA Clinical Information System (CIS), (A2) 146
 - guidelines for organization of in rheumatology: combined working group report, 333
 - in rheumatology: the challenge of outcome and quality of life, (A2) 77
 - Stanford Health Assessment Questionnaire (HAQ) as tool for, (A2) 146
- Auditing long term progression of rheumatoid arthritis, (A2) 145
- Au(I)/Au(III) redox system underlies the anti-inflammatory effect of gold (I) drugs, such as aurothiomalate. A hypothesis, (A2) 131
- Auranofin efficacy and tolerability in rheumatoid arthritis: two years follow-up, (A2) 126
- Australia, rheumatology in, 273
- Autoantibodies
- and disease, what do the results mean, (A2) 254
 - IgG subclass distribution in patients with autoimmune rheumatic diseases, (A2) 52
 - immunoglobulins and Gm allotypes in nodal generalized osteoarthritis, 605
 - in pet dogs owned by patients with systemic lupus erythematosus, (A1) 4
 - in systemic lupus erythematosus and urticarial vasculitis, (A2) 59
 - to the cornea in patients with corneal melt in association with autoimmune systemic disease, (A2) 51
- Autogenic training in rheumatoid arthritis - a pilot study, (A1) 15
- Autoimmune disease
- immune response to and expression of cross-reactive retroviral gag sequences, 735
 - sex hormones in, (A2) 196
 - sulphasalazine induced, 115
- Autoimmune responses to articular cartilage proteoglycan core protein in patients with inflammatory and non-inflammatory arthritis, (A2) 44
- AVALTRONI D *See* Cervini C
- AWAD M *See* Nahir AM
- AXFORD JS, ALAVI A. Alteration in normal glycosylation control mechanisms in rheumatoid arthritis, (A2) 88
- AXFORD JS, BOMFORD AB, REVELL P, WAIT I, HAMILTON EDB. Case of haemochromatosis arthritis, 547
- AXFORD JS *See also* Alavi A
- Axial bone mass in rheumatoid arthritis: comparison of dual-photon and dual-energy X-ray absorptiometry, (A2) 65
- Axon reflex flare responses in patients with fibromyalgia syndrome, (A2) 203
- AYAD S *See* Hoyland JA
- AYDIN R *See* Dilsen; Oral A
- AYRES B *See* Ames DE
- Azapropanone, proteoglycan synthesis is induced by and inhibited by indomethacin in patients with osteoarthritis of the knee, (A2) 201
- Azathioprine
- association of response with purine enzyme levels in rheumatoid arthritis, (A2) 207
 - daily and alternate-day treatment in rheumatoid arthritis: a twelve-week controlled clinical trial, (L) 501
- AZOULAY E *See* Kessler M
- B-lymphocyte repertoire analysis in RA synovia, (A2) 205
- Back pain disability compared in patients attending rheumatology, osteopathic and chiropractic clinics, (A1) 24
- Back school effects in chronic low back pain patients, (A2) 147
- Back to front, examining research priorities in rheumatology, 193
- BACON PA *See* Cotzias T; Gerova Z; Roussou E
- Bacterial lipopolysaccharide detection in synovial fluid using an amplified ELISA assay, (A1) 2
- Bacterial superantigens in pathogenesis of reactive arthritis, (A2) 41
- BAGCHI U *See* Prasad ML
- BAHABRI S *See* Al-Dalaan AN
- BAILLIE K, STAMP J. British health professionals in rheumatology, (E) 363
- BAILLY S *See* di Giovine FS
- BAJOCCHI G *See* Canazza S
- Baker's cysts in 948 knees, sonographic study, (A2) 134
- BAKKER C *See* van der Linden SJ
- Balneoherapy, control study of effect on low-back pain disease, (A2) 121
- BALOGH Z *See* Kurth G
- BALSA A *See* Muñoz-Fernández S
- BALZA E *See* Cutolo M
- BANCROFT A *See* Lau CH
- BANKHEAD C *See* Symmons DPM
- BARATELLI E *See* Brogini M
- BARBADO FJ *See* Muñoz-Fernández S
- BARNES J *See* Will RK
- BARNES L *See* Veale D
- BAROVIĆ J *See* Krajnc I
- BAROVIĆ J *See* Turk Z
- Barr K *See* Dearlove SM
- BARRERA P, JANSSEN EM, BOERBOOMS AMTH, VAN DE PUTTE LBA, SAUERWEIN RW, VAN DER MEER JWM. Effects of a single weekly doses of methotrexate on circulating cytokines and cytokine production in patients with rheumatoid arthritis, (A2) 36
- BARRETT EM *See* Chakravarty; Thomson W
- BARRY C *See* Foley-Nolan D
- BARRY M. Whiplash injuries, (E) 579
- BARTLE L *See* Loose LD
- BARTLE LM *See* Rokita H; Sipe JD
- BARTLETT A *See* Rodriguez de la Serna A
- BARTOLONI S, SAITTA A, MILETO G, MARINO A, LA GAMBA MR, FRISINA N. Efficacy and tolerability of auranofin in rheumatoid arthritis: two years follow-up, (A2) 126
- BARTON N *See* Jones A
- BASCH CM *See* Simon LS
- BASKARHAN V *See* Thompson P
- BASSIOUNI H *See* Abdel-Hamid Osman A
- BASSIOUNI HM *See* Bassiouni M; Kamel M
- BASSIOUNI M, EMAM EF, EL-FEKI MB, BASSIOUNI HM. Assessment of crepitus in osteoarthritis by phonarthography, (A2) 202
- BATES J *See* Fordham JW
- BAUM H *See* Wasil M
- BAX DE *See* Peel NFA
- BAYLISS M *See* Hazell P
- BAYLISS MT. Osteoarthritis, pathogenesis, (A2) 237
- BAYLISS MT *See also* Hardingham TE; Hickery MS; Pittsides AA; Platt D; Worrall JG
- BÉLY M, APÁTHY Á. Disease modifying factor, miliary tuberculosis in rheumatoid arthritis, (A2) 186
- BÉLY M *See also* Szűts I
- BECH PEDERSEN P *See* Lyngberg K
- Behçet's disease
- abnormalities of T-cell subsets, (A2) 185
 - and arthritis of familial Mediterranean fever: two further members of seronegative arthritis, (A2) 184
 - association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation, (A2) 185
 - CD3+CD4-CD8- and CD3+CD4+CD8+ lymphocyte analysis in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease, (A2) 42

- diagnostic (classification) criteria evaluation - towards internationally agreed criteria, 299
- neurological involvement, (A2) 184
- oral ulceration clinical differentiation, 767
- pulmonary artery aneurysms: report of 22 cases, (A2) 199
- TNF α , IL-6 production and superoxide generation, (A2) 214
- BEIER JM, ANDERSEN L, HANSEN TM, FREDERIKSEN PB. Gastrointestinal accumulation of indium-111 labelled granulocytes in reactive arthritis, 543
- BEIGHTON P, RAMESAR R, VILJOEN D. Molecular defect in familial osteoarthritis of the hip in Southern Africa, (A2) 101
- BEIZTEGUI A. See Manzanecque L
- BELCH JFF. Snake oil, (L) 788
- BELCH JFF, LAU CS, MURPHY E. Pilot study with oral Iloprost, a prostacyclin analogue, in patients with Raynaud's syndrome and systemic sclerosis, (A2) 55
- BELCH JFF. See also Lau CH: Lau CS
- BELL AL. See Magill M
- BELL J. See Bowness P
- BELL JI. See Bowness P: Pile KD
- BELLAMY N, BUCKANAN WW, CHALMERS A, FORD PM, KEAN WF, KRAAG GR, CAMPBELL J. Tenoxicam (Mobiflex/Tilcotil) versus diclofenac (Voltaren) in osteoarthritis of the knee: a Canadian multicenter study, (A2) 155
- BELLO S. See Scagliusi P
- BENITO-URBINA S. See Arnalich F
- BENOIT D. See De Keyser F
- BENRAAD TH. See Laan R
- BERGMANN A. See Kurth G
- BERMAN P. See Jones AC
- BERNARD I, THEBUD-LASSAK R, PELSTER B. Safety of acemetacin: analysis of spontaneously reported gastrointestinal adverse drug reactions, (A2) 176
- BERNARD I. See also Heininger K: Thebud-Lassak R
- BERNHARD GC. Double-blind, randomized comparison of nabumetone and aspirin in treatment of patients with rheumatoid arthritis, (A2) 164
- BERNSTEIN R. See Brennan P
- Bewirkt eine Enzym- oder Goldtherapie bei chronischer Polyarthritis Veränderungen immunologischer Parameter, (A2) 132
- BEYELER C, ARMSTRONG M, DALY A, IDLE JR, ASTBURY C, BIRD HA. Debrisoquine (DBQ) oxidation polymorphisms do not predispose to rheumatoid arthritis, (A2) 7
- Debrisoquine genotype as a marker of susceptibility to ankylosing spondylitis, (A2) 9
- BEYELER CH, SCHLAPBACH P, GERBER NJ, FAHRER H, HASLER F, VAN DER LINDEN SM, BÜRG U, FUCHS WA, EHRENGRUBER H. Diffuse idiopathic skeletal hyperostosis (DISH) of the elbow: cause of elbow pain. Controlled study, 319
- BEYELER CH. See also Schlappbach P
- BEYNON HLC, DAVIES KAA, HASKARD DO, HAROUTONIAN R, WALPORT MJ. Immune complexes directly activate platelets and neutrophils causing an increase in endothelial permeability, (A2) 98
- BEZZI A. See Govoni M: La Corte R
- BHALLA A. See Osteoporosis, 206
- BHALLA AK. See O'Neill TW
- BHAMBHANI M, CRISP A, COMPTON JE. Differential involvement of lumbar and dorsal spine in osteoporosis, (A1) 18
- BHAMBHANI M. See also Cook NJ
- BHAMBHANI MM. Ascorbic acid, plasma concentrations in osteoporotic outpatients, (L) 142
- BHOOLA KD, ELSON CJ, DIEPPE PA. Kinins, key mediators in inflammatory arthritis, 509
- BIALOWSKA G. See Fenrych W
- Bicycle training improved the subjective scores in patients with rheumatoid arthritis, (A2) 217
- BIJL H. See Choy EHS
- BIJLSMA JWJ. See Lefeber F: Nijfeld J: van den Brink HR: van der Heide A: Weusten BLAM: Witbrink B
- BILLIGMANN PW. See Pelster B
- BILLINGHAM MEJ, HICKS C, SMITH W. Monoclonal anti-IL2 receptor therapy of experimental arthritis, (A2) 103
- BILLINGHAM MEJ. See also Hicks C
- BINT AJ. See Deighton CM
- Biological indices of the inflammatory activity of juvenile rheumatoid arthritis - comparative valuation, (A2) 113
- BIRCAN I. See Arman MI
- BIRD HA. An expanding journal, (E) 1
- Joint hypermobility, 205
- BIRD HA. See Astbury C: Beyeler C: Dearlove SM
- BIRD L. See Yousuf Ali S
- BIRO A. See Chikanza IC
- BIRRELL F, ADEBAJO A, HAZELMAN B, SILMAN AJ. High prevalence of joint hypermobility in rural Nigerian population, (A2) 63
- BISHOP S. See Jones DRE
- BIZZARRI F. See Montanaro M
- BLAAUW AAM, NOHLMANS MKE, LEFFERS P, GOEITHE HS, VAN DER LINDEN SJ. Lyme borreliosis, very infrequent cause of arthritis of undetermined aetiology in southern part of Netherlands, 401
- BLACK C, ISENBERG DA. Mixed connective tissue disease - goodbye to all that, 695
- BLACK C. See also Brennan P: Whyte J
- BLACK CM. See Darton K: Gendi N: Magoulas T: O'Mahoney SA: Stephens CO: Stevens W
- BLAKE DR. Is exercise bad for inflamed joints, (A2) 233
- BLAKE DR. See also Asmar G: Dowling EJ: Fairburn K: Farrell AJ: Kaul A: Smith EC: Stevens CR: Walsh DA: Watson A: Williams RB
- BLAKE GM. See Ryan PJ
- BLAKE S. See Noble DP
- BLANCHE P, SARAUX A, TAEIAMN H, SICARD D, MENKES CJ. Arthritis and HIV infection in Kigali, Rwanda, (A2) 200
- BLANCO F, KALSIJT, RAVIRAJAN C, ISENBERG DA. IgG subclass distribution of auto-antibodies in patients with autoimmune rheumatic diseases, (A2) 52
- BLANKENSTEIN MA. See van den Brink HR
- BLANN AD. Von Willebrand factor antigen levels, high, associated with increased mortality in connective tissue disease, (L) 211
- BLASETTI P. See Salaffi F
- Blindness prevention in giant cell arteritis by corticosteroid treatment, 103
- BLOCKX P. See Driessens M
- BLOOM SR. See Williams RB
- BLOWER PR. See Melange R
- BOCKOW G. See Tindall EA
- BODMAN K. See Jeddi PA
- BÖRNER D. See Langer M
- Body mass index, musculoskeletal pain relationship in Omanis, 81
- BOERBOOMS A. See Kerstens P
- BOERBOOMS AMT, VAN HEERVELD HAEM, VAN DEN HOOGEN FHJ, FISELIER T. Chorea and primary antiphospholipid syndrome, (A2) 232
- BOERBOOMS AMT. See also van den Hoogen FHJ
- BOERBOOMS AMT. See Barrera P
- BOEY ML. See Fong KY
- BOHAR F. See Krajnc I
- BOHLEGA S. See Al-Dalaan AN
- BOLTEN W, MELO GOMES JA, STEAD H, GEIS GS. Gastrointestinal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis, 753
- BOMFORD AB. See Axford JS
- BOND A, JONES MG, YOUNG A, HAY FC. IgG, IgA and IgM glycosylation in immunoglobulin heavy and light chains and immune complexes from patients with rheumatoid arthritis, (A2) 52
- BOND A. See also Jones MG
- Bone and cytokines, 149
- density values measured by DEXA in patients treated with salmon calcitonin nasal spray and calcium, (A2) 142
- metabolism and sex hormones in postmenopausal women with rheumatoid arthritis treated with corticosteroids, (A2) 140
- study in patients with rheumatoid arthritis, (A2) 141
- turnover markers in systemic sclerosis: a preliminary study, (A2) 216
- whole body density in postmenopausal rheumatoid arthritis, (A2) 97
- Bone mineral density by dual energy X-ray absorptiometry in families with osteogenesis imperfecta, (A2) 66
- in joint hypermobility syndrome, (A2) 64
- loss in early rheumatoid arthritis, (A2) 97
- in men with rheumatoid arthritis: effect of low dose corticosteroids, (A1) 19
- and scintigraphic evaluation in osteopathia striata, (A2) 231
- values in the Hungarian population: a comparative DEXA study, (A2) 142
- BONGRAND P. See Mege L
- BOONSANER K, LOUTHRENOO W, MEYER S, SCHUMACHER JR HR. Dominancy effect on severity in rheumatoid arthritis, 77
- BOOT-HANDFORD RP. See Hoyland JA
- BOOTH S. See Pepys MB
- BOQUET D. See Pérez-Edo L
- BORG A. See Dawes PT
- BORG AA, DAVIS MJ, DAWES PT, SHADFORTH MF, FOWLER PD. Rifampicin in early rheumatoid arthritis, (A2) 124
- BORG AA, DAVIS MJ, FOWLER PD, SHADFORTH MF, DAWES PT. Use of stroke index (SI) to distinguish between non-steroidal anti-inflammatory drugs and SAARDS in rheumatoid arthritis, (A2) 36
- BORG AA, DAWES PT, MATTEY DL. Antibodies to cytokeratin-18 in rheumatoid arthritis, (A2) 14

- BORG AA *See also* Close DR
Borrelia burgdorferi detection in synovial tissue using the polymerase chain reaction, (A2) 88
Borrelia infection, polymyalgia rheumatica as delayed sequela, (L) 647
 BORTOLUSSI R *See* Valentini M
 BOSCH X *See* Vivancos J
 BOSCH-GIL JA *See* Simeon-Aznar CP
 BOSWELL RF *See* Croft PR
 BOTTÀ V *See* Brogginì M
 BOTTO M *See* Hohler T
 BOURA P, KOUNTOURAS J, ZAHRIODAKI E, TSAPAS G. Tolfenamic acid (Gantil) in rheumatoid arthritis: effect on the immunologic profile, (A2) 174
 BOURKE ME, SNAITH ML, ISENBURG D. Review of extraglandular manifestations of primary Sjögren's syndrome, (A1) 6
 BOWNESS P, BELL J. T-cell receptors and rheumatic disease: approaches to repertoire analysis, 3
 BOWNESS P, MOSS P, BELL J, McMICHAEL A. Identification of novel Clostridial enterotoxin superantigen, (A2) 40
 BOWNESS P, WORDSWORTH BP, MOSS P, McMICHAEL AJ, BELL JI. T cell receptor usage of synovial lymphocytes from a patient with reactive arthritis, (A2) 40
 BOYKINOV IN, MICHAÏLOVA DM. Biological indices of the inflammatory activity of juvenile rheumatoid arthritis - comparative valuation, (A2) 113
 BOŽINOVSKI G *See* Grlićkov M
 BRACKERTZ D. Dose-finding and efficacy studies with OM-8980 (Subreum), (A2) 123
 BRADLEY H *See* Emery P
 BRANCO JC, TAVARES V, QUEIROZ MV. Adult fibromyalgia: causative and modulating factors and forms of onset, (A2) 228
 BRATTSTRÖM M. who would be involved in patient care, (A2) 249
 BRAITTY JR *See* Rotherham JR: Rotherham NE
 BRAUTBAR C *See* de Vries N
 BRAVO T *See* Quevedo V
 BREEDVELD FC *See* Eggemeijer F: Kloppenburg M: Landewé RBM: ten Wolde S: van Zeven D
 BREEN AC *See* Gillies JH
 BRENNAN P *See* Venn G
 BRENNAN FM, MAINI RN, FELDMANN M. TNF α , pivotal role in rheumatoid arthritis, 293
 BRENNAN FM *See also* Cope AP: Deleuran BW: Gibbons DL
 BRENNAN P, SILMAN A, BLACK C, BERNSTEIN R, COPPOCK J, MADDISON P, SHEERAN T, STEVENS C, WOLLHEIM F. UK SCLERODERMA STUDY GROUP. Skin involvement measure reliability in scleroderma, 457
 BRESNIHAN B. Synovial lining cells in chronic arthritis, (E) 433
 BRESNIHAN B *See also* Callaghan M: Crowley JJ: Doherty E: Mulherin D: Veale D
 BRIDGES AB *See* Lau CH
 BRIGGS DC *See* Stephens CO: Whyte J
 British health professionals in rheumatology, (E) 363
 British Paediatric Rheumatology Group news, 627
 BRITO I *See* Quevedo V: Vaz C
 BROGGINI M, BARATELLI E, CAPPELLI A, GHIRINGHELLI D, BOTTÀ V, MARCONI A. Clodronate for management of pain in endosteal hyperostosis, (A2) 228
 BROGGINI M, MARCONI A, BARATELLI E, CAPPELLI A, RIBOLDI L. Bone mineral density and scintigraphic evaluation in osteopathia striata, (A2) 231
 BROGGINI M *See also* Cimmino MA
 BROMELL J *See* Gush RJ
 Bronchiectasis and rheumatoid disease: is there an association, 691
 BROOKES S *See* Venables P
 BROOKES SM, CLARK DM, SHATTLES WG, VENABLES PJW, LAMEY P, MAINI RN. Primary salivary gland epithelial cell cultures as model of autoimmunity in Sjögren's syndrome, (A2) 188
 BROOKES SM, PANDOLFINO YA, MITCHELL TJ, VENABLES PJW, SHATTLES WG, CLARK DA, ENTWISTLE A, MAINI RN. Immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease, 735
 BROOKS PM. Rheumatology in Australia, 273
 BROQUET P *See* David MJ
 BROTHERTON DH *See* Henney AM
 BROWN CMS *See* Mageed RA
 BROWN NS *See* Lim KL
 BROWN-GALATOLA CH, HALL ND. Impaired suppressor cell activity due to surface sulphhydryl oxidation in rheumatoid arthritis, 599
 Brufen: extent of isomeric conversion of R- ibuprofen to S+ ibuprofen, (A2) 152
 BUCHANAN NMM, D'CRUZ D, HUGHES GRV, MATHEWS JA. Electrophysiological study of peripheral nerve function in Wegener's granulomatosis, (A2) 83
 Bucillamine-induced nephropathy, clinopathological findings in patients with rheumatoid arthritis, (A2) 134
 BUCKANAN WW *See* Bellamy N
 BUCKLAND-WRIGHT JC, MACFARLANE DG, JASANI MK, LYNCH JA. Quantitative microfocal radiography detects changes in OA knee joint space width in patients on diclofenac sodium vs placebo, (A2) 95
 BUCKLAND-WRIGHT JC *See also* Chikanza IC: Clarke GS
 BÜRGI U *See* Beyeler Ch: Schlapbach P
 BURNIE JP *See* Donohoe M
 BUSKILA D *See* Langevitz P
 BUTLER MG *See* Waller A
 BUTLER PJG *See* Pepys MB
 BUTLER RC *See* Ashton IK
 BUTLER S *See* Hussain W
 BUTTAR R *See* Will RK
 BUTUN B *See* Arman MI
 BYRNE JM, GRIFFITH SM, HEALD G, SHORTER J, SCOTT DL, JAMES MF, DACRE JE. How symmetrical is rheumatoid arthritis of the hands, (A1) 15
 BYRON WD *See* Rotherham JR
 BYRON MA *See* Pimm TJ
 C1q-deficiency, complete functional and SLE: a case report, (A2) 195
 C3 serum level relationship with anti-nDNA binding activity and fluorescent antinuclear antibody titers in patients with systemic lupus erythematosus, (A2) 182
 C3D measurement by ELISA: correlations with SLE disease activity, (A2) 59
 C-reactive protein, *in vivo* turnover studies in man, (A2) 100
 Calcinosi and the antincentromere antibody: its clinical, radiological and immunogenetic aspects, 9
 Calcitonin
 plasma level modifications of B/endorphins in course of treatment with synthetic salmon calcitonin versus synthetic cel calcitonin, (A2) 223
 use of intranasal in treatment of algodystrophy, (L) 567
 Calcium pyrophosphate dihydrate deposition disease, confusional syndrome as presenting form, (L) 144, 569
 CALDWELL T *See* Gough A
 CALIN A, KENNEDY LG. Impact of social status on outcome and employability in ankylosing spondylitis, (A1) 1
 CALLAGHAN M, WHELAN A, FEIGHERY C, BRESNIHAN B. Effects of IL-2 on *in vitro* rheumatoid factor production, (A2) 26
 ČALOVSKI J *See* Grlićkov M
 CALVIN J *See* Pountain G
 CAMBRIDGE G *See* Ehrenstein MR
 Campath-1H humanised anti-lymphocyte antibody, treatment of rheumatoid arthritis, (A2) 103
 CAMPBELL J *See* Bellamy N
 CAMPION G *See* Jevtić V: Rozman B
 CAMPS J *See* Eggemeijer F
 CANAZZA S, SCAGLIARINI R, GAMBERINI S, BAJOCCHI G, LA CORTE R, TROTTA F, PAZZI P. Gastric damage, dyspeptic symptoms and chronic NSAID use in arthritic patients, (A2) 173
 CANAZZA S *See also* Govoni M: La Corte R
 Canine disuse atrophy, proteoglycan aggregate profiles in the Pond-Nuki dog model of osteoarthritis, (S1) 7
 CANNIZZARO R *See* Valentini M
 CAÑETE JD, SANMARTÍ R, COLLADO A, ERCILLA G, ARMENGOL P, VENDERELL J, GRATACÓS J, MUÑOZ-GÓMEZ J. Non-association between 9.2KB Pvull RFLP and seronegative spondyloarthropathies in Spain, 743
 CAPEL PJ *See* Niefeld J
 CAPELL H *See* Murphy EA: Porter DR
 CAPELL HA *See* Murphy EA
 CAPELLI A *See* Cimmino MA
 Capillary microscopy of the oral mucosa in systemic sclerosis, (A2) 188
 CAPO C *See* Mège L
 CAPONE A *See* Capone M
 CAPONE M, SABER S, MUSCOLO V, MASSARO M, CAPONE A. Cyclosporin A in therapy refractory rheumatoid arthritis, (A2) 130
 CAPOREALI R, NEGRI C, ASTALDI-RICOTTI GCB, ROSSI S, MONTECUCCO C. Association between anti-hnRNP A1 protein antibodies, Raynaud's phenomenon and esophageal dysmotility in SLE patients, (A2) 191
 CAPOREALI R *See also* Cimmino MA: Montecucco C
 CAPPELLI A *See* Brogginì M
 CAPRON MH *See* Florent Ch: Savineau C
 CAPROTTI M *See* Montecucco C
 CAPROTTI P *See* Montecucco C
 CARAPETI M *See* Plater-Zyberk C
 CARBONELL J *See* Pérez-Edo L
 CARDENAL A *See* Muñoz-Fernández S
 Cardiac abnormalities in joint hypermobility syndrome, (A2) 63
 Cardiac involvement in connective tissue disease detected by Doppler echocardiography, (A2) 230
 Cardiovascular abnormalities in connective tissue diseases, (A2) 232
 Cardiovascular disorders in patients with ankylosing spondylitis, (A2) 219

- CARDOSO L See Pinto MJ
- CARLE WK, KILL DC. Nabumetone compared with indomethacin in treatment of osteoarthritis in general practice, (A2) 166
- CARLINO G See Grassi W
- CARPENTER A. NMR imaging - what can it tell us, (A2) 242
- CARPENTER TA, EVERETT JR, HALL LD, HARPER GP, HODGSON R, JAMES MF
Differences between the magnetic resonance appearance of medial and lateral cartilage in the rat knee, (A2) 136
Magnetic resonance imaging of rat knee pathology and the effects of treatment: a longitudinal study, (A2) 136
- CARR AJ See Williams RB
- CARRABBA M, PARESE E, ANGELINI M, MAHEU E, GUILLON GB, GROUIN JM, PERBELLINI A. Efficacy and safety of different dose-schedules of intra-articular injections of hyaluronic acid in painful and hydrarthral osteoarthritis of the knee, (A2) 127
- CARRABBA M See Galanti A
- CARRUBA G See Cutolo M
- Cartilage link protein, HSP65 and the arthritogenic nonapeptide, cellular immunity to in patients with inflammatory and non inflammatory arthritis, (A2) 44
- Cartilage oligomeric matrix protein
increased serum concentrations. A prognostic marker in early rheumatoid arthritis, 593
a novel marker of cartilage turnover detectable in synovial fluid and blood, 583
- CARTONI D See De Castro S
- CASPERZ C See Will RK
- CASSAR J See Ames DE
- CASSISA A See Meliconi R
- CASTAGNETTA L See Cutolo M
- CASTAGNOLI M See Pandolfi A
- CASTELLANO JA See Pascual E
- CASTELLOTE E. Polymyalgia rheumatica and panarthritis nodosa, (L) 431
- CASTRO A See Fernandez-Cortijo J: Lima J
- CASTRO S See De Clercq L
- CASWELL AM See Leong WS
- CATS A See Janssen M
- CAVANAGH G See Foster H
- CAVE M See Vecchio P
- CAWLEY MID See Cook NJ: Kidd BL: Smith RW
- CAWLEY PJ, MORRIS IM. Study to compare efficacy of two methods of skin preparation prior to joint injection, 847
- CD2 receptor gene, activation-induced changes in expression of murine, (A2) 196
- CD3+CD4-CD8- and CD3+CD4+CD8+ lymphocyte analysis in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease, (A2) 42
- CD5+ B-lymphocytes, antigen induced immunoglobulin isotype switch and somatic mutation in the variable region genes, (A2) 187
- CD5+B cells: possible target for action of disease-modifying anti-rheumatic drugs in rheumatoid arthritis, (A2) 191
- CD8+ T lymphocyte level value in distinguishing polymyalgia rheumatica from early rheumatoid arthritis, (A2) 91
- CD23, elevated soluble representing disease activity in SLE, (A2) 91
- CD38+CD8+ T cells are increased in the peripheral blood of SLE patients, (A2) 43
- CD44 expression in human cartilage and bone, (A2) 11
- CD45RB low expression, can depressed cytokine production by rheumatoid synovial helper T cells be attributed to, (A2) 26
- Cell surface and extracellular matrix, interaction between, (E) 74
- Cellular immunity to cartilage link protein, HSP65 and the arthritogenic nonapeptide in patients with inflammatory and non inflammatory arthritis, (A2) 44
- Cellular proliferation extent in rheumatoid synovium and pannus, (A2) 17
- Central neurological manifestations of primary Sjögren's syndrome, 787
- CERAVOLO P See Galanti A
- Cervical and lumbar spine disease correlation in ankylosing spondylitis, (A2) 73
- Cervical spine involvement in rheumatoid arthritis: a clinical, neurological and radiological evaluation, (A2) 226
- Cervical vertebral column affection in chronic polyarthritis: incidence, correlations, complications, (A2) 226
- CERVINI C, AVALTRONI D, PIRANI O, TITTARELLI E, GRASSI W. Sonography of metacarpophalangeal joints in rheumatoid arthritis by 13MHz transducer, (A2) 224
- CERVINI C See also Allegrezza-Giulietti A: Grassi W: Salaffi F
- CHACON P See Fernandez-Cortijo J
- CHAKRAVARTY K. Polymyalgia rheumatica, delayed sequelae of *Borrelia* infection, (L) 647
- CHAKRAVARTY K, MURRAY K, WEBLEY M. Autogenic training in rheumatoid arthritis - a pilot study, (A1) 15
- CHAKRAVARTY K, PHAROAH PGP, LIM K, SCOTT DGI. Intra-articular steroid for knee synovitis: to rest or not to rest, (A2) 81
- CHAKRAVARTY K, SCOTT DGI, MCCANN BG. Neutropenic enterocolitis, fatal, associated with sulphasalazine therapy for rheumatoid arthritis, 351
- CHAKRAVARTY K, SCOTT DGI. Oligoarthritis, presenting feature of occult coeliac disease, 349
- CHAKRAVARTY K, SYMMONS DPM, BARRETT EM, SCOTT DGI. Arthritis following immunisation: a report of 21 cases, (A2) 116
- CHAKRAVARTY K, WEBLEY M. Longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine, 829
- CHALMERS A See Atkins CJ: Bellamy N
- CHAMBERLAIN MA See Main DMG
- CHAMBERS JBC See Mishra M
- CHAN CE See Lee SS
- Change over time sensitivity of four health status instruments in rheumatoid arthritis, (A2) 151
- CHARLES P See Adebajo AO: Foster H
- CHARLES PJ, MAINI RN. ANCA in rheumatoid arthritis, (A2) 206
- CHARLES PJ, SHATTLES W, FOSTER H, PEASE CT, GRIFFITHS I, MAINI RN. Serology and rheumatogenetics of extraglandular primary Sjögren's syndrome, (A2) 47
- CHARLOT J See Dreiser RL
- CHASEN MR. Successful treatment of gold-induced aplastic anaemia with granulocyte macrophage colony stimulating factor, (L) 428
- CHASSAGNE PH. Spinal cord compression revealing destructive arthropathy of atlanto-occipital joint associated with beta-2 microglobulin amyloidosis in a haemodialysed patient, (L) 427
- CHATAIN M See Roques CF
- CHAU KF See Lee SS
- CHAUDHURI S. Rheumatologist in India, 113
- Chemonucleolysis, new paradiscal injection technique for relief of back spasm after, 491
- CHEN JIFAN, LI SONGHUA, QUI LIANQUN. Tong Bi Ling for the treatment of rheumatoid disease: an observation of 52 cases, (A2) 125
- CHEN K-H See Yu C-L
- CHEN Y-S See Yu C-L
- CHERIN P. Total body irradiation failure in polymyositis: report of three cases, (L) 282
- CHERNAJOVSKY Y See Corcoran AE
- CHERNOVA SI See Gontar IP
- CHEROUTRE L See De Clercq L
- CHIDWICK K See Asmar G
- CHIECO-BIANCHI F, HEDLEY K, PANAYI GS, KINGSLEY GH. Bacterial superantigens in pathogenesis of reactive arthritis, (A2) 41
- CHIKANZA I See Farahat MNMR
- CHIKANZA IC, CLARKE GS, GRAHAME R, BUCKLAND-WRIGHT JC. Quantitative microfolcal radiography detects the onset of erosion repair in patients with RA treated early with myocrisin, (A2) 96
- CHIKANZA IC, CUTBUSH S, BIRO A, STEIN M, LUTALO S, SACHS J, LANCHBURY J. HLA DRB allelic variation and rheumatoid arthritis in Zimbabwe, (A2) 8
- CHIKANZA IC, PETROU P, KINGSLEY G, CHROUSOS G, PANAYI GS. Hypothalamic-pituitary-adrenal (HPA) axis defective regulation in rheumatoid arthritis is not a consequence of chronic inflammation per se, (A2) 28
- CHIKANZA IC See also Choy EHS: Clarke GS
- CHILD A, KAINULAINEN K, POPE FM, GRAHAME R, PELTONEN L. Two unique fibrillin gene mutations in UK Marfan syndrome patients with joint hypermobility, (A2) 87
- CHILD A See also Mishra M: Ryan PJ
- CHILD AH See Henney AM
- CHING DWT, PETRIE JP, KLEMP P, JONES JG. Injection therapy of superficial rheumatoid nodules, 775
- Chiropractic clinics, back pain disability compared in patients attending rheumatology, osteopathic and chiropractic clinics, (A1) 24
- Chlamydia trachomatis*, search for in synovial fluids from patients with reactive arthritis using the polymerase chain reaction and antigen detection methods, 31
- Chloroquine and cyclosporine synergistically inhibit the proliferation of T-cell clones: cyclosporine interferes with interleukin 2 production whereas chloroquine inhibits interleukin 2 responsiveness, (A2) 27
- Chloroquine-induced vitiligo in a patient with juvenile onset rheumatoid arthritis, (L) 790
- Chondrocyte
collagen metabolism in osteoarthritis, (A2) 70
human metabolism in vitro, nifedipine hydrochloride effects, (A2) 70
- Chondroitin sulphate proteoglycans, synovial expression of decorin and biglycan, (A2) 68
- Chondroprotective drugs effects on experimental papain arthropathy, (A2) 131
- Chorea and primary antiphospholipid syndrome, (A2) 232
- CHOY EHS, CHIKANZA IC, KINGSLEY GH, BUL H, SANDERS ME, PANAYI GS. Chimeric anti-CD4 monoclonal antibody in rheumatoid arthritis, (A2) 102

- CHOY EHS, KINGSLEY GH, CORKILL MM, PANAYI GS. Intramuscular and oral methylprednisolone during induction of chrysotherapy in rheumatoid arthritis, (A2) 35
- CHRISTIANSEN C. Osteoporosis, how should we treat our patients, (A2) 247
- CHROUSOS G *See* Chikanza IC
- CHU CQ, FIELD M, ALLARD S, ABNEY E, FELDMANN M, MAINI RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair, 653
- CHU CQ *See also* Deleuran BW
- CIMMINO MA, ACCARDO S, MONTECUCCO C, CAPORALI R, CAPPELLI A, BROGGINI M. Sun exposure and polymyalgia rheumatica, (A2) 217
- CIMMINO MA, QUERCI G, ACCARDO S. Absence of flares of rheumatoid synovitis after intravenous iron administration, (A2) 33
- CINAR A *See* Dilşen G
- CIOMPI ML *See* Puccetti L
- Circadian rhythms and sustained-release flurbiprofen (Froben SR, Fluga-lin SR) in the treatment of ankylosing spondylitis, (A2) 161
- Cirrhosis, primary biliary, osteopenia in, (A1) 20
- CLAAS FHJ *See* ten Wolde S
- CLAGUE RB. Arthritis models, 13
- CLARK DA *See* Brookes SM
- CLARK DM *See* Brookes SM
- CLARKE AK *See* Emery P; Will RK
- CLARKE GS, SAUNDERS A, CHIKANZA IC, GRAHAME R, BUCKLAND-WRIGHT JC. Erosion area measurement comparison from macroradiographs with Larsen's score of conventional radiographs in rheumatoid hands, (A2) 35
- CLARKE GS *See also* Chikanza IC
- CLARKSON RWE, SANDERS PA, GRENNAN DM. Complement C4 null alleles as marker of gold or D-penicillamine toxicity in treatment of rheumatoid arthritis, 53
- CLARKSON RWE *See also* McMahon MJ
- Class II antigen, soluble, in synovial fluid as parameter of disease in patients with arthritis, (A1) 9
- CLAXSON AW *See* Dowling EJ
- CLEARY J *See* Abdel-Salam A
- CLERICO P *See* Cutolo M
- Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients, 811
- Clinical measurements suitable to follow-up ankylosing spondylitis, (A2) 72
- Clinical seminar, 133
- Clinical study of older age onset rheumatoid arthritis with comparison to an early onset group, (A2) 216
- Clinical subsets in psoriatic arthritis: is there a need to re-classify, (A2) 92
- Clinical terms project, (E) 723
- Clinical trials, correlation among variables in rheumatoid arthritis, (A2) 143
- Clinical validation, expert system 'Rheuma' on a PC, (A2) 150
- Clinically normal skin becomes sclerodermatous when transplanted into a sclerodermatous area, 707
- Clodronate for management of pain in endosteal hyperostosis, (A2) 228
- CLOSE DR, NIXON N, BORG AA, DAWES PT, STANWORTH DR, MATTEY DL. Natural killer (NK) cell IgG Fc gamma III receptor (CD16) and monocyte CD-14 expression - correlation with IgA-alpha-1-antitrypsin (IgA-AAT) in normal and rheumatoid arthritis (RA) sera, (A2) 43
- Clostridial enterotoxin superantigen, identification of novel, (A2) 40
- Clostridium septicum* arthritis, non-traumatic, in a patient with caecal carcinoma, (L) 571
- CLOUTIER J-M *See* Pelletier J-P
- COACCIOLI S, ALLEGRA A, PUXEDDU A. Nabumetone, clinical efficacy vs non-steroidal anti-inflammatory drugs pool. An initial experience, (A2) 169
- COARI G, DE CATA A, IAGNOCCO A. Sonographic study of Baker's cysts in 948 knees, (A2) 134
- COARI G *See also* Sorgi ML
- COCA A *See* Vivancos J
- Coeliac disease, occult, oligoarthritis as presenting feature, 349
- COGON D *See* Croft P
- COHEN MG. HLA-DR3, C4A*QO and toxicity from gold in rheumatoid arthritis, (L) 645
- Cold challenge, skin blood flow without temperature recovery of the fingers following, (A2) 55
- COLLADO A *See* Cañete JD
- Collagen
- autoantibodies in juvenile onset arthritis, (A2) 46
- gene segregation analysis in two families with joint hypermobility syndrome, 169
- Collagen arthritis and oral tolerance, (L) 213, (L) 283
- Collagen induced arthritis model, glycosylation of IgG, (A2) 53
- COLLANTES E, TINAHONES F, PINEDA M, SORIGUER F, SÁNCHEZ P. Apoptotic C in hyperuricemic patients, (A2) 21
- COLLINS I *See* O'Reilly D
- COLLINS NA *See* Pugh MT
- COLMAN AW. Pocket computers in clinical rheumatology, (L) 645
- Colony-stimulating factors measured in parallel bioassays and immunoassays, (A2) 190
- COLVILLE-NASH P *See* Da Silva JAP
- Combination therapy in RA: sulphasalazine and methotrexate, (A2) 32
- Competence question in Canada, 623
- Complement C4 null alleles as marker of gold or D-penicillamine toxicity in treatment of rheumatoid arthritis, 53
- Complement component C3 polymorphisms, simple method for identifying, (A2) 10
- Complement factor 2 (C2) deficiency: a family study, (A2) 9
- COMPSTON JE *See* Bhambhani M
- Computer-assisted morphometry, microscopic fibrillation measurement in optical sections of hydrated articular cartilage, (A2) 202
- Computers in medical audit: experience with NE Thames RHA Clinical Information System (CIS), (A2) 146
- Confusional syndrome as presenting form of calcium pyrophosphate dihydrate deposition disease, (L) 144, (L) 569
- Congenital heart block (CHB), detection of maternal antibodies to RO and LA: prognostic value for foetal outcome, (A2) 186
- Connective tissue disease
- anti-collagen antibodies in, (A2) 199
- anti-RNP-positive, high prevalence of mitral valve lesions, (A2) 57
- cardiac involvement detected by Doppler echocardiography, (A2) 230
- evaluation of esophageal disorders in 32 patients, (A2) 181
- high von Willebrand factor antigen levels associated with increased mortality in connective tissue disease, (L) 211
- immunology, 136
- Connective tissue disorders, genetic mapping, (E) 147
- CONNOLLY P *See* Sheeran T
- CONTE-DEVOLX B *See* Poet JL
- Contracting in rheumatology, (E) 289
- Contrast enhanced MRI of hand joints in rheumatoid arthritis, seronegative spondyloarthritis and erosive osteoarthritis, (A2) 138
- Controlling mechanisms of synthesis and release of secretory phospholipase A₂, (A2) 109
- CONWAY SC, CREED FH, MARKS JS, SYMONS DPM. Is the onset of rheumatoid arthritis triggered by life events, (A2) 30
- COOK NJ, CAWLEY MID, BHAMBHANI M, HALLAM CG, STEVENSON FK. Soluble class II antigen in synovial fluid as parameter of disease in patients with arthritis, (A1) 9
- COOMBS G *See* McKenna F
- COOPER AM. Polymyositis presenting as groin pain, (L) 283
- COOPER C. Osteoporosis, who should we treat, (A2) 245
- COOPER C *See also* Croft P; McAlindon TE
- COOPER R *See* Mather HC
- COOPER RG, ST CLAIR FORBES W, JAYSON MIV. Radiographic demonstration of paraspinal muscle wasting in patients with chronic low back pain, 389
- COOPER RG *See also* Holt I; Jeracitano D
- COPE AP, ADERKA D, DOHERTY M, GIBBONS DL, BRENNAN FM, MAINI RN, WALLACH D, FELDMANN M. Soluble tumour necrosis factor receptors are increased in the sera and synovial fluids of patients with rheumatic diseases, (A2) 211
- COPE AP, BRENNAN FM. Cytokine measurements in biological fluids, (E) 721
- COPE AP *See also* Gibbons DL
- COPPOCK J *See* Brennan P
- COPPOCK JS *See* Farrell AJ; Pugh MT
- CORBISHLEY T *See* Ferri C
- CORCORAN AE, TURNER M, GRAY PW, BROWN A, KISSONERGHIS A-M, CHERNAJOSKY Y, FELDMANN M. Structure/function studies on the extracellular domain of the human P55 TNF receptor, (A2) 112
- CORDINER S *See* Gordon C
- CORE P *See* Grassi W
- CORKILL MM *See* Choy EHS
- CORMIER C, HILLIQUIN P, MENKES CJ. Effects of intravenous aminopropylidene diphosphonate in patients with refractory Paget's disease, (A2) 65
- Corneal melt, autoantibodies to the cornea in patients with corneal melt in association with autoimmune systemic disease, (A2) 51
- CORRIGALL V, DOLAN AL, EVANS JG, PANAYI GS. Value of CD8+ T lymphocyte levels in distinguishing polymyalgia rheumatica from early rheumatoid arthritis, (A2) 91
- Corticosteroid pulse therapy complications in rheumatoid arthritis, (A2) 125
- Cost effectiveness of rheumatology, (A2) 248
- COSTA A *See* Rodriguez de la Serna A
- COSTA L, ALCINO S, AFONSO C, PALMARES J, ARAUJO D, LOPES VAZ A. Neurological involvement in Behçet's disease, (A2) 184
- COSTA L *See also* Pinto MJ; Quevedo V

- Costovertebral joint changes in ankylosing spondylitis with thoracic pain, 413
- COTONAT J See Roques CF
- COTZIAS T, SHEERAN TP, BACON PA. Anxiety levels in patients with primary and secondary Raynaud's phenomenon, (A1) 21
- COUGHLAN J See Eustace S
- COUGHLAN RJ See Foley-Nolan D; McCarthy CJ
- COVINGTON M See Venn G
- COX N See Gallivan S
- COX NL See Farrell A; Williams RB
- CRAMPTON EL See Rotherham JR
- Cranial arteritis, tumour necrosis factor alpha localisation, (A2) 24
- CREAMER P. Flow cytometry and rheumatic disease, 465
- CREAMER P, HALL ND. Quantitation of IL2 receptor P75 chain on RA mononuclear cells, (A2) 208
- CREAMER P, KIRWAN J. Seronegative systemic lupus erythematosus, 619
- CREED FH See Conway SC
- CRIGHTON A, FERREL W, MACDONALD A, STURROCK RD. Impaired proprioception of the proximal interphalangeal joints of the hand in rheumatoid arthritis, (A1) 16
- CRISP A See Bhamhani M
- CROFT P, COOPER C, WICKHAM C, COGGON D. Hip involvement in generalized osteoarthritis, 325
- CROFT P, HAYTON R, COGGON D, COOPER C. Farming and osteoarthritis of the hip, (A2) 92
- CROFT PR, SCHOLLUM J, RIGBY AS, BOSWELL RF, SILMAN AJ. Fibromyalgia symptoms in the general population, (A2) 64
- CROFT PR, ZONCA M, POPE D, O'NEILL T. Disability associated with shoulder problems in the community, (A2) 62
- CROFT PR See also Rigby AS
- Crohn's disease, osteoporosis in, (A2) 141
- CROWLEY JJ, DONNELLY S, TOBIN M, FITZGERALD O, BRESNIHAN B, MAURER BJ, QUIGLEY PJ. Left ventricular diastolic dysfunction in ankylosing spondylitis: correlation with disease severity, (A2) 74
- CSEUZ R. Azathioprine, daily and alternate-day treatment in rheumatoid arthritis: a twelve-week controlled clinical trial, (L) 501
- Cuboid microcrystals, histomorphologic analysis in human articular cartilage, (A2) 71
- CUENCA-LUQUE R See Simeon-Aznar CP
- CULORA G. Gouty arthropathy and synovial uric acid, (L) 791
- CUNNINGHAM DS See Gardner DL
- CURREY HLF See Kirwan JR
- CUSHNAGHAN J, KIRWAN J, DIEPPE PA, DACRE J. Should weight bearing or non-weight bearing knee radiographs be used in longitudinal studies of knee osteoarthritis, (A1) 17
- Cutaneous vasculitis, treatment with disulone, (A2) 126
- CUTBUSH S See Chikanza IC
- CUTOLO M, ACCARDO S, SERIOLO B, DECESARI F, VILLAGGIO B, CLERICO P, FERRACINI R, CARRUBA G, FECAROTTA E, CASTAGNETTA L. Identification of androgen receptors in synovial macrophage-like cells: significance in rheumatoid arthritis, (A2) 16
- CUTOLO M, BALZA E, SUN MZ, PONASSI M. Evidence of tenascin in normal synovial tissue: variations in osteoarthritis, (A2) 201
- CUVELIER C See Mielants H
- CUXART A See Juncá J
- Cyclosporin A
- L-tryptophan associated eosinophilia myalgia syndrome course and treatment, (A2) 218
 - long-term assessment of tolerability in psoriatic arthritis, (A1) 25
 - long-term treatment of rheumatoid arthritis with, (A2) 128
 - in therapy refractory rheumatoid arthritis, (A2) 130
- Cyclosporine and chloroquine synergistically inhibit the proliferation of T-cell clones: cyclosporine interferes with interleukin 2 production whereas chloroquine inhibits interleukin 2 responsiveness, (A2) 27
- Cystic fibrosis arthritis. A report of five cases, 535
- Cytidine deaminase
- increased spontaneous release by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus, 675
 - and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function, 235
- Cytokeratin, demonstration in endothelial cells of the synovial microvasculature *in situ* and *in vitro*, (A2) 14
- Cytokeratin-18, antibodies to in rheumatoid arthritis, (A2) 14
- Cytokine
- and bone, 149
 - depressed production by rheumatoid synovial helper T cells attributed to low level CD45RB expression, (A2) 26
 - detection at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair, 653
 - and growth factor effects on proteoglycan turnover in articular cartilage, (S1) 1
 - and inhibitors - the future, (A2) 241
 - inhibitors and eicosanoids, (A2) 234
 - inter-relationships and their association with disease activity in arthritis, 725
 - interactions in synovial fluid: colony-stimulating factors measured in parallel bioassays and immunoassays, (A2) 190
 - measurements in biological fluids, (E) 721
 - modulation by Tenidap in systemic lupus erythematosus, (A2) 25
 - proinflammatory, effect of tenidap and naproxen on production, (A2) 175
 - released by heat shock protein-activated rheumatoid synovial fluid mononuclear cells suppress cartilage proteoglycan synthesis, (A2) 114
 - synovial compartment mRNA, polymerase chain reaction technique, (A2) 23
 - and Tenidap effects on fibroblast proliferation, (A2) 25
- Cytotoxic T cell (CD8+CD28+) selective decrease in peripheral blood in idiopathic inflammatory myopathies, (A2) 42
- CZISKE R See Jaekel WH
- DA SILVA JAP, COLVILLE-NASH P, SCOTT DL, WILLOUGHBY DA. Sex hormones protect cartilage from inflammation-induced degradation, (A2) 112
- DA SILVA JAP, PEERS SH, FLOWER RJ, WILLOUGHBY DA. Sex hormones influence the HPA axis anti-inflammatory response, (A2) 111
- DA SILVA JAP See also Moore AR
- DACRE J See Cushnaghan J
- DACRE JE. Measuring disease progression in rheumatology, (A2) 243
- DACRE JE See also Byrne JM
- DAHA MR See Kloppenburg M; Landewé RBM
- DAHLSTRÖM B See Eckernäs S
- DAINOTTO F See Luziatelli S; Pandolfi A; Zorzin LR
- DALY A See Beyeler C
- D'AMARO J See ten Wolde S
- DANNESKJOLD-SAMSOE B See Lyngberg K
- DANTIA P See Kaskani E
- DARLINGTON GA See Langevit P
- DARTON K, BLACK CM. Heat distribution pattern and nailfold capillary damage in patients with primary Raynaud's phenomenon and systemic sclerosis, (A2) 54
- DASGUPTA B See Iannone F
- DASTIS C See Manzanecque L
- DAVID MJ, VIGNON E, PESCHARD MJ, BROQUET P, LOUISOT P, RICHARD M. Effects of non-steroidal anti-inflammatory drugs on glycosyltransferase activity from human osteoarthritic cartilage, (S1) 13
- DAVIES GD See Mackworth-Young CG
- DAVIES KAA See Beynon HLC
- DAVIS MJ See Borg AA
- DAVIS P
- Antineutrophil cytoplasmic antibodies in rheumatoid arthritis, (L) 859
 - Question of competence in Canada, 623
- DAVIS P See also Jubry A
- DAWES P See Doherty M
- DAWES PT, BORG A. Therapy seminar, 137
- DAWES PT See also Borg AA; Close DR; Matthey DL; Pugh MT
- DAWSON J See Hull RG
- DAWSON S See Ledingham J
- DAYER J-M. Eicosanoids and cytokine inhibitors, (A2) 234
- D'CRUZ D, HOUSSIAU F, HUGHES GRV. West Indian race, U1-RNP and Sm antibodies: possible risk factors for lupus nephritis and vasculitis, (A2) 58
- D'CRUZ D, HUGHES GRV. Systemic vasculitis: a study of 88 patients, (A2) 60
- D'CRUZ D, SCHNEIDER M, KHAMASHTA MA, HUGHES GRV. Laminin P1 levels in lupus nephritis, (A2) 58
- D'CRUZ D, TAYLOR J, AHMED T, ASHERSON R, KHAMASHTA M, HUGHES GRV. Complement factor 2 (C2) deficiency: a family study, (A2) 9
- D'CRUZ D See also Buchanan NMM
- D'CRUZ DP, ASHERSON RA, WISNIESKI J, KHAMASHTA MA, HUGHES GRV. Autoantibodies in systemic lupus erythematosus and urticarial vasculitis, (A2) 59
- D'ERRICO A See Meliconi R
- D'HAESE D See De Keyser F
- DE ABREU R See Kerstens P
- DE CASTRO S, CARTONI D, SORGI ML, MIGLIAU G, GIANNANTONI P, SANTOPADRE P, ZOPPINI A. Cardiac involvement in connective tissue disease detected by Doppler echocardiography, (A2) 230
- DE CATA A See Coari G
- DE CLERCQ L, CASTRO S, VERSTRAETE K, MAERTENS M, CHEROUTRE L, MIELANTS H, VERBRUGGEN G, VEYS EM. Cervical spine involvement in rheumatoid arthritis: a clinical, neurological and radiological evaluation, (A2) 226
- DE JONG PTVM See Markusse HM
- DE JOUBERT JJ See Roelofs JA
- DE KEYSER F, LUYTEN H, VANNEUILLE B, D'HAESE D, BENOIT D, VER-

- BRUGGERS G, VEYS EM. Characterization of anti-SSA autoimmune response by Western immunoblotting with HELA cell cytoplasmic extract, (A2) 212
- DE MIGUEL E See Arnalich F
- DE NAYER J See Haanen HCM
- DE SILVA L See Thompson P
- DE VOS M See Mielants H
- DE VRIES N, RÖNNINGEN KS, TILANUS MGJ, ROMBOUTS A, SEGAL R, EGE-LAND T, THORSBY E, VAN DE PUTTE LBA, BRAUTBAR C. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1-subtype, (A2) 7
- DE VRIES RRP See ten Wolde S
- DEAN G, HOYLAND JA, DONN R, JAYSON MIV, DENTON J. Mast cells in synovium and synovial fluid in osteoarthritis, (A2) 123
- DEAN MF, MARTIN H. N-terminal peptide from link protein is taken up and degraded by monocytes, B-cells and chondrocytes, (A2) 197
- DEANER AN See Huston GJ
- DEARLOVE SM, BARR K, NEUMANN V, ISDALE A, BIRD HA, GOOI HC, WRIGHT V. Non-steroidal anti-inflammatory drug effect on faecal flora and bacterial antibody levels in rheumatoid arthritis, 443
- De l'action de misoprostol sur la croissance cellulaire et la synthèse de la matrice par des chondrocytes humains, (A2) 130
- Debrisoquine
genotype as a marker of susceptibility to ankylosing spondylitis, (A2) 9
oxidation polymorphisms do not predispose to rheumatoid arthritis, (A2) 7
- Decorin mRNA localisation in synovium from rabbits with antigen-induced arthritis, (A2) 197
- DECESARI F See Cutolo M
- DECKERS K See Driessens M
- DEEGAN RJ See Foley-Nolan D
- DEIGHTON CM. Antiviral antibodies in rheumatoid arthritis discordant HLA-identical same-sexed sibling pairs, (L) 357
- DEIGHTON CM, FAY A, WALKER DJ. Rheumatoid arthritis in thyroid disease positive and negative same-sexed sibships, 13
- DEIGHTON CM, GRAY J, McDONAGH J, WALKER DJ. Failure to detect urinary anti-*Proteus* antibodies more frequently in rheumatoid arthritis patients compared with controls, (A1) 4
- DEIGHTON CM, GRAY J, WALKER DJ. Specificity of anti-*Proteus* antibody response in rheumatoid arthritis, (A1) 3
- DEIGHTON CM, GRAY JW, BINT AJ, WALKER DJ. Anti-*Proteus* antibodies in rheumatoid arthritis same-sexed sibships, 241
- DEIGHTON CM, ROBERTS DF, WALKER DJ. Greater disease severity predicts rheumatoid arthritis concordance in same-sexed siblings, (A1) 13
- DEIGHTON CM, WALKER DJ. HLA genes are unimportant in clinically mild rheumatoid arthritis, (A2) 85
- DEIGHTON CM, WALKER DJ. HLA-DR phenotypes in rheumatoid arthritis disease expression and familiarity, (A2) 189
- DEIGHTON CM See also McDonagh J
- DEIMLING M See Glückert K
- DEKKER PJ, ISDALE AH. Sensorineural hearing loss in juvenile chronic arthritis, 711
- DELEURAN B See Field M
- DELEURAN BW, CHU CQ, FIELD M, BRENNAN FM, KATSIKIS P, FELDMANN M, MAINI RN. Interleukin-1 α , type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis, 801
- DELJANIN ILIĆ M, MARKOVIĆ Z, STANKOVIĆ A, ILIĆ S, MARKOVIĆ V. Cardiovascular disorders in patients with ankylosing spondylitis, (A2) 219
- DELLA CIOPPA G See Atkins CJ
- DELVES PJ See Jeddli PA
- DELYARGYIS N See Galatas ID
- DEMŠAR F See Jevtić V: Rozman B
- DEN OTTER W See Niefeld J: Wilbrink B
- DENMAN AM. Novel treatment for rheumatoid arthritis, (E) 577
- DENMAN AM See also Hylton W
- DENT C See Hazell P
- DENTON A See Hammond A
- DENTON J See Dean G: Holt I
- DEODHAR AA, SIMPSON JB, AKHTAR N, WOOLF AD. Measurement of hand bone mineral content by dual energy X-ray absorptiometry: development of the method in normals and its application in rheumatoid arthritis, (A2) 68
- DEODHAR AA, WOOLF AD. Bone mineral density by dual energy X-ray absorptiometry in families with osteogenesis imperfecta, (A2) 66
- Deoxyypyridinoline and pyridinoline urinary excretion correlate with disease activities in first year of early rheumatoid arthritis, (A2) 30
- Depression on withdrawal of indomethacin, (L) 211
- DEQANI D See Govoni M
- DEQUEKER J See Abdel-Hamid Osman A
- Dermatomyositis treated with cyclosporin A, (L) 855
- DESCAMPS M See Duquesnoy B
- DEVAUX M See Duquesnoy B
- DHILLON VB, KEELING DM, RIDGWAY GL, SNAITH ML, ISENBERG DA. Treponemal infection coexisting with systemic lupus erythematosus, 345
- DI GIOVINE FS. Retroviruses seminar, 135
- DI GIOVINE FS, BAILLY S, SIM E, KITCHIN P, DUFF GW. Lentiviral sequences, failure to detect in rheumatoid arthritis patients, (A2) 204
- DI GIOVINE FS See also Wilson AG
- DI LEONARDO M See Varga J
- Diabetes mellitus, osteoarticular manifestations, (A2) 120
- Diabetes type I, gene interactive with HLA-DR4 in susceptibility to is not involved in rheumatoid arthritis, (A2) 6
- Diagnostic (classification) criteria evaluation in Behçet's disease - towards internationally agreed criteria, 299
- Dialysis-associated arthropathy: multicentre survey of 171 patients receiving haemodialysis for over 10 years, 157
- DIAMADIS V See Vougiouka O
- DIAS A See Vaz C
- Diclofenac and indomethacin, comparative clinical trial in patients with rheumatoid arthritis, (A2) 172
- Diclofenac-induced gastroduodenal mucosal ulcer prevention by misoprostol: a one year study, (A2) 180
- Diclofenac/misoprostol, gastroduodenal safety and efficacy of the fixed combination in the treatment of osteoarthritis, 753
- DIEPPE P.
Osteoarthritis, 132
Osteoarthritis, prospects for treatment, (A2) 238
What research should the Arthritis and Rheumatism Council be funding, (E) 649
- DIEPPE PA See Bhoola KD: Cushnaghan J: Ismaiel S: McAlindon TE: McAlindon TE
- Dietary knowledge and weight status in the rheumatology out-patient clinic, (A1) 14
- Differences between the magnetic resonance appearance of medial and lateral cartilage in the rat knee, (A2) 136
- Diffuse idiopathic skeletal hyperostosis (DISH)
of the elbow: cause of elbow pain. Controlled study, 319
prevalence of palpable finger joint nodules. A controlled study, 531
- Digestive tract haemorrhage, étude épidémiologique prospective sur les héorragies digestives hautes observées sur une période de 3 mois dans 20 centres hospitaliers Français: résultats préliminaires, (A2) 172
- DIJKMANS BAC See Eggemeijer F: Jansen M: Janssen M: Kloppenburg M: Landewé RBM
- DUS H See Driessens M
- DİLŞEN G, ORAL A, AYDIN R, SEPIÇİ V, ÇINAR A, ALPASLAN B, ERDOĞAN F. Circumstances around falls and resultant hip fractures, (A2) 151
- DİLŞEN G See also Oral A
- DİLŞEN N, KÖNİÇİ M, ARAL O, ÖCAL L, İNANÇ M. Arthritis of familial Mediterranean fever and Behçet's disease: two further members of seronegative arthritis, (A2) 184
- DİLŞEN N See also Köniçi M: Mege L
- Disability
associated with shoulder problems in the community, (A2) 62
and knee pain in community, 189
- DIŞÇI R See Köniçi M
- Disease
activity influence on steroidhormone levels in peripheral blood of patients with rheumatoid arthritis, (A2) 28
activity measurement in clinical trials on rheumatoid arthritis, provisional guidelines, (E) 793
modification: is it possible, (A2) 239
- Disease modifying
antirheumatoid drugs, variations amongst rheumatologists in prescribing and monitoring, 477
drug for juvenile chronic arthritis, 635
factor, miliary tuberculosis in rheumatoid arthritis, (A2) 186
new agents, (A2) 240
- Disulone, treatment of cutaneous vasculitis with, (A2) 126
- DIXIE J See Gallivan S
- DIXON ASTJ. Rheumatology and rheumatological research, a mismatch, (E) 145
- DMARDs, steroids and NSAIDs affecting acute phase proteins, (A2) 257
- Do patients hear what they are told, (A2) 148
- DOHERTY E, MULHERIN D, YANNI G, BRESNIHAN B. Family and peer relationships in adult patients with chronic arthritis since childhood, (A2) 79
- DOHERTY M, DAWES P. Guidelines on undergraduate curriculum in the UK, 409
- DOHERTY M See also Cope AP: Hopkinson ND: Jones A: Jones AC: Ledingham J: Regan M: Samanta A

- DOHERTY SM See Wilkinson M
 DOLAN AL See Corrigan V
 Dominance effect on severity in rheumatoid arthritis, 77
 DONN R See Dean G; Hoyland JA
 DONNAN SJ See Symmons DPM
 DONNELL D See Khokher MA
 DONNELLY S, AMOS R, NORTON AJ, ROHATINER AZS, SCOTT DL, SYMMONS DPM. Rheumatoid arthritis and lymphoma, patient with, 107
 DONNELLY S, DOYLE DV. Cyclosporin A - long-term assessment of tolerability in psoriatic arthritis, (A1) 25
 DONNELLY S, WELSH G, SCOTT DL. Comparison of patient satisfaction index with the arthritis impact measurement scales, (A2) 75, (A2) 94
 DONNELLY S See also Crowley JJ
 DONOHOE M, MATTHEWS RC, BURNIE JP, HAY E, HOLT PJL. Fungal HSP 90 and SLE, (A2) 46
 DONOVAN S See Aldwinckle TJ
 DORAN M See Hobbs RN
 Dose-finding and efficacy studies with OM-8980 (Subreum), (A2) 123
 Dose response relationship of the uricosuric drug irtemazole: double-blind multicentric trial, (A2) 133
 DOSEYEN A See Arman MI
 DOUCHAIN F See Pertuiset E
 DOWD GSE See Waller A
 DOWLING EJ, CLAXSON AW, LILLIE C, BLAKE DR. Human recombinant manganese superoxide dismutase suppresses disease activity in adjuvant arthritis, (A2) 99
 DOYLE DV See Donnelly S; Hammond A
 DR3 association with susceptibility to and severity of primary Sjögren's syndrome in a family study, 309
 DR4 and DR1 frequency in newly diagnosed cases of rheumatoid arthritis and inflammatory arthritis found in a population survey, (A2) 84
 DR-positive peripheral blood lymphocyte increase in nodal generalised osteoarthritis, (A2) 119
 DREISER RL, LOPEZ A, CHARLOT J. Etude de l'efficacité et de la tolérance du gel d'etofenamate dans le traitement des entorses déignées de la cheville, (A2) 156
 DREISSENS M. Use of intranasal calcitonin in treatment of algodystrophy, (L) 567
 DREISSENS M, DECKERS K, DIJS H, VERHEYEN G, MOENS M, NAESSENS G, BLOCKX P. Use of intranasal synthetic salmon calcitonin in treatment of reflex sympathetic dystrophy stage I, (A2) 80
 DRINOVEC J See Krajnc I
 DRIČKOVÁ V, MASARYK P, ŽLNAY D. Influence of sustained-release ibuprofen (Brufen Retard) on mobility of the spine in patients with osteoarthritis of the hip, (A2) 122
 Drug containers and domestic containers, difficulties with in elderly and patients with rheumatoid arthritis, (A2) 145
 Drug hypersensitivity occurrence in patients with Sjögren's syndrome, (A2) 127
 Dry eye syndrome in nodal generalised osteoarthritis, (A2) 67
 DUCI D See Galanti A
 DUDHIA J See Noble DP
 DUFF GW. Cytokines and inhibitors - the future, (A2) 241
 DUFF GW See also di Giovine FS; Wilson AG
 DUTS AJ See Niefeld J; Venn G
 DULARAY B, WESTCOTT CI, ELSON CJ. IL-1 secreting cell assay and its application to cells from patients with rheumatoid arthritis, 19
 DULIOUST A See Hilliquin P
 DUQUESNOY B, SAILE R, HACHULLA E, FLIPO RM, DEVAUX M, KANDOUSSI M, GOSSET D, DESCAMPS M, JANIN A, MARCHANDISE X. Significance of 123-I labeled serum amyloid P component scan, (A2) 138
 DÜRK H, KÖTTER I, SAAL JG. L-tryptophan associated eosinophilia myalgia syndrome course and treatment with cyclosporin A, (A2) 218
 DURIE M See Melarange R
 DYSON H See Foley-Nolan D
 Dyspareunia, chronic: Sjögren's syndrome. Another clinical presentation, (A2) 57
 EASTELL R See Gough A; Peel NFA
 EBERHARDT K See Forslind K
 EBRAHIM S See Thompson P
 ECKERNÄS S, FALCK G, DAHLSTRÖM B, SINGER P. Tenoxicam (ALGANEX) versus naproxen in osteoarthritis: a double-blind multicenter study following long term administration (6 months), (A2) 154
 EDELSTEN C, LEAK A, MULLER S, GRAHAM EM, WOO P. Human S- antigen autoantibodies have a normal prevalence in juvenile chronic arthritis and are not associated with histone antibodies, (A2) 45
 EDGAR JDM. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis, (L) 859
 EDGE K See Herrick AL
 EDMONDS SE See Fairburn K; Williams RB
 Education, undergraduate in musculoskeletal diseases, 279
 EDWARDS A See Kirwan JR
 EDWARDS JCW. Arthroscopy seminar, 125
 EDWARDS JCW See also Pitsillides AA; Wilkinson LS; Worrall JG
 Efficacy and safety of different dose-schedules of intra-articular injections of hyaluronic acid in painful and hydrarthroidal osteoarthritis of the knee, (A2) 127
 Effusion, traumatic, effects of flurbiprofen on the intra-articular environment, (A2) 158
 EFRAT G See Magoulas T
 EGELAND T See de Vries N
 EGGELMEIJER F, CAMPS J, PAPAPOULOS SE, PAUWELS EKJ, DIJKMANS BAC, BREEDVELD FC. Axial bone mass in rheumatoid arthritis: comparison of dual-photon and dual-energy X-ray absorptiometry, (A2) 65
 EGGELMEIJER F, PETIT P, DIJKMANS BAC. Knee arthroplasty, total, infection due to *Gemella haemolysans*, 67
 EGIDO J See Gutierrez S
 EHNREGRUBER H See Beyeler Ch; Schlapbach P
 EHRENSTEIN MR, ISENBERG D. Isotype switch in the generation of human monoclonal anti-DNA antibodies from a patient with SLE, (A2) 49
 EHRENSTEIN MR, LEAKER B, ISENBERG D, CAMBRIDGE G. Two human monoclonal anti-myeloperoxidase antibodies derived from peripheral blood, (A2) 48
 EHRENSTEIN MR, SWANA M, KEELING D, ASCHERSON R, ISENBERG DA. Anti DNA antibodies in the primary antiphospholipid syndrome (PAPS), (A1) 5
 Eicosanoids and cytokine inhibitors, (A2) 234
 EL-FEKI MB See Bassiouni M
 EL-HADIDI K See Gush RJ
 Elbow pain, diffuse idiopathic skeletal hyperostosis (DISH) of the elbow: cause of. Controlled study, 319
 Electrophysiological study of peripheral nerve function in Wegener's granulomatosis, (A2) 83
 Elemental diet use and subsequent food reintroduction in rheumatoid arthritis, (A2) 80
 ELLIS GA, WILLIAMS RB, EDMONDS SE, BLAKE DR. Novel technique to measure oxygen partial pressure in the rheumatoid knee, (A2) 18
 ELLIS RM See Gillies JH
 ELSON CJ See Bhoola KD; Dularay B; Ismael S
 EMAM EF See Bassiouni M
 EMERY N See Gallivan S
 EMERY P. Validity of surrogate markers in rheumatic disease and the role of APPs in inflammation, (A2) 256
 EMERY P, BRADLEY H, ARTHUR V, TUNN E, WARING R. Genetic factors influencing the outcome of early arthritis - role of sulphoxidation status, 449
 EMERY P, CLARKE AK, KILL DC. Double-blind, randomised comparison of nabumetone and naproxen in rheumatoid arthritis, (A2) 167
 EMERY P See also Gado K; Gordon C; Gough A; Janssen BA; Matthews NC
 EMMERSON BT See Vecchio PC
 B/Endorphins, plasma level modifications in course of treatment with synthetic salmon calcitonin versus synthetic eel calcitonin, (A2) 223
 Endosteal hyperostosis, clodronate for management of pain, (A2) 228
 Endothelial cell stimulating angiogenesis factor (ESAF) in patients with ankylosing spondylitis, (A2) 15
 Endothelin plasma concentration, exercise causes rise in rheumatoid arthritis, (A2) 16
 Endothelin-1 serum levels in systemic sclerosis, (A2) 13
 Endothelium-derived haemostatic factors and the antiphospholipid syndrome, (A2) 189
 ENSOR M See Hammond A
 Entese, human and bovine contain type I and type II collagens, (A2) 69
 ENTWISTLE A See Brookes SM
 Eosinophilia myalgia syndrome course and treatment with cyclosporin A, (A2) 218
 Eosinophilic fasciitis: an atypical case, (A2) 231
 Epicondylitis, use of laser Doppler flowmetry and transcutaneous oxygen tension electrodes to assess local autonomic dysfunction, (A1) 22
 Epidemiology of NSAID effects and side effects, (A2) 250
 Epithelial cell proliferation, tissue microdissection and quantification applied to duodenal mucosa in patients taking NSAIDs, (A2) 174
 ERICILLA G See Cañete JD
 ERDOĞAN F See Dilşen G
 Ergebnisse einer randomisierten, doppelblinden 1-Jahresstudie mit oralen Enzymen im Vergleich zur oralen Goldtherapie bei Patienten mit chronischer Polyarthrit, (A2) 133
 ERHARDT LJ See Geis GS
 ERK M See İmeryüz N
 ERKELLER-YUKSEL FM, ISENBERG DA, HANNET I, STRAUSS K, LYDYARD PM. CD38+CD8+ T cells are increased in the peripheral blood of SLE patients, (A2) 43
 Erosion area measurement comparison from macroradiographs with Larsen's score of conventional radiographs in rheumatoid hands, (A2) 35
 Erythema multiforme after intradural injection of prednisolone acetate, (L) 717

- ESCANYÉ JM *See* Kaminsky P
- ESCUERO D. Central neurological manifestations of primary Sjögren's syndrome, (L) 787
- ESPINACH J *See* Lima J
- ESPINOZA IR *See* Vasey FB
- Etofenamate
 etude de l'efficacité et de la tolérance du gel d'etofenamate dans le traitement des entorses déignées de la cheville, (A2) 156
 in oily solution: new facilities for treatment of severe inflammatory pain, (A2) 157
 penetration kinetics in pig skin after topical application of rheumon cream, Methodology and in vitro results, (A2) 158
 topical treatment of ankle dislocations with an etofenamate containing gel. Results of a randomized, placebo-controlled double-blind study, (A2) 157
- EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCIIT), work of, (E) 219
- European rheumatology - a need for greater understanding, (E) 217
- EUSTACE S, COUGHLAN J, MCCARTHY CJ. Ankylosing spondylitis, a comparison of clinical and radiographic features in men and women, (A1) 1
- Evaluation of an out-patient education programme for people with rheumatoid arthritis, (A2) 77
- EVANS E *See* Matthey DL
- EVANS JG *See* Corrigan V
- EVANS RA *See* Stanley JK
- EVERETT JR *See* Carpenter TA
- EVISON G *See* O'Neill TW
- Exercise
 bad for inflamed joints, (A2) 233
 causes a rise in plasma endothelin concentration in patients with rheumatoid arthritis, (A2) 16
 induces rises in plasma von Willebrand factor in rheumatoid arthritis, (A2) 110
- Existentially-humanistic psychotherapy in rheumatological rehabilitation, (A2) 150
- Expanding journal, (E) 1
- Experimental arthritis
 monoclonal anti-IL2 receptor therapy, (A2) 103
 role of persistent mycobacteria in reactivation, (A2) 5
- Experimental osteoarthritis, synovial fluid IL-6 is raised, (A2) 214
- Expert system 'Rheuma' on a PC in clinical validation, (A2) 150
- Extraarticular manifestations of rheumatoid arthritis in Turkey based on analysis of 110 cases, (A2) 224
- Extracellular matrix and cell surface, interaction between, (E) 74
- Extracorporeal photochemotherapy, (L) 789
- treatment of refractory rheumatoid arthritis, (A2) 208
- EYRE S *See* Gough A
- EYRES KS *See* Abdel-Salam A
- FACCINI A *See* Meliconi R
- Factor VIII related antigen acts as a marker of disease activity in adult dermatomyositis treated with cyclosporin A, (A2) 231
- FAHRER H *See* Beyelei Ch
- FAINT J *See* Gough A
- FAIRBURN K, NAZHAT NB, SAADALLA-NAZHAT RA, EDMONDS SE, BLAKE DR. Detection of an oxidising species in synovial fluid by electron spin resonance spectroscopy: evidence for *in vivo* production of reactive oxygen species, (A2) 19
- FAKHOURY RJ *See* Jones PB
- FALCK G *See* Eckernäs S
- Falls, circumstances around and resultant hip fractures, (A2) 151
- Familial clustering of anti-topoisomerase-I antibodies, (A2) 87
- Familial osteoarthropathies of the hip, molecular defect, in Southern Africa, (A2) 101
- Family and peer relationships in adult patients with chronic arthritis since childhood, (A2) 79
- FARAHAT MNMR, YANNI G, POSTON R, CHIKANZA I, PANAYI GS. Rheumatoid and osteoarthritic synovial membranes, immunohistological and functional differences, (A1) 10
- FARAHAT MNMR, YANNI G, POSTON R, PANAYI GS. Gold treatment in rheumatoid arthritis diminishes IL-8 expression and monocyte numbers at two weeks, (A2) 89
- FAREWELL VT *See* Langevitz P
- Farming and osteoarthritis of the hip, (A2) 92
- FARNDON P *See* Rai A
- FARR M *See* Roussou E
- FARRELL AJ, BLAKE DR, PALMER RMJ, MONCADA S. Elevated synovial and serum nitrite suggest increased nitric oxide synthesis in rheumatic diseases, (A2) 20
- FARRELL AJ, JUPP RA, BLAKE DR. Serum angiotensin converting enzyme activity is lower in rheumatoid arthritis patients than age and sex matched controls, (A2) 110
- FARRELL AJ, WILLIAMS RB, STEVENS CR, BLAKE DR, COX NL. Exercise induces rises in plasma von Willebrand factor in rheumatoid arthritis, (A2) 110
- FARRELL AJ, ZAPHIROPOULOS GC, COPPOCK JS, STRUTHERS GR. Prospective study of anti-streptococcal antibody titres in inflammatory joint disease, (A2) 190
- FARROW P *See* Loose LD
- FAST JH *See* van den Hoogen FHJ
- FAY A *See* Deighton CM
- FECAROTTA E *See* Cutolo M
- FEDOR J *See* Szüts I
- FEEHALY J *See* Samanta A
- FEIGHERY C *See* Callaghan M
- FEINENDEGEN LE *See* Lanyi E
- FELDMANN M *See* Brennan FM; Chu CQ; Cope AP; Corcoran AE; Deleuran BW; Gibbons DL
- FELLEZ A *See* Roques CF
- Felty's syndrome, antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in sera, 185
- Female hormones and pregnancy, examination of role as risk factors for rheumatoid arthritis using male population as control group, 395
- FENER P, RICARD-BLUM S, GILLET P, NETTER P, POUREL J, GAUCHER A. Human and bovine entheses contain type I and type II collagens, (A2) 69
- FENER P *See also* Kaminsky P; Pourcel J
- FENYCH W, ZIELIŃSKA M, LACKI J, BIAŁOWSKA G, ZIMMERMANN-GÓRSKA I. Inhibitory influence of non-steroidal anti-inflammatory drugs on the metabolism of polymorphonuclear granulocytes, (A2) 171
- FERNANDES M *See* Pinto MJ
- FERNANDEZ-CORTIJO J, CHACON P, LIMA J, FONOLLOSA V, CASTRO A, MARSA S, SOLANS R, LIENCE E, VILARDELL M. Increased Lp (a) levels in patients with systemic sclerosis, (A2) 17
- FERNANDEZ-CORTIJO J *See also* Lima J
- FERRACINI R *See* Cutolo M
- FERRILL W *See* Crighton A
- FERRI C, GRECO F, LONGOMBARDO G, LA CIVITA L, PALLA P, MAZZONI A, MORETTI A, CORBISHLEY T, HIGHFIELD P. Hepatitis C virus and mixed cryoglobulinaemia, (A2) 101
- FERRI C *See also* Riente L
- FETHERSTON TJ *See* Rai A
- Fibrillin gene mutations, two unique, in UK Marfan syndrome patients with joint hypermobility, (A2) 87
- Fibrinogen expression, interleukin-1 receptor antagonist (IRAP) regulation, (A2) 213
- Fibrinolysis, extra and intradural fibrosis and HLA-DR type, (A2) 12
- Fibromyalgia
 adult: causative and modulating factors and forms of onset, (A2) 228
 symptoms in the general population, (A2) 64
- Fibromyalgia syndrome
 axon reflex flare responses, (A2) 203
 sleep disturbance and lumbar hyperlordosis and their influence on the aetiology, (A2) 221
- Fibrosis, extra and intradural, fibrinolysis and HLA-DR type, (A2) 12
- FIEDOROWICZ-FABRYCY I, KUCHARSKA E. Long-term observations of patients with Wegener's granulomatosis. Prevention of relapses based on antineutrophil cytoplasmic antibody titre, (A2) 192
- FIELD M, SWALLOW R, DELEURAN B, FOULIS A, STURROCK RD. Tumour necrosis factor alpha, localisation in cranial arteritis, (A2) 24
- FIELD M *See also* Chu CQ; Deleuran BW
- Finger joint nodules, prevalence of palpable in diffuse idiopathic skeletal hyperostosis (DISH). A controlled study, 531
- FISELIER T *See* Boerbooms AMT
- FITZGERALD O. Connective tissue disease immunology, 136
- FITZGERALD O *See also* Crowley JJ; Mulherin D; Veale D
- FITZPATRICK R, ZIEBLAND S, JENKINSON C, MOWAT A, MOWAT A. Generic health status instrument in assessment of rheumatoid arthritis, 87
- FITZPATRICK R *See also* Mowat A
- Fixed flexion deformity treatment of the knee in rheumatoid arthritis using Flowtron intermittent compression stocking, 41
- FLEISCHMANN RM *See* Tindall EA
- FLEMING J *See* Samanta A
- FLETCHER DM *See* Wade AG
- FLIPO RM *See* Duquesnoy B
- FLIS I *See* Turk Z
- FLORENT CH, ZALCBERG M, CAPRON MH. Etude épidémiologique prospective sur les hémorragies digestives hautes observées sur une période de 3 mois dans 20 centres hospitaliers Français: résultats préliminaires, (A2) 172
- FLORESCU A *See* Pödenphant J
- Flow cytometry and rheumatic disease, 465
- FLOWER RJ. Lipocortin, what is it and what does it mean, (E) 506
- FLOWER RJ *See also* Da Silva JAP
- Flurbiprofen
 (Cebutid LP) tolerability, efficacy and impact on quality of life of sus-

- tained-release in osteoarthritis of the hip and knee: general practice study with 12,005 patients, (A2) 162
- (Cebutid LP) tolerability, efficacy and quality of life evaluation of sustained-release in osteoarthritis of the hip and knee: a study by French rheumatologists, (A2) 161
- effects on the intra-articular environment in patients with traumatic effusions, (A2) 158
- (Froben Retard) efficacy and tolerability of sustained release in arthritis: hospital-based studies in Belgium and Holland, (A2) 159
- (Froben SR, Flugal SR), Circadian rhythms and sustained-release in the treatment of ankylosing spondylitis, (A2) 161
- (Froben SR, Foben Suscap) sustained release, efficacy and tolerability in arthritis: general practice studies in the UK and Holland, (A2) 160
- (Froben SR) sustained release, and piroxicam, therapeutic activity and tolerability in osteoarthritis of the knee, (A2) 160
- FOGELMAN I See Ryan PJ
- FOLEY-NOLAN A See Foley-Nolan D
- FOLEY-NOLAN D, DEEGAN RJ, FOLEY-NOLAN A, BARRY C, COUGHLAN RJ, HONE R. Skeletal tuberculosis, (A2) 221
- FOLEY-NOLAN D, ROWBOTHAM D, KEARNEY M, O'MALLEY A, DYSON H, MARTIN M. Serial measurement of proteinuria using spot creatinine index in rheumatoid patients, (A2) 218
- FONG KY, LOIZOU S, BOEY ML, WALPORT MJ. Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus, 453
- FONOLLOSA V See Fernandez-Cortijo J: Lima J
- FONT J See Vivancos J
- FORBES CD See Lau CS
- FORD PM See Bellamy N
- FORDHAM JW, JONES S, PITCHER O, BATES J, KHAN A, SIMPSON D. Open access bone densitometry - the first 1000 referrals, (A2) 229
- FORNASARI M See Valentini M
- FORSLEND K, EBERHARDT K, JONSSON A, SAXNE T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis, 593
- FOSTER H, WALKER D, CHARLES P, KELLY C, CAVANAGH G, GRIFFITHS I. DR3 association with susceptibility to and severity of primary Sjögren's syndrome in a family study, 309
- FOSTER H See also Charles PJ
- FOULIS A See Field M
- FOURNIER S See Larbre J-P
- FOWLER PD See Borg AA
- FRACASSO A See Valentini M
- FRANCHIMONT P See Reginster JY
- FRANZ J, HUGO H, OLTHOFF H, FRIEDLANDER R. Pustulous arthroosteopathy with exocrinopathy, (A2) 232
- FREDERIKSEN PB See Beier JM
- Free radical scavenging effects of tenidap, a new anti-inflammatory drug, (A1) 28
- FREEMAN MAR See Kirwan JR
- FREEMONT AJ. Synovial fluid lipid crystal significance in patient with isolated monoarthritis, (CC) 183
- FREEMONT AJ See also Herrick AL: Hoyland JA
- FRESQUET A See Rodriguez de la Serna A
- FRIEDLANDER R See Franz J
- FRIES JF. Real disease modification: is it possible, (A2) 239
- FRISINA N See Bartolone S
- FRITZ P See Saal JG
- FRIZZIERO L See Meliconi R
- Frozen shoulder, abnormal temperature control suggesting sympathetic dysfunction in the shoulder skin, 539
- FUCHS WA See Beyeler Ch: Schlapbach P
- L-Fucose treatment in rheumatoid arthritis, clinical and laboratory outcomes, (A2) 205
- FUJINAMI T See Yoshida A
- FUJITA T See Shiozawa K
- Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study, (L) 502
- Fungal HSP 90 and SLE, (A2) 46
- GADO K, EMERY P. Suprascapular nerve block (SSNB) for shoulder pain. When to use it, (A2) 82
- GADO K See also Gordon C
- GAFFEN JD. Cell surface and extracellular matrix, interaction between, (E) 74
- GAGNIER RP See Kochman RL
- Gait analysis, comparative in different patterns of foot arthritis, (A2) 29
- Galactosaminoglycuronoglycan-sulfate influence on the action of PMN cell migration in the presence of chemoattractants, (A2) 109
- Galactosyltransferase-associated protein kinase gene structure and IgG glycosylation in autoimmune strains of mice, (A2) 47
- GALANTI A, PARESC E, CERAVOLO P, MARSANO S, DUCI D, CARRABBA M. Tenoxicam in acute low back pain: an open comparative study versus diclofenac, (A2) 155
- GALATAS ID, KARRAS D, PAPAIOANOU D, DELYARGYIS N. Immunoglobulin E levels in ankylosing spondylitis, (A2) 198
- GALBRAITH I See Murphy EA
- GALEOTTI L See Govoni M
- GALINIER-PUJOL A See Poet JL
- GALL H See Saal JG
- GALLIVAN S, SHERLAW-JOHNSON C, YOUNG A, COX N, EMERY N, GOUGH A, JAMES D, DIXIE J, WINFIELD J, WILLIAMS P. Auditing long term progression of rheumatoid arthritis, (A2) 145
- GAMBARI PF See Ostuni PA
- GAMBERINI S See Canazza S: La Corte R
- GANDZHA IM See Lysenko GI
- GARCÍA-BRAGADO F See Manzanque L
- GARDNER DL, CUNNINGHAM DS. Microscopic fibrillation measurement in optical sections of hydrated articular cartilage by computer-assisted morphometry, (A2) 202
- GARDNER DL See also Salter DM
- GARTON MJ, GORDON PM, RENNIE JAN. Pseudosepsis in rheumatoid arthritis due to cellular and lipid abnormalities in synovial fluid, 625
- GARTON MJ, REID DM. Bone mineral density in men with rheumatoid arthritis: effect of low dose corticosteroids, (A1) 19
- Gastric damage, dyspeptic symptoms and chronic NSAID use in arthritic patients, (A2) 173
- Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - influence of age, smoking, ulceration and *Helicobacter pylori*, (A1) 27
- Gastrointestinal safety
- of arthroec in osteoarthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
- of arthroec in rheumatoid arthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
- and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis, 753
- Gastrointestinal accumulation of indium-111 labelled granulocytes in reactive arthritis, 543
- Gastroptomy, incidence of NSAID induced in unselected patients, (A2) 173
- GÁSZ A See Kurth G
- GAUCHER A See Fener P: Kessler M
- GAZIC M See Turk Z
- GAZZETTO G See Ostuni PA
- GEBOREK P, MÄNSSON B, HELLMER G, SAXNE T. Cytidine deaminase and lactoferrin in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function, 235
- GEIS GS, ERHARDT LJ, STEAD H. Prevention of diclofenac-induced gastroduodenal mucosal ulcers by misoprostol: a one year study, (A2) 180
- GEIS GS See also Bolten W: Kochman RL: Stead H: Woods EM
- Gemella haemolysans*, total knee arthroplasty infection, 67
- GENDI N, GORDON T, TANNER SB, BLACK CM. Evolution of case of overlap syndrome with systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus, 783
- General practitioner/rheumatology interface. Proceedings of meeting held between general practitioners and rheumatologists, (L) 209
- Generic health status instrument in assessment of rheumatoid arthritis, 87
- Genetic factors influencing the outcome of early arthritis - role of sulphoxidation status, 449
- Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene, (A2) 86
- Genetic mapping in connective tissue disorders, (E) 147
- Genetic variants of type II collagen are not associated with rheumatoid arthritis, (A2) 86
- Genetic variation in the tumour necrosis factor alpha promoter, (A2) 23
- GENTRY C. Effects of active metabolite of nabumetone on the synthesis of normal canine articular cartilage *in vitro*: comparison with other non-steroidal anti-inflammatory drugs, (A2) 168
- GENTRY C See also Melarange R
- GEORGE A See Gordon C
- GERBER LH See O'Connell PG
- GERBER NJ See Beyeler Ch: Schlapbach P
- GERDES N See Jaekel WH
- GERMAIN BF See Vasey FB
- GEROVA Z, MARSHALL JM, SHEERAN TP, BACON PA, WESTWOOD D. Peripheral vascular changes evoked by emotional stress in patients with primary Raynaud's syndrome, (A1) 21
- GHATEI M See Williams RB
- GHIRINGHELLI D See Brogini M
- GHOZLAN R, LABORDE C
- Tolerability, efficacy and impact on quality of life of sustained-release flurbiprofen (Cebutid LP) in osteoarthritis of the hip and knee: general practice study with 12,005 patients, (A2) 162

- Tolerability, efficacy and quality of life evaluation of sustained-release flurbiprofen (Cebutid LP) in osteoarthritis of the hip and knee: a study by French rheumatologists, (A2) 161
- GIANNANTONI P *See* De Sauts S
- Giant cell arteritis
blindness prevention by corticosteroid treatment, 103
interleukin 6 production: comparison of serum levels and production by peripheral blood lymphocytes, (A2) 212
steroid treatment, (L) 431
- GIBBONS DL, MITCHELL TJ, COPE AP, MAINI RN, BRENNAN FM, FELDMANN M. Increased expression of tumour necrosis factor receptors on cells isolated from rheumatoid arthritis synovial joints, (A2) 211
- GIBBONS DL *See also* Cope AP
- GIBSON T. Clinical seminar, 133
- GIBSON T *See also* Ryan PJ
- GIDÓFALVY E *See* Szűts I
- GIJÓN J *See* Muñoz-Fernández S
- GIJÓN-BAÑOS J *See* Arnalich F
- GILLET P *See* Fener P
- GILLIES JH, ELLIS RM, GUPPY N, BREEN AC, HUNT N, LAXTON AH. Back pain disability compared in patients attending rheumatology, osteopathic and chiropractic clinics, (A1) 24
- GLADMAN DD *See* Langevitz P
- GLASNOVIC M *See* Ristic M
- GLEICHMANN E, KUBICKA-MURANYI M, GRIEM P, GOEBEL C. Au(I)/Au(III) redox system underlies the anti-inflammatory effect of gold (I) drugs, such as aurothiomalate. A hypothesis, (A2) 131
- D-Glucaric acid in rheumatoid arthritis, (A2) 115
- GLÜCKERT K, KLADNY B, PONSEL O, DEIMLING M. MRI of the knee joint with measurement of cartilage signal intensity and relaxation times to determine different stages of cartilage hydration - a future aspect to identify human early osteoarthritis, (A2) 139
- GLÜCKERT K *See also* Herrmann J
- Glucose 6-phosphate dehydrogenase low activity preceding osteoarthritis, (A2) 69
- Glycosaminoglycan
epitope changes on proteoglycans in acute knee joint trauma synovial fluids, (A2) 117
synthesis, signal transduction in by cultured chondrocytes and its inhibition by inflammatory cell-derived hydrogen peroxide, (S1) 27
- Glycosylation
control mechanisms, alteration in normal and rheumatoid arthritis, (A2) 88
of IgG in the collagen induced model of arthritis, (A2) 53
- Glycosyltransferase activity, non-steroidal anti-inflammatory drugs effects in human osteoarthritic cartilage, (S1) 13
- Gm allotypes in nodal generalized osteoarthritis, 605
- GMP-140 expression is transiently induced by hypoxia on human endothelial cells, (A2) 99
- GOCHOCO CH *See* Smith PL
- GOEBEL C *See* Gleichmann E
- GOEI THE HS *See* Blaauw AAM; Landewé RBM
- Gold
longitudinal study of pulmonary function in patients with rheumatoid arthritis, 829
treatment in rheumatoid arthritis diminishes IL-8 expression and monocyte numbers at two weeks, (A2) 89
- Gold (I) drugs, Au(I)/Au(III) redox system underlies the anti-inflammatory effect of gold (I) drugs, such as aurothiomalate. A hypothesis, (A2) 131
- Gold-induced aplastic anaemia, successful treatment with granulocyte macrophage colony stimulating factor, (L) 428
- GONGGRYP LA. Chloroquine-induced vitiligo in a patient with juvenile onset rheumatoid arthritis, (L) 790
- GONTAR IP, CHERNOVA SI, YAQUB RAZA M, ZBOROVSKY AB. Clinical and immunological parallels in systemic sclerosis and rheumatoid arthritis, (A2) 183
- GONZÁLEZ E *See* Gutierrez S
- GONZÁLEZ-GANCEDO P *See* Arnalich F
- GOODSTONE NJ *See* Hobbs RN
- GOOI HC *See* Dearlove SM
- GORDON C, ROBINSON M, GADO K, GEORGE A, CORDINER S, RICHARDSON K, VINEK N, EMERY P. Measurement of C3D by ELISA: correlations with SLE disease activity, (A2) 59
- GORDON C *See also* Roussou E
- GORDON PM *See* Garton MJ
- GORDON T *See* Gendi N
- GORONZY JJ *See* Roche NE
- GOSSET D *See* Duquesnoy B
- GOTTSCHALK R *See* Kaltwasser JP
- GOUDIE RB *See* Murphy EA
- GOUGH A, FAINT J, HUISOON A, SALMON M, EMERY P. HLA DR locus has no association with early rheumatoid arthritis, (A2) 85
- GOUGH A, HUISOON A, LILLEY J, EYRE S, EMERY P. Bone mineral density loss in early rheumatoid arthritis, (A2) 97
- GOUGH A, PEEL N, CALDWELL T, EASTELL R, EMERY P. Urinary pyridoxine and deoxypyridinoline excretion correlate with disease activities in first year of early rheumatoid arthritis, (A2) 30
- GOUGH A *See also* Gallivan S; Janssen BA
- GOULDER MA *See* Muldoon CG
- Gout
due to renal disease, 63
management in Sydney. Comparison of practices of varying groups of practitioners, (A2) 144
phagocytosis of urate crystals in synovial fluid obtained from asymptomatic knees, (A2) 20
synovial fluid analysis from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout, (A2) 219
- Gouty arthropathy and synovial uric acid, (L) 791
- GOVONI M, MENEGALE G, LA CORTE R, GALEOTTI L, VALDINOCI R, CANAZZA S, BEZZI A, DEQANI D, TROTTA F. Phenotypic characterization of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis by cytofluorimetric analysis, (A2) 193
- GOWEN M. Osteoporosis, who are we treating, (A2) 246
- GOWEN M *See also* MacDonald BR
- GRACHEV ID.
Actively-passive prolong pathogenetic hypnosis in rheumatology, (A2) 231
Existentially-humanistic psychotherapy in rheumatological rehabilitation, (A2) 150
- GRAHAM EM *See* Edelsten C
- GRAHAME R.
Confusional syndrome as presenting form of calcium pyrophosphate dihydrate deposition disease, (L) 569
Transcutaneous NSAID therapy, (A2) 252
- GRAHAME R *See also* Chikanza IC; Child A; Clarke GS; Henney AM; Mishra M; Ryan PJ
- GRANFORS A *See* Mäki-Ikela O
- GRANFORS K *See* Laheesmaa R; Mäki-Ikela O
- GRANT ME *See* Hoyland JA
- Granulocyte macrophage colony stimulating factor, successful treatment of gold-induced aplastic anaemia, (L) 428
- GRASSI W, CORE P, CARLINO G, CERVINI C. Capillary microscopy of the oral mucosa in systemic sclerosis, (A2) 188
- GRASSI W *See also* Cervini C
- GRATACÓS J *See* Cañete JD
- GRAU JM *See* Vivanos J
- GRAY J *See* Deighton CM; McDonagh J
- GRAY JW *See* Deighton CM
- GRAY PW *See* Corcoran AE
- GREAVES M *See* Lindsay N
- GRECO F *See* Ferri C
- GRENNAN DM *See* Clarkson RWE; McMahon MJ
- GRESSER U, KAMILLI I, SCHMIDT P, ZÖLLNER N. Dose-response relationship of the uricosuric drug irtemazole: double-blind multicentric trial, (A2) 133
- GRESSER U *See also* Kamilli I; Rauh G
- GRIEM P *See* Gleichmann E
- GRIFFITH SM *See* Byrne JM
- GRIFFITHS I *See* Charles PJ; Foster H
- GRIFFITHS ID. New National Health Service Trusts and rheumatology, (E) 361
- GRIFFITHS ID, HASLOCK I, AMOS R, SCOTT DL. Guidelines for organization of audit in rheumatology: combined working group report, 333
- GRIFFITHS ID *See also* Kelly CA
- GRINDULIS KA *See* Samanta A
- GRILČKOV M, PUŠEVSKI A, ČALOVSKEI J, MARINA N, KAFEDIJSKA I, NIKOLOVSKA M, BOŽINOVSKI G, PERČINKOVA S, ANTOVA D. Relationships between serum C3 levels, with anti-nDNA binding activity and fluorescent antinuclear antibody titers in patients with systemic lupus erythematosus, (A2) 182
- GROMNICA-IHLE E, HEIDLER TH, SCHRÖDER H. Affection of the cervical vertebral column in chronic polyarthritis: incidence, correlations, complications, (A2) 226
- GROMNICA-IHLE E *See also* Hüge H
- GROUIN JM *See* Carraba M
- Growth factor and cytokine effects on proteoglycan turnover in articular cartilage, (S1) 1
- GUDBJÖRNSSON B. Sjögren's syndrome and inflammatory bowel diseases, (L) 429
- GÜL A *See* Mege L
- Guidelines for organization of audit in rheumatology: combined working group report, 333
- GUILLEMEN F *See* Pourel J
- GUILLLOT M *See* Pertuiset E
- GUILLLOU GB *See* Carraba M
- GUPPY N *See* Gillies JH

- GUSH RJ, EL-HADIDY K, BROMELL J, JAYSON MIV. Skin blood flow without temperature recovery of the fingers following cold challenge, (A2) 55
- GUSH RJ, JAYSON MIV. Quantification of skin elasticity and tethering in scleroderma, (A2) 53
- GUSTI R *See* Ostuni PA
- GUSSEVA NG *See* Stephens CO
- Gut in spondylarthropathies: recent studies, (A2) 72
- GUTIERREZ S, ZARCO P, PALACIOS I, GONZÁLEZ E, EGIDO J, HERRERO-BEAUMONT G. Involvement of platelet activating factor and tumour necrosis factor in pathogenesis of joint inflammation in rabbits, (A2) 24
- GUVEN A *See* Arman MI
- 1H- and 13C-NMR spectroscopy can be used to record both biochemical and biophysical properties of synovial fluid, (A2) 210
- HAAGSMA C, VAN RIEL P, VAN DE PUTTE L. Combination therapy in RA: sulphasalazine and methotrexate, (A2) 32
- HAAGSMA C *See also* van Riel P
- HAANEN HCM, JACOBS PJC, SCHARDUIN GHC, DE NAYER J, HAUWAERT C, VANDERSTRAETEN G, VLOTES PW, TEBBS VM. Efficacy and tolerability of sustained release flurbiprofen (Froben Retard, Froben Suscap) in arthritis: hospital-based studies in Belgium and Holland, (A2) 159
- HAASTERS J. Nabumetone treatment of joint injuries caused by sporting activities. An open clinical trial of efficacy and tolerability, (A2) 162
- HACHULLA E *See* Duquesnoy B
- Haem oxygenase (HO-1) in synovial fluid cells, (A2) 19
- Haemochromatosis arthritis case, 547
- Haemodialysis, spinal cord compression revealing destructive arthropathy of atlanto-occipital joint associated with beta-2 microglobulin amyloidosis, (L) 427
- HAHN D *See* Kamilli I
- HALE G *See* Watts RA
- HALKJAER KRISTENSEN J *See* Lyngberg K
- HALL GM, O'GARA C, WILTSHIRE P, SPECTOR TD. Whole body bone density in postmenopausal rheumatoid arthritis, (A2) 97
- HALL LD *See* Carpenter TA
- HALL N *See* Will RK
- HALL ND *See* Brown-Galatola CH: Creamer P
- HALL GM *See also* James IT: Spector TD
- HALLAM CG *See* Cook NJ
- HALLIWELL B *See* Wasil M
- HAMID BNA *See* Arnold MM
- HAMILTON EDB *See* Axford JS
- HAMMOND A, DENTON A, ENSOR M, SCOTT DL, DOYLE DV. Which clinical measurements are suitable to follow-up ankylosing spondylitis, (A2) 72
- HAMMOND A, DOYLE DV. Computers in medical audit: experience with NE Thames RHA Clinical Information System (CIS), (A2) 146
- HAMURYUDAN V, YURDAKUL S, TÜZÜN H, MORAL F, ÖZYAZGAN Y, PAZARLI H, MAT C, TÜZÜN Y, YAZICI H. Pulmonary artery aneurysms in Behçet's syndrome: report of 22 cases, (A2) 199
- Hand
- bone mineral content measurement by dual energy X-ray absorptiometry: development of the method in normals and its application in rheumatoid arthritis, (A2) 68
 - joints, contrast enhanced MRI in rheumatoid arthritis, seronegative spondyloarthritis and erosive osteoarthritis, (A2) 138
 - and upper limb problems of instrumental musicians, 265, (L) 572
- HANNAFORD PC *See* Rigby AS
- HANNET I *See* Erkeller-Yuksel FM
- HANSEN M, HØRSLEV-PETERSEN K, STOLTENBERG M, LORENZEN I, RISTELI L, RISTELI J. Type I collagen metabolism in rheumatoid arthritis. Effects of pulse treatment with methylprednisolone, (A2) 129
- HANSEN M *See also* Stoltzenberg M
- HANSEN TM *See* Beier JM
- HARDINGHAM T *See* Hazell P: Venn G
- HARDINGHAM TE, BAYLISS MT, RAYAN V, NOBLE DP. Effects of growth factors and cytokines on proteoglycan turnover in articular cartilage, (S1) 1
- HARDINGHAM TE *See also* Hickery MS: Lewthwaite JC: Noble DP: Platt D
- HARKISS G *See* Anderson A
- HARLEY SL *see* Stevens CR
- HARMER I *See* Mackworth-Young CG
- HARMOND M-F *See* Savineau C
- HAROUTONIAN R *See* Beynon HLC
- HARPER GP *See* Carpenter TA
- HARRIS P *See* Spector TD
- HART DJ, SPECTOR TD. Cigarette smoking and risk of osteoarthritis: the Chingford study, (A2) 61
- HART DJ *See also* Spector TD: Thompson PW
- HART TK *See* Smith PL
- HARVEY GR *See* Whyte J
- HASHIMOTO K *See* Varga J
- Hashimoto's disease and rheumatoid arthritis, (A2) 232
- HASKARD DO *See* Beynon HLC: Mason JC: Wilkinson LS
- HASLER F *See* Beyeler Ch
- HASLOCK I. Contracting in rheumatology, (E) 289
- HASLOCK I, MACFARLANE D. Intra-articular and soft tissue injection techniques: an audit of practice, (A1) 29
- HASLOCK I *See also* Griffiths ID
- HATZ HJ, HELMKE K, LÖFFLER W. Diagnosis and therapy of adult onset Still's disease, (A2) 194
- HAUWAERT C *See* Haanen HCM
- HAVENGA K *See* Janssen M
- HAWKEY CJ. Non-steroidal anti-inflammatory drugs, gastro intestinal effects, (A2) 251
- HAWKINS PN. Looking at amyloid in patients, (A2) 244
- HAWKINS PN *See also* Vigushin DM
- HAY CRM *See* Hay EM
- HAY E *See* Donohoe M
- HAY EM. Systemic lupus erythematosus, 207
- HAY EM, PATTERSON D, KAMAGUTI-YAMAGA A, TOMURA S, HOLT PJL, HAY CRM. Soluble thrombomodulin: marker of vascular endothelial injury in vasculitis and systemic lupus erythematosus, (A2) 90
- HAY FC *See* Bond A: Jones MG
- HAYES JH, TRACEY A, MCKENNA F. Stanford Health Assessment Questionnaire (HAQ) as tool for audit, (A2) 146
- HAYEZ JP *See* Szpalski M
- HAYTON R *See* Croft P
- HAZELL P, DENT C, BAYLISS M, HARDINGHAM T. Changes in glycosaminoglycan epitopes on proteoglycans in acute knee joint trauma synovial fluids, (A2) 117
- HAZES JMW *See* Riste L: van Zeben D
- HAZLEMAN B. Soft tissue rheumatism, 135
- HAZLEMAN B *See also* Birrell F: Workman E
- HAZLEMAN BL *See* Adebajo AO: Pountain G: Vecchio P: Watts RA
- HEALD G *See* Byrne JM
- Health assessment questionnaire as predictor of non-steroidal peptic ulceration, (A1) 27
- Health status, self-efficacy, social support and adherence with health guidelines in patients with rheumatoid arthritis, (A2) 148
- Heat distribution pattern and nailfold capillary damage in patients with primary Raynaud's phenomenon and systemic sclerosis, (A2) 54
- Heat shock protein-activated rheumatoid synovial fluid mononuclear cells, cytokines released by, suppress cartilage proteoglycan synthesis, (A2) 114
- HEATH L *See* Jeddi PA
- HEDFORS E *See* Lundberg I
- HEDLEY K *See* Chicco-Bianchi F
- HEIDLER TH *See* Gromnica-Ihle E
- HEINEGÅRD D *See* Saxne T
- HEININGER K, THEBUD-LASSAK R, BERNARD I. Acemetacin, a well tolerated NSAID with minor irritation of the gastric mucosal membrane, (A2) 177
- HEININGER K *See also* Thebud-Lassak R
- Helicobacter pylori* infection and gastric damage in arthritic patients taking anti-inflammatory drugs, (A2) 204
- HELLIWELL PS
- Occupational rheumatology: are we using the wrong model, (E) 73
- Psoriatic arthritis, DIP or not DIP, that is the question, (L) 431
- HELLIWELL PS, SMEATHERS JE, MUMFORD D, WRIGHT V. Analysis of the contribution of physical and psychological factors to the pain and disability experienced in repetitive strain injury, (A1) 22
- HELLIWELL PS *See also* Wright V
- HELLMER G *See* Geborek P
- HELME RD *See* Reilly PA
- HELME K *See* Hatz HJ
- HEMSLEY AG, HULL G, TODD I, POWELL RJ. Analysis of CD3+CD4- CD8- and CD3+CD4+CD8+ lymphocytes in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease, (A2) 42
- HENDERSON B *See* Lewthwaite JC: Noble DP
- HENDERSON E *See* Thompson PW
- HENDERSON F *See* Lindsay AJ
- HENNESSY E *See* Silman AJ
- HENNEY AM, BROTHERTON DH, CHILD AH, HUMPHRIES SE, GRAHAME R. Collagen gene segregation analysis in two families with joint hypermobility syndrome, 169
- Hepatitis C virus and mixed cryoglobulinaemia, (A2) 101
- HERBERT KE *See* Agambar L
- Hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene, genetic linkage analysis, (A2) 86
- HERRERO-BEAUMONT G *See* Gutierrez S
- HERRICK AL, EDGE K, PERKINS C, JAYSON MIV. Weight status and dietary knowledge in the rheumatology out-patient clinic, (A1) 14

- HERRICK AL, FREEMONT AJ, OOGARAGH P, MARCUSON R, JAYSON MIV. IgM anticardiolipin antibodies and vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation, (A2) 50
- HERRICK AL, MARCUSON R, FREEMONT AJ, JAYSON MIV. Clinically normal skin becomes sclerodermatous when transplanted into a sclerodermatous area, 707
- HERRMANN J, HOFMANN G, GLÜCKERT K, STARK W, WIRTZ P, WESELOH G. Osteoarthritis assessment in a working study group, (A2) 122
- HERRMANN J, HOFMANN G, GLÜCKERT K, STARK W, WIRTZ P, WESELOH G. Risk factors of osteoarthritis of the knee, (A2) 119
- HESHMATI F See Menkes CJ
- HEWLETT S, KIRWAN JR. Patient satisfaction with function in rheumatoid arthritis, (A1) 13
- HICKERY MS, BAYLISS MT, HARDINGHAM TE. Proteoglycan biosynthesis in human articular cartilage, (A2) 118
- HICKS C, BILLINGHAM MEJ. Role of persistent mycobacteria in reactivation of experimental arthritis, (A2) 5
- HICKS C See also Billingham MEJ
- High resolution computed tomography (HRCT) of the thorax in patients with rheumatoid arthritis and interstitial lung disease, (A2) 96
- HIGHFIELD P See Ferri C
- HIGHTON J See Poole ES
- HILL J See Astbury C
- HILL JL See Mäki-Ikola O
- HILLARBY MC See McMahon MJ
- HILLIQUIN P, DULIOUST A, MENKES CJ. Paf-acether and T lymphocyte functions in rheumatoid arthritis, (A2) 209
- HILLIQUIN P, JOB-DESLANDRE C, LAZARETH JP, MENKES CJ. Treatment of cutaneous vasculitis with disulone, (A2) 126
- HILLIQUIN P See also Cormier C; Menkes CJ
- HILLSON JL See Kalsi J
- HILSON AJW See O'Mahoney SA
- HILTON I See Hull RG
- Hip
fractures, circumstances around falls, (A2) 151
involvement in generalized osteoarthritis, 325
and knee total replacement bring long term overall benefit in osteoarthritis and rheumatoid arthritis, (A2) 78
osteoarthritis, radiographic progression, (A2) 95
- HIROHATA K See Matsubara T
- HLA
alleles in systemic sclerosis: association with pulmonary hypertension and outcome, 609
class I, class II determinants in rheumatoid arthritis patients in Turkey, (A2) 222
and disease association, noninherited maternal HLA antigens (NIMA) influence occurrence of rheumatoid arthritis, (A2) 84
genes are unimportant in clinically mild rheumatoid arthritis, (A2) 85
9.2KB PvuII RFLP non-association with seronegative spondyloarthropathies in Spain, 743
variants and rheumatoid disease severity, (A2) 8
- HLA-B27, cross reactivity with microbial antigens, 221
- HLA-B27 positive inflammatory rheumatic disease, diagnosis, (A1) 2
- HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1-subtype, (A2) 7
- HLA-DR3, C4A*QO and toxicity from gold in rheumatoid arthritis, (L) 645
- HLA-DR4, gene interactive with in susceptibility to type I diabetes is not involved in rheumatoid arthritis, (A2) 6
- HLA-DR
association with rheumatoid arthritis in three black South African groups, (A1) 12
heterozygosity contributes susceptibility to severe rheumatoid arthritis, (A2) 209
locus has no association with early rheumatoid arthritis, (A2) 85
phenotypes in rheumatoid arthritis disease expression and familiarity, (A2) 189
type, extra and intradural fibrosis and fibrinolysis, (A2) 12
- HLA-DRB allelic variation and rheumatoid arthritis in Zimbabwe, (A2) 8
- HOBBS RN, GOODSTONE NJ, DORAN M, ASHTON BA. Cellular immunity to cartilage link protein, HSP65 and the arthritogenic nonapeptide in patients with inflammatory and non-inflammatory arthritis, (A2) 44
- HOBBS RN, GOODSTONE NJ, DORAN M, JONES CE, MEE JB, ASHTON BA. Autoimmune responses to articular cartilage proteoglycan core protein in patients with inflammatory and non-inflammatory arthritis, (A2) 44
- Hodgkin's disease development in the course of primary Sjögren's syndrome, 561
- HODGSON R See Carpenter TA
- HOFMANN G See Herrmann J
- HOGEGEW M See Markuss M
- HOGG R See Russell P
- HOHLER T, BOTTO M, ROUTIER R, MORLEY BJ, WALPORT MJ. Complement component C3 polymorphisms, simple method for identifying, (A2) 10
- HOLEWIJN M See Wilbrink B
- HOLLINRAKE K See Pugh MT
- HOLLIS S See McMahon MJ
- HOLT I, COOPER RG, DENTON J, MEAGER A, HOPKINS SJ. Cytokine interrelationships and their association with disease activity in arthritis, 725
- HOLT PJL See Donohoe M; Hay EM; John SL; O'Reilly D
- HONE R See Foley-Nolan D
- HOPKINS SJ See Holt I
- HOPKINSON ND, POWELL RJ, DOHERTY M. Autoantibodies, immunoglobulins and Gm allotypes in nodal generalized osteoarthritis, 605
- HOPKINSON ND See also Jones DRE
- Hormone replacement therapy, North Humberstone osteoporosis screening project - one year review of acceptance of hormone replacement therapy (HRT) and its cost to a general practice, (A1) 19
- HORSFALL AC, ROSE LM. Pathogenic effects of maternal autoantibodies in the fetus, (A2) 187
- HORSFALL AC See also Rose LM
- HØRSLEV-PETERSEN K See Hansen M; Stoltenberg M
- HORVÁTH A See Kurth G
- HOSIE G, KIRWAN J. Polymyalgia rheumatica and its treatment in general practice, (A2) 143
- Hospital admissions, acute, non-steroidal anti-inflammatory drug usage and requirement in elderly, 45
- HOUGH D See Whyte J
- HOUSIANAKOU I See Kaskani E
- HOUSIAU F See D'Cruz D
- HOUTMAN PM, STENGER AAME, PASMA HR, SPOELSTRA P. *Pneumocystis carinii* pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis, (A2) 34
- HOVENDEN JL. Non-traumatic *Clostridium septicum* arthritis in a patient with caecal carcinoma, (L) 571
- HOWELL DS, MULLER F, MANICOURT DH. A mini review: proteoglycan aggregate profiles in the Pond-Nuki dog model of osteoarthritis and in canine disuse atrophy, (S1) 7
- HOWELLS GL See Kaul A
- HOYLAND JA, FREEMONT AJ, JAYSON MIV. Endothelial cell changes in uninvolved skin of systemic sclerosis patients, (A2) 198
- HOYLAND JA, THOMAS JT, DONN R, JAYSON MIV, MARRIOTT A, AYAD S, BOOT-HANDFORD RP, GRANT ME, FREEMONT AJ. Chondrocyte collagen metabolism in osteoarthritis, (A2) 70
- HOYLAND JA See also Dean G
- HPA axis anti-inflammatory response, sex hormone influence, (A2) 111
- HSP65, cartilage link protein and the arthritogenic nonapeptide, cellular immunity to in patients with inflammatory and non-inflammatory arthritis, (A2) 44
- HUBER-BRUNING O See Lafeber F
- HÜGE H, MARK S, GROMNICA-IHLE E, SCHNEIDER W. Histopathologic and immunopathologic investigations in primary and secondary Sjögren's syndrome, (A2) 192
Primären und sekundären Sjögren syndrom, (A2) 194
- HUGE H See Franz J
- HUGHES DE See also Salter DM
- HUGHES DE, SALTER DM, SIMPSON R. CD44 expression in human cartilage and bone, (A2) 11
- HUGHES GRV, KHAMASHITA M. Lupus comes of age, 773
- HUGHES GRV See also Ahmed K; Ames DE; Buchanan NMM; D'Cruz DP
- HUGHES J See Lim KL
- HUGHES P See Lindsay N
- HUGHES R. Seronegative arthritis, 771
- HUGHES R See also Salih H
- HUGHES RA, ALLARD SA. Rheumatology in Russia: an opportunity to help, 849
- HUGHES RA, ROWE IF, SHANSON D, KEAT ACS. Septic bone, joint and muscle lesions associated with human immunodeficiency virus infection, 381
- HUGKULSTONE C See Regan M
- HUISSON A See Gough A
- HUITFELDT B See Kirwan JR
- HULL G See Hemsley AG
- HULL RG, HILTON I, DAWSON J. Do patients hear what they are told, (A2) 148
- HULL RG See also Jenkins EA
- Human articular cartilage
age-related changes in tensile properties: comparative study between femoral head and talus of the ankle, (A1) 12
oligonucleotides inhibiting IL-1-induced synthesis of IL-6 prevent IL-1-induced inhibition of proteoglycan synthesis, (A2) 121
- Human calcitonin (hCT), nasal, effects on bone turnover in Paget's

- disease of bone - implications for treatment of other metabolic bone diseases, 35
- Human immunodeficiency virus infection and arthritis in Kigali, Rwanda, (A2) 200
- septic bone, joint and muscle lesions associated with, 381
- Human P55 TNF receptor, structure/function studies on the extracellular domain, (A2) 112
- Human phospholipase AU2u measurement in arthritis plasma using newly developed sandwich ELISA, 175
- Human recombinant manganese superoxide dismutase suppresses disease activity in adjuvant arthritis, (A2) 99
- Human S-antigen autoantibodies have a normal prevalence in juvenile chronic arthritis and are not associated with histone antibodies, (A2) 45
- HUMPHRIES SE See Henney AM
- HUNDER GG See Roche NE
- HUNT N See Gillies JH
- HUNT S See Tennant A
- HUNTER J See Workman E
- HUNTER JA See Murphy EA
- HURLEY MV, O'FLANAGAN SJ, NEWHAM DJ. Muscle strength and inhibition in rheumatoid arthritis patients and following Souter-Strathclyde elbow arthroplasty, (A2) 225
- HUSBY G, KVIEEN TK. Epidemiology of NSAID effects and side effects, (A2) 250
- HUSSAIN W, WATKISS S, MALLOY N, BUTLER S, SITUNAYAKE RD. Satisfaction, knowledge and compliance in a rheumatology outpatient clinic, (A2) 149
- HUSTON GJ, DEANER AN, NAYLOR JR. Test/inform/retest: useful technique in undergraduate rheumatology teaching, 49
- HUTCHISON DCS See Wasil M
- Hyaluronan concentration in synovial fluid, intra-articular corticosteroid effects, (A2) 21
- Hyaluronan synthase distribution in synovium, (A1) 11
- Hyaluronic acid, efficacy and safety of different dose-schedules of intra-articular injections in painful and hydrarthroidal osteoarthritis of the knee, (A2) 127
- HYDER E See Salih H
- Hydrocortisone treatment of rheumatoid hand synovitis using a regional block technique, (A1) 29
- Hydrotherapy, a 12 weeks clinical trial to the effect of hydrotherapy in a thermominal institution compared with hydrotherapy in a hospital-exercise-bath in patients with rheumatoid arthritis, (A2) 31
- HYER RN See Pile KD
- HYLTON W, SMITH-BURCHNELL C, PELTON BK, PALMER RG, DENMAN AM, MALKOVSKY M. Polyclonal origin of rheumatoid synovial T-lymphocytes, 55
- Hyperuricaemia
- apoprotein C in, (A2) 21
- risk factors associated to: a case control study, (A2) 222
- Hypoadrenalism, adrenal infarction and splinter haemorrhages in the primary antiphospholipid syndrome, 117
- Hypothalamic-pituitary-adrenal (HPA) axis defective regulation in rheumatoid arthritis is not a consequence of chronic inflammation per se, (A2) 28
- Hypothyroidism and thyroid antibodies in polymyalgia rheumatica, (L) 214
- 123-I labeled serum amyloid P component scan significance, (A2) 138
- IAGNOCO A See Coari G; Sorgi ML
- IANNONE F, DASGUPTA B, KINGSLEY GH, PANAYI GS. Selective cytotoxic T cell (CD8+CD28+) decrease in peripheral blood in idiopathic inflammatory myopathies, (A2) 42
- IASCONE C See Sorgi ML
- Ibuprofen
- influence of dosing times on clinical response to sustained-release Brufen Retard in patients with rheumatoid arthritis, (A2) 159
- influence of sustained-release (Brufen Retard) on mobility of the spine in patients with osteoarthritis of the hip, (A2) 122
- nabumetone and combination of ibuprofen and misoprostol in osteoarthritic patients, (A2) 165
- Idiopathic inflammatory myopathy
- clinopathological observations in the Indian population, 835
- selective cytotoxic T cell (CD8+CD28+) decrease in peripheral blood in, (A2) 42
- IDLE JR See Beyerle C
- IgG
- glycosylation and galactosyltransferase-associated protein kinase gene structure in autoimmune strains of mice, (A2) 47
- and IgA antibody responses against porins in *Yersinia*-triggered reactive arthritis, 315
- IgA and IgM glycosylation in immunoglobulin heavy and light chains and immune complexes from patients with rheumatoid arthritis, (A2) 52
- subclass distribution of auto-antibodies in patients with autoimmune rheumatic diseases, (A2) 52
- IGLESIAS E See Arnalich F
- IgM anticardiolipin antibodies and vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation, (A2) 50
- IgM-rheumatoid factors measured by ELISA in non-rheumatoid sera: comparison of human and rabbit Fc fragments as antigens, (L) 141
- IL2 receptor
- P75 chain quantitation on RA mononuclear cells, (A2) 208
- soluble in polymyalgia rheumatica and giant cell arteritis (PMR/GCAG), and during prednisolone treatment per se, (A1) 7
- IL-1 secreting cell assay and its application to cells from patients with rheumatoid arthritis, 19
- IL-1beta effect on proteoglycan metabolism in mature equine cartilage *in-vitro*, (A2) 117
- IL-2 effects on *in vitro* rheumatoid factor production, (A2) 26
- IL-6 in synovial fluid is raised in early experimental osteoarthritis, (A2) 214
- ILIĆ S See Deljanin Ilić M
- ILLINGWORTH KJ See McMahon MJ
- Iloprost, a prostacyclin analogue, pilot study with oral in patients with Raynaud's syndrome and systemic sclerosis, (A2) 55
- Imaging, 129
- IMERYÜZ N, YAZICI H, KOÇAK H, ERK M, ÖDER A, KARCIER SM, ÖZKAN M, YURDAKUL S, ÖZDOĞAN H. Pericardial involvement in rheumatoid arthritis in Turkey, (A2) 223
- Immune complexes directly activate platelets and neutrophils causing an increase in endothelial permeability, (A2) 98
- Immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease, 735
- Immunisation, arthritis following: a report of 21 cases, (A2) 116
- Immunogenetics of rheumatoid arthritis and the Arthritis and Rheumatism Council's National Repository, 701
- Immunoglobulin E levels in ankylosing spondylitis, (A2) 198
- Immunoglobulins
- and Gm allotypes in nodal generalized osteoarthritis, 605
- total, and specific antibodies to self gut bacteria in ankylosing spondylitis, (A2) 48
- Immunolocalisation of adhesion molecules in synovium and skin in psoriatic arthritis, (A2) 89
- Immunology of inflammatory arthritis, 131
- IMURA S See Shiozawa K
- In vitro* investigation of the free radical scavenging effects of tenidap, a new anti-inflammatory drug, (A1) 28
- INANÇ M See Dilşen N; Konice M; Mege L
- Independence in young people with arthritis, (A2) 149
- India, rheumatologist in, 113
- Indomethacin
- comparison with nabumetone on human gastric morphology and blood flow, (A2) 166
- depression on withdrawal, (L) 211
- and diclofenac, comparative clinical trial in patients with rheumatoid arthritis, (A2) 172
- nabumetone compared with in treatment of osteoarthritis in general practice, (A2) 166
- and nabumetone effects on human gastric bicarbonate secretion *in vivo*, (A2) 167
- and nabumetone general practice comparison in the treatment of osteoarthritis, (A2) 168
- proteoglycan synthesis is induced by azapropalone and inhibited by indomethacin in patients with osteoarthritis of the knee, (A2) 201
- therapy of inflammatory rheumatic joint diseases, (A2) 176
- Inflammatory activity evaluation in rheumatoid arthritis: comparison of MR contrast enhanced imaging with clinical findings, (A2) 210
- Inflammatory arthritis
- frequency of DR4 and DR1 in newly diagnosed cases of rheumatoid arthritis and inflammatory arthritis found in a population survey, (A2) 84
- immunology, 131
- kinins as key mediators, 509
- Inflammatory rheumatic joint diseases, therapy with acemetacin and indomethacin, (A2) 176
- Infrared thermography, what is its place in rheumatology in the 1990s, 337, (L) 857
- INGLESE P See Scagliusi P
- Injection techniques, intra-articular and soft tissue: an audit of practice, (A1) 29
- Injection therapy of superficial rheumatoid nodules, 775
- Inpatient facility use comparison between two similar rheumatology units, (A2) 74
- Insulin-like growth factor 1
- effect of age accounts for apparent correlation with sclerosis and osteophysis in osteoarthritis of the knee, (A2) 213 2

- levels are normal in knee osteoarthritis and low in DISH. (A2) 71
- Integrin expression by human articular chondrocytes, 231
- Interferon gamma production and T cell proliferation inhibition by minocycline after stimulation with anti-CD3 monoclonal antibodies. (A2) 41
- Interleukin-1 receptor antagonist
blocks interleukin-1-induced synovitis, but not antigen-induced arthritis in the rabbit. (A2) 114
differentially regulates both *in vivo* and *in vitro* serum amyloid and fibrinogen expression. (A2) 213
- Interleukin-1 α , type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis, 801
- Interleukin-1 β , tumour necrosis factor alpha and transforming growth factor-beta effects on the induction of cartilage resorption by ATP. (A2) 22
- Interleukin-6 production in patients with giant cell arteritis and polymyalgia rheumatica: comparison of serum levels and production by peripheral blood lymphocytes. (A2) 212
- Intermittent hydrostatic compressive force stimulates exclusively the proteoglycan synthesis of osteoarthritic human cartilage, 437
- INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE. Diagnostic (classification) criteria evaluation in Behçet's disease - towards internationally agreed criteria, 299
- Intra-articular corticosteroid effects on hyaluronan concentration in synovial fluid. (A2) 21
- Intra-articular and soft tissue injection techniques: an audit of practice. (A1) 29
- Intra-articular steroid for knee synovitis: to rest or not to rest. (A2) 81
- Intranasal synthetic salmon calcitonin use in treatment of reflex sympathetic dystrophy stage I. (A2) 80
- Intravenous drug abusers, osteoarthral infection in. A ten years experience. (A2) 79
- Investigation of the utility of ovine nasal mucosa *in vitro* for evaluating the elcatonin formulation component ammonium glycyrrhizate. (A2) 231
- Iron
increased stores, possible downregulating effects on erythropoietin responsiveness in rheumatoid arthritis. (L) 212
intravenous administration, absence of rheumatoid synovitis flares after. (A2) 33
- Itemazole, dose-response relationship of the uricosuric drug: double-blind multicentric trial. (A2) 133
- IRVINE AE See Magill M
- ISAACS JD See Watts RA
- ISDALE A See Dearlove SM
- ISDALE AH, IVESON JM. Synovial cysts and sarcoid synovitis, 497
- ISDALE AH See also Dekker PJ
- ISENBERG D See Bourke ME; Ehrenstein MR; Longhurst C
- ISENBERG DA. Autoantibodies and disease, what do the results mean. (A2) 254
- ISENBERG DA See also Black C; Blanco F; Dhillon VB; Ehrenstein MR; Erkeller-Yuksel FM; Kalsi J; Menon S; Walport MJ
- ISMAEL S, ATKINS RM, PEARSE MF, DIEPPE PA, ELSON CJ. Articular cartilage, susceptibility of normal and arthritic human to degradative stimuli, 369 3
- Isolated angitis of the central nervous system. (A2) 232
- Isotype switch in the generation of human monoclonal anti-DNA antibodies from a patient with SLE. (A2) 49
- ITO H See Nishikai M
- IVESON JM See Isdale AH 4
- JABBARIN A See Nahir AM
- JACKSON G See Mishra M
- JACOBI E See Jaekel WH
- JACOBS JWG See van der Heide A; Weusten BLAM
- JACOBS PJC See Haanen HCM
- JACOBS R See Waller A
- JAECKEL WH, GERDES N, CZISKE R, JACOBI E. Rheumatic symptoms in the general population - physical and psychosocial impact. (A2) 78
- JALAL MZ, MAHMOOD IH, AL-HAMAMI FA. Comparative clinical trial of indomethacin and diclofenac in patients with rheumatoid arthritis. (A2) 172
- JAMES D See Gallivan S
- JAMES IM, WYNN PARRY CB. Performing arts medicine. (E) 795
- JAMES IT, HALL GM, THOMPSON PW, PERRETT D. Increased levels of urinary collagen cross links in females with rheumatoid arthritis. (A2) 27
- JAMES IT See also Thompson PW
- JAMES MF See Byrne JM; Carpenter TA
- JANIN A See Duquesnoy B
- JANSSEN M, DIJKMANS BAC, LAMERS CBHW, ZWINDERMAN AH, VANDENBROUCKE JP. Prospective study by gastroscopy of the predictive value of supposed risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. (A2) 31
- JANSSEN BA, GOUGH A, WINKLES J, EMERY P. Neopterin level reduction in both spontaneous and drug-induced remission in rheumatoid arthritis. (A2) 29
- JANSSEN EM See Barrera P
- JANSSEN M, DIJKMANS BAC, VAN DER SLUYS FA, VAN DER WIELEN JGB, HAVENGA K, VANDENBROUCKE JP, LAMERS CBH, ZWINDERMAN AH, CATS A. Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases, 747
- JARH O See Jevtić V; Rozman B
- JASANI MK See Buckland-Wright JC
- JASZEWSKI R See White R
- JAULHAC B See Pourel J
- JAYSON MIV See Cooper RG; Dean G; Gush RJ; Herrick AL; Hoyland JA; Jeracitano D; McMahon MJ
- JEDDI PA, SUMAR N, BODMAN K, LUND T, POUNCEY L, HEATH L, KIDD VJ, DELVES PJ. Galactosyltransferase-associated protein kinase gene structure and IgG glycosylation in autoimmune strains of mice. (A2) 47
- JEHANNE M See Pertuiset E
- JENKINS EA, HULL RG. District paediatric rheumatology clinics: the requirements for supporting services. (A1) 17
- JENKINS EA, WOOD A, HULL RG, MCCRAE FM, THOMAS AL. What happens on a rheumatology ward. (A2) 147
- JENKINSON C See Fitzpatrick R; Mowat A
- JERACITANO D, COOPER RG, LYON LJ, JAYSON MIV. Abnormal temperature control suggesting sympathetic dysfunction in the shoulder skin of patients with frozen shoulder, 539
- JEUGMANS-HUYNEN AM See Register JY
- JEURISSEN M See Kerstens P
- JEVTIĆ V, ROZMAN B, KOS-GOLJA M, DEMŠAR F, JARH O, CAMPION G, MUŠIČIĆ P, WATT I. Contrast enhanced MRI of hand joints in rheumatoid arthritis, seronegative spondyloarthritis and erosive osteoarthritis. (A2) 138
- JEVTIĆ V See also Rozman B
- JIMINEZ SA See Varga J
- JOB-DESLANDRE C See Hilliquin P
- JOHN SL, MORGAN K, TULLO A, HOLT PJJ. Autoantibodies to the cornea in patients with corneal melt in association with autoimmune systemic disease. (A2) 51
- JOHNSTON C See Juby A
- Joint
mobility, musculoskeletal pain relationship in Omanis, 81
replacements, cancelled: the multidisciplinary approach to closing the audit loop. (A1) 16
tenderness measurement, validation of electronic method for measuring in rheumatoid arthritis. (A2) 76
- Joint hypermobility, 205
high prevalence in rural Nigerian population. (A2) 63
- Joint hypermobility syndrome
bone mineral density. (A2) 64
cardiac abnormalities. (A2) 63
collagen gene segregation analysis in two families, 169
- Joint injuries caused by sporting activities, nabumetone treatment. (A2) 162
- JONES A, BARTON N, PATRICK M, DOHERTY M. Tophaceous pyrophosphate deposition with extensor tendon rupture, 421
- JONES A See also Samanta A
- JONES AC, BERMAN P, DOHERTY M. Non-steroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions, 45
- JONES AKP. Pain centre existence. (E) 290
- JONES CE See Hobbs RN
- JONES DRE, HOPKINSON ND, BISHOP S, RICHARDS NP, POWELL RJ. Autoantibodies in pet dogs owned by patients with systemic lupus erythematosus. (A1) 4
- JONES JG. Rheumatoid arthritis nodules as result of manual work. (L) 143
- JONES JG See also Ching DWT
- JONES MG, ROBERTSON JF, BOND A, HAY FC. Glycosylation of IgG in the collagen induced model of arthritis. (A2) 53
- JONES MG See also Bond A
- JONES PB, FAKHOURY RJ, WEISS JB. Increased levels of angiogenesis factor activity correlate with inflammatory index in ankylosing spondylitis. (A2) 12
- JONES S See Fordham JW; Pugh MT
- JONSSON A See Forslind K
- JORDANA-COMAJUNCOSA R See Simeon-Aznar CP
- JUBY A, JOHNSTON C, DAVIS P, RUSSELL AS. Antinuclear and antineutrophil cytoplasmic antibodies (ANCA) in sera of patients with Felty's syndrome, 185
- JULIS I See Podrazký V
- JUNCA J, TURAL C, CUXART A, OLIVÉ A. Anti-intrinsic factor antibodies in systemic lupus erythematosus. (A2) 49
- JUPP RA See Farrell AJ

- Juvenile arthritis
and coeliac disease, (L) 791
ophthalmological screening, should the frequency of screening be based on the risk of developing chronic iridocyclitis, 633
- Juvenile chronic arthritis
human S-antigen autoantibodies have a normal prevalence in and are not associated with histone antibodies, (A2) 45
is there a disease-modifying drug, 635
sensorineural hearing loss, 711
seronegative, ophthalmological screening in: a personal view, 631
and Wegener's granulomatosis, 121
- Juvenile onset arthritis, collagen autoantibodies in, (A2) 46
- Juvenile rheumatoid arthritis
biological indices of the inflammatory activity - comparative valuation, (A2) 113
chloroquine-induced vitiligo, (L) 790
- KAFEDJISKA I See Gričkov M
- KAINULAINEN K See Child A
- KALLENBERG CGM. Anti-neutrophil cytoplasmic antibodies and vasculitis, (A2) 255
- KALSI J See Longhurst C
- KALSI JT, RAVIRAJAN C, WINSKA WLOCH H, MULLER S, OPLIGER I, HILLSON JL, ISENBERG DA. Analysis of three new idiotypes associated with lupus autoantibodies, (A2) 195
- KALSI JT See also Blanco F
- KALTWASSER JP, KIRSCHFINK M, WIGAND R, GOTTSCHALK R. Complete functional C1q-deficiency and SLE: a case report, (A2) 195
- KAMAGUTI-YAMAGA A See Hay EM
- KAMEL M, SERAFI T, BASSIOUNI HM. Clinical and laboratory outcomes of L-fucose treatment in rheumatoid arthritis, (A2) 205
- KAMILLI I, GRESSER U, HAHN D, VOGL T, ZÖLLNER N. Urate deposition: scintigraphy and magnetic resonance imaging, (A2) 135
- KAMILLI I See also Gresser U; Rauh G
- KAMINSKY P, WALKER P, ROBIN-L'HERBIER B, FENER P, ESCANYÉ JM, POUREL J. ³¹P-NMR spectroscopy in myotonic dystrophy, (A2) 203
- KANDOUSSI M See Duquesnoy B
- KANIS JA. Use of intranasal calcitonin in treatment of algodystrophy, 568
- KAPAH P See Mason JC
- KARCIER SM See İmeryüz N
- KARIM SN See Murphy EA
- KARRAS D See Galatas ID
- KASKANI E, HOUSIANAKOU I, PATRIKOS D, MARAGOU M, RONDOGIANNI PH, ALEVIKAKI C, KESSE-ELIA M, DANTIS P. Serum type III procollagen peptide levels in patients with systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis, (A2) 227
- KATRAK CA See Kelly CA
- KATSIKIS P See Deleuran BW
- KATZ DR. Arthritis and Rheumatism Council fellowships, 797
- KAUL A, MACEY M, BLAKE DR, HOWELLS GL, STEVENS CR, WILLIAMS DM. GMP-140 expression is transiently induced by hypoxia on human endothelial cells, (A2) 99
- KAY EA, PULLAR T. Variations amongst rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs, 477
- KEAN WF See Bellamy N
- KEARNEY M See Foley-Nolan D
- KEAT A See Salih H
- KEAT ACS See Hughes RA
- KEELING D See Ehrenstein MR
- KEELING DM See Dhillon VB
- KEEN JH See O'Reilly D
- KELLY C See Foster H
- KELLY CA, KATRAK A, GRIFFITHS ID. Pancreatic function in patients with primary Sjögren's syndrome, (A1) 5
- KELLY CA, McDONAGH J, OWEN JP. High resolution computed tomography (HRCT) of the thorax in patients with rheumatoid arthritis and interstitial lung disease, (A2) 96
- KEMPSON GE. Human articular cartilage, age-related changes in tensile properties: comparative study between femoral head and talus of the ankle, (A1) 12
- KENNEDY LG See Calin A
- KENT C See Pugh MT
- KERSTENS P, BOERBOOMS A, LAMBOOY L, JEURISSEN M, DE ABREU R, VAN DE PUTTE L. Association of purine enzyme levels and response to azathioprine in rheumatoid arthritis, (A2) 207
- KESSE-ELIA M See Kaskani E
- KESSLER M, NETTER P, AZOULAY E, MAYEUX D, PERE P, GAUCHER A. Dialysis-associated arthropathy: multicentre survey of 171 patients receiving haemodialysis for over 10 years, 157
- KHALIL Z See Reilly PA
- KHAMASHTA M See D'Cruz D; Hughes GRV
- KHAMASHTA MA See Ahmed K; D'Cruz DP
- KHAN A See Fordham JW
- KHOKHER MA, DONNELL D. Effects of Nefopam hydrochloride on human chondrocyte metabolism in vitro, (A2) 70
- KHURANA K See Abraham DJ
- KIDD BL, CAWLEY MID. HLA B27 positive inflammatory rheumatic disease, diagnosis, (A1) 2
- KIDD VJ See Jeddi PA
- KILL DC See Carle WK; Emery P; Wade AG
- KILPATRICK M See Rai A
- KIMURA T See Matsubara T
- KING V See Vecchio P
- KINGSLEY G See Chikanza IC
- KINGSLEY GH See Chieco-Bianchi F; Choy EHS; Iannone F
- KINIKLI G, KURTAŞ Y, TURGAY M, YLAÇIN P, ARASIL T. HLA class I, class II determinants in rheumatoid arthritis patients in Turkey, (A2) 222
- Kinins, key mediators in inflammatory arthritis, 509
- KIRBY DS See Loose LD
- KIRK F See Magill M
- KIRKHAM B See Tratkiewicz J
- KIRSCHFINK M See Kaltwasser JP
- KIRWAN J See Creamer P; Cushnaghan J; Hosie G
- KIRWAN JR, EDWARDS A, HUITFELDT B, THOMPSON PW, CURREY HLF. Course of established ankylosing spondylitis and effects of sulphasalazine over 3 years, (A2) 82
- KIRWAN JR, SNOW S, YOUNG PJ, FREEMAN MAR, CURREY HLF. Total hip and knee replacement bring long term overall benefit in osteoarthritis and rheumatoid arthritis, (A2) 78
- KIRWAN JR See also Hewlett S; McAlindon TE
- KISHIDA T See Shiozawa K
- KISSONERGHIS A-M See Corcoran AE
- KITA M See Shiozawa K
- KITCHIN P See di Giovine FS
- KLADNY B See Glückert K
- KLEIN G, KULLICH W. Ergebnisse einer randomisierten, doppelblinden 1-Jahresstudie mit oralen Enzymen im Vergleich zur oralen Goldtherapie bei Patienten mit chronischer Polyarthritis, (A2) 133
- KLEIN G See also Kullich W
- KLEMP P. Anticardiolipin antibodies and a severe subset of systemic lupus erythematosus, (L) 567
- KLEMP P See also Ching DWT
- KLINKHOFF A See Atkins CJ
- KLOPPENBURG M, MILTENBURG AMM, VERDONK MJA, DAHA MR, BREEDVELD FC, DIJKMANS BAC. Minocycline inhibits T cell proliferation and interferon gamma production after stimulation with anti-CD3 monoclonal antibodies, (A2) 41
- Knee
chronically inflamed joint, plasma xanthine oxidase activity increases on exercise, (A2) 220
degenerative joint disease, subchondral bone changes leading to, (A2) 120
human rheumatoid, vascularity assessment and angiogenesis in the synovial lining, (A2) 98
medial and lateral cartilage in rat, differences between magnetic resonance appearance, (A2) 136
pain and disability in community, 189
pathology of rat, magnetic resonance imaging and the effects of treatment: a longitudinal study, (A2) 136
study of rheumatoid by arthro-CT, (A2) 137
total arthroplasty, infection due to *Gemella haemolysans*, 67
- Knee joint
acute trauma, changes in glycosaminoglycan epitopes on proteoglycans in synovial fluids, (A2) 117
MRI with measurement of cartilage signal intensity and relaxation times to determine different stages of cartilage hydration - a future aspect to identify human early osteoarthritis, (A2) 139
- KOÇAK H See İmeryüz N
- KOCHMAN RL, GEIS GS, GAGNIER RP, STEAD H. Long-term efficacy and safety of arthrotec in patients with rheumatoid arthritis, osteoarthritis or ankylosing spondylitis, (A2) 179
- KONİÇE M, İNANÇ M, DİLŞEN N, ARAL O, ÖCAL L, DIŞÇI R. Systemic lupus erythematosus in Turkey: a survival study, (A2) 200
- KONİÇE M See also Dilşen N
- KOOL J, NABER FB, MEINDERSMA J, ALDWINCKLE TJ. Efficacy and tolerability of sustained-release flurbiprofen (Froben SR, Foben Suscap) in arthritis: general practice studies in the UK and Holland, (A2) 160
- KOPPESCHAAR HPF See van den Brink HR
- KOS-GOLJA M See Jevtić V; Rozman B
- KOSKI JM.
Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica, 201
Ultrasonography of the subtalar and midtarsal joints, (A2) 135
- KÖTTER I See Dürk H
- KOTZE TJ See Roelofs JA
- KOUNTOURAS J See Boura P
- KOYAMA K See Yoshida A

- KRAAG GR See Bellamy N
- KRAJNC I, BOHAR F, TÜRK Z, BAROVIĆ J, NIKOLIĆ-KOPSA I, DRINOVCÉ J, NIKOLIĆ T. Control study of effect of balneotherapy on low-back pain disease, (A2) 121
- KRAKA AR See Loose LD
- KRAUS A. Muscular involvement in systemic rheumatoid vasculitis, (L) 355
- KRISCHER U See Laitko S
- KRÜGER K, SCHATTENKIRCHNER M, PETERSEN AK, SHAND N. Long-term treatment of rheumatoid arthritis with cyclosporin A, (A2) 128
- KUBICKA-MURANYI M See Gleichmann E
- KUCHARSKA E See Fiedorowicz-Fabrycy I
- KULLICH W, KLEIN G. Bewirkt eine Enzym- oder Goldtherapie bei chronischer Polyarthritis Veränderungen immunologischer Parameter, (A2) 132
- KULLICH W See also Klein G
- KUMAR A See Singh YN
- KUMARATNE DS See Sheeran T
- KURODA T See Matsubara T
- KURTAIS Y See Kinkli G
- KURTH G, BALOGH Z, TANKA D, REVICZKY A, HORVÁTH A, BERGMANN A, TORMA O, GÁSZ A. Measurement of synovial fluid cell cartilage degradation capacity with ^{35}S , (A2) 113
- KVIEN TK See Husby G
- KWAN JTC See Wedderburn LR
- KWAN TH See Lee SS
- LACKI J See Fenrych W
- LA CIVITA L See Ferri C
- LA CORTE R, MENEGALE G, BEZZI A, GAMBERINI S, SCAGLIARINI G, CANAZZA S, PAZZI P, TROTTA F. *Helicobacter pylori* infection and gastric damage in arthritic patients taking anti-inflammatory drugs, (A2) 204
- LA CORTE R See also Canazza S; Govoni M
- LA GAMBA MR See Bartolone S
- LAAN R, VAN RIEL P, VAN DE PUTTE L. Short term effect of low dose prednisone therapy on disease activity and functional capacity in patients with rheumatoid arthritis, (A2) 32
- LAAN R, VAN RIEL P, VAN LAARHOVEN J, VAN ERNING L, LEMMENS A, RUIJS S, BENRAAD TH, VAN DE PUTTE L. Short term effect of low dose prednisone therapy on bone metabolism and lumbar mineral density in patients with rheumatoid arthritis, (A2) 33
- LAAN RFJM. Vertebral osteoporosis in rheumatoid arthritis patients: effects of low dose prednisone therapy, (L) 573
- LAAN RFJM, VAN RIEL PLCM, VAN ERNING LTHO, LEMMENS JAM, RUIJS SHJ, VAN DE PUTTE LBA. Osteoporosis, vertebral in rheumatoid arthritis patients: effect of low dose prednisone therapy, 91
- LÁNYI E. Bone mineral density values in the Hungarian population: a comparative DEXA study, (A2) 142
- LABORDE C See Ghozlan R
- Lactoferrin and cytidine deaminase in inflammatory synovial fluids. Indicators of local polymorphonuclear cell function, 235
- LAFFEBER F, VELDTHUIZEN JP, VANROY JLAM, HUBER-BRUNING O, BULSMA JWI. Intermittent hydrostatic compressive force stimulates exclusively the proteoglycan synthesis of osteoarthritic human cartilage, 437
- LAFont A See Pérez-Edo L
- LAHESMAA R, SKURNIK M, GRANFORS K, MÖTTÖNEN T, SAARIO R, TOIVANEN A, TOIVANEN P. Molecular mimicry in pathogenesis of spondyloarthropathies. Critical appraisal of cross-reactivity between microbial antigens and HLA-B27, 221
- LAHESMAA R See also Mäki-Ikola O
- LAIDLAW DAH. Steroid treatment in giant cell arteritis, (L) 431
- LAITKO S, KRISCHER U. Whipple's disease - a differential diagnostic challenge, (A2) 232
- LAMBERT CM. Hand and upper limb problems of instrumental musicians, 265
- LAMBOUY L See Kerstens P
- LAMERS CBH See Janssen M
- LAMERS CBHW See Jansen M
- LAMEY P See Brookes SM
- Laminin P1 levels in lupus nephritis, (A2) 58
- LAMONT IL See Poole ES
- LAN JL, WU CH. Detection of *Mycobacterium tuberculosis* antigen in synovial fluid of patients with rheumatoid arthritis, 615
- LANCHBURY J See Chikanza IC
- LANCHBURY JS See Pile KD
- LANDEWÉ RBM, MILTENBURG AMM, VERDONK MJ, BREEDVELD FC, DAHA MR, DIJKMANS BAC. Cyclosporine and chloroquine synergistically inhibit the proliferation of T-cell clones: cyclosporine interferes with interleukin 2 production whereas chloroquine inhibits interleukin 2 responsiveness, (A2) 27
- LANDEWÉ RBM, PEETERS R, MASEK BA, VERREUSEL RLP, GOEI HS. A 12 weeks clinical trial to the effect of hydrotherapy in a thermal institution compared with hydrotherapy in a hospital-exercise-bath in patients with rheumatoid arthritis, (A2) 31
- LANDTHALER M See Rauh G
- LANGER M, BÖRNER D, RICHTER B. Penetration kinetics of etofenamate in pig skin after topical application of rheumon cream, Methodology and in vitro results, (A2) 158
- LANGEVITZ P, BUSKILA D, GLADMAN DD, DARLINGTON GA, FAREWELL VT, LEE P. HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome, 609
- LANYI E, SCHADEN W, FEINENDEGEN LE. Hashimoto's disease and rheumatoid arthritis, (A2) 232
- LAOUSSADI S See Menkes CJ
- LARBRE J-P, FOURNIER S, PERRET P, LLORCA G. Relapsing polychondritis or Coxsackie infection, (A2) 231
- LARBRE J-P, PERRET P, FOURNIER S, LLORCA G. Toxicity of sulfhydryl compounds in rheumatoid arthritis: results of meta-analysis, (A2) 132
- LARBRE J-P See also Moore AR
- Laser
- Doppler flowmetry and transcutaneous oxygen tension electrodes to assess local autonomic dysfunction in epicondylitis, (A1) 22
- therapy, low powered for rheumatoid arthritis, (A2) 81
- treatment of rotator cuff tendinitis, (A2) 61
- LATCHMAN D See Longhurst C
- LAU CS, BRIDGES AB, MUIR A, SCOTT N, BANCROFT A, BELCH JFF. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon, 375
- LAU CS, McLAREN M, WALKER M, FORBES CD, BELCH JFF. Baseline plasma fibrinolysis in 164 patients with Raynaud's phenomenon, (A1) 20
- LAU CS, MORLEY KD, MUIR A, BELCH JFF. Lack of correlation between red cell membrane essential fatty acid concentration and disease activity variables in patients with rheumatoid arthritis, (A1) 28
- LAU CS See also Belch JFF
- LAU EMC See Symmons DPM
- LAVABRE C. Erythema multiforme after intradural injection of prednisolone acetate, (L) 717
- LAWTON JWM See Lee SS
- LAXTON AH See Gillies JH
- LAY CS, BELCH JFF. *In vitro* investigation of the free radical scavenging effects of tenidap, a new anti-inflammatory drug, (A1) 28
- LAZARETH JP See Hilliquin P
- LEAK A See Edelsten C
- LEAK AM. Ophthalmological screening in seronegative juvenile chronic arthritis: a personal view, 631
- LEAKER B See Ehrenstein MR
- LEBRANCHU Y See Mason JC
- LEDINGHAM J, DAWSON S, PRESTON B, DOHERTY M.
- Radiographic patterns of hip osteoarthritis, (A1) 18
- Radiographic progression of hip osteoarthritis, (A2) 95
- LEDINGHAM JM. Amyloid arthropathy complicating myelomatosis: successful treatment with radiosynovectomy, (L) 718
- LEE P See Langevitz P
- LEE RD See Attnold MM
- LEE SS, LAWTON JWM, CHAN CE, LI CS, KWAN TH, CHAU KE. Antilactoferrin antibody in systemic lupus erythematosus, 669
- LEFFERS P See Blaauw AAM
- Left ventricular diastolic dysfunction in ankylosing spondylitis: correlation with disease severity, (A2) 74
- LEMMENS A See Laan R
- LEMMENS JAM See Laan RFJM
- LENOIR G See Pertuiset E
- Lentiviral sequences, failure to detect in rheumatoid arthritis patients, (A2) 204
- LEONG WS, RUSSELL RGG, CASWELL AM.
- Effects of interleukin 1beta, tumour necrosis factor alpha and transforming growth factor-beta on the induction of cartilage resorption by ATP, (A2) 22
- Extracellular ATP and tumour necrosis factor alpha interact in stimulating the production of prostaglandin E by human articular chondrocytes, (A2) 22
- LEWTHWAITE JC, HARDINGHAM TE, HENDERSON B. Interleukin-1 receptor antagonist blocks interleukin-1-induced synovitis, but not antigen-induced arthritis in the rabbit, (A2) 114
- LEWTHWAITE JC See also Noble DP
- LI CS See Lee SS
- LI SONGHUA See Chen Jifan
- LIAO T-S See Yu C-L
- LIENCE E See Fernandez-Cortijo J
- LILLEY J See Gough A
- LILLIE C See Dowling EJ
- LIM K See Chakravarty KJ
- LIM KL. *Pneumocystis carinii* pneumonia following immunosuppressive therapy in systemic lupus erythematosus, (L) 643
- LIM KL, ABDUL-WAHAB RA, HUGHES J, BROWN NS, POWELL RJ. Is urine neopterin an indicator of disease activity in patients with systemic

- lupus erythematosus - comparison with ESR and C3 degradation products, (A2) 56
- LIMA J, FONOLLOSA V, FERNANDEZ-CORTIJO J, CASTRO A, MARSAI S, ROSELLÓ J, SIMEON C, ESPINACH J, ALONSO F, VILARDELL M. Prostacyclin-thromboxane unbalance in systemic sclerosis patients: a possible role in endothelial damage, (A2) 15
- LIMA J *See also* Fernandez-Cortijo J
- LIMBURG PC *See* van Rijswijk MH
- LIN W-M *See* Yu C-L
- LINDSAY N, HENDERSON F, MALIA R, GREAVES M, HUGHES P. Serum masks inhibition of thrombin-induced prostacyclin release produced by anticardiolipin antibodies, 179
- Link protein N-terminal peptide is taken up and degraded by monocytes, B-cells and chondrocytes, (A2) 197
- Lipocortin, what is it and what does it mean, (E) 506
- LIPSKY PE. Adhesion molecules - can we stop cells getting into joints, (A2) 235
- LITTLEJOHN GO *See* Reilly PA
- LIU W-H. Renal vein thrombosis in Chinese systemic lupus erythematosus with high titre anticardiolipin antibody, (L) 787
- LLORCA G *See* Larbre J-P
- LLOYD DB. Depression on withdrawal of indomethacin, (L) 211
- LÓPEZ E *See* Pascual E
- LÖFFLER W *See* Hatz HJ
- LOGAR D *See* Rozman B
- LOHMANN SIEGEL K *See* O'Connell PG
- LOIZOU S *See* Fong KY; Mackworth-Young CG
- Long-term second-line treatment: prospective drug survival study, 253
- LONGHURST C, RAVIRAJAN C, WINSKA-WILOCH H, KALSI J, LATCHMAN D, ISENBERG D. VH gene usage in human/human hybridoma derived monoclonal antibodies from SLE patients, (A2) 215
- Longitudinal study of pulmonary function in patients with rheumatoid arthritis treated with gold and D-penicillamine, 829
- LONGOMBARDO G *See* Ferri C
- LOOSE LD, SIPE J, KIRBY DS, KRASKA AR, WEINER ES, SHANAHAN WR, FARROW P. Inhibition of acute phase protein production by tenidap - new antirheumatic agent, (A2) 257
- LOOSE LD, SIPE JD, BARTLE L. Modulation of acute phase proteins by tenidap, (A2) 175
- LOOSE LD *See also* Rokita H; SiPE JD
- LOPES VAZ A *See* Costa L; Pinto MJ; Quevedo V; Vaz C
- LOPEZ A *See* Dreiser RL
- LORENZEN I *See* Hansen M; Stollenberg M
- LOUISOT P *See* David MJ
- LOUTHRENOO W *See* Boonsaner K
- Low back pain
control study of effect of balneotherapy on disease, (A2) 121
risk factors in women, (A2) 62
- Low back pain, acute
objective functional assessment of tenoxicam, (A2) 153
tenoxicam in: an open comparative study versus diclofenac, (A2) 155
- Low back pain, chronic
effects of back school, (A2) 147
radiographic demonstration of paraspinal muscle wasting, 389
- Lp (a) increased levels in patients with systemic sclerosis, (A2) 17
- LUESLEY D *See* Sheeran T
- Lumbar spine mobility variation measured over a 24-hour period, 329
- Lumbar syndrome, magnetotherapy in, (A2) 116
- LUNARDI C, MARGUERIE C, SO AKL. Evidence for restricted T-cell receptor beta-chain heterogeneity and clonal expression in rheumatoid synovitis, (A2) 104
- LUNARDI C, MARGUERIE C, WALPORT MJ, SO AK. Tgammadelta cells and their subsets in blood and synovial fluid from patients with rheumatoid arthritis, 527
- LUND T *See* Jeddi PA
- LUNDBERG I, NYMAN U, PETTERSSON I, HEDFORS E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients, 811
- Lupus
autoantibodies, analysis of three new idiotypes associated with, (A2) 195
comes of age, 773
pentraxins, CRP and SAP interactions with cell nuclei, (A2) 102
- Lupus nephritis
laminin P1 levels, (A2) 58
and vasculitis risk factors, West Indian race, U1-RNP and Sm antibodies, (A2) 58
- LUQMANI RA *See* Sheeran T
- LUTALO S *See* Chikanza IC
- LUYTEN H *See* De Keyser F
- LUZIATELLI S, PANDOLFI A, PACIUCCHI A, DAINOTTO F. Plasma level modifications of B/endorphin in course of treatment with synthetic salmon calcitonin versus synthetic eel calcitonin, (A2) 223
- LUZIATELLI S *See also* Pandolfi A; Zorzini LR
- LYDYARD PM *See* Erkeller-Yuksel FM
- Lyne borreliosis, very infrequent cause of arthritis of undetermined aetiology in southern part of Netherlands, 401
- Lymphoedema of the upper limb in psoriatic arthritis, (A2) 73
- Lymphoma and rheumatoid arthritis, patient with, 107
- LYNCH JA *See* Buckland-Wright JC
- LYNCH M *See* Phelan M
- LYNCH MP *See* Phelan MJ
- LYNGBERG K, PEDERSEN BK, ANDERSEN V, HALKJAER KRISTENSEN J, DANESKJOLD-SAMSØE B, BECH PEDERSEN P. Bicycle training improved the subjective scores in patients with rheumatoid arthritis, (A2) 217
- LYON LJ *See* Jeracitano D
- LYSENKO GI, GANDZHA IM, ANTONENKO VT. Pathogenetic and diagnostic role of anti-DNAase autoantibodies at diffuse diseases of connective tissue, (A2) 182
- McALINDON TE, COOPER C, KIRWAN JR, DIEPPE PA. Knee pain and disability in community, 189
- McALINDON TE, TEALE D, DIEPPE PA.
Insulin-like growth factor 1: effect of age accounts for apparent correlation with sclerosis and osteophysis in osteoarthritis of the knee, (A2) 213
Insulin-like growth factor 1 levels are normal in knee osteoarthritis and low in DISH, (A2) 71
- McBURNAY A *See* Sheldon P
- McCANN BG *See* Chakravarty K
- McCARTHY CJ, REGAN M, COUGHLAN RJ. Treatment of rheumatoid hand synovitis with hydrocortisone using a regional block technique, (A1) 29
- McCARTHY CJ *See also* Eustace S
- McCLOSKEY EV *See* Spector TD
- McCOLLUM R *See* Pelletier J-P
- McCORMICK JN, SITUNAYAKE RD, WOJTACHA D, SIM AK. Treatment of rheumatoid arthritis with essential fatty acids, (A2) 37
- McCRAE FC *See* Wood A
- McCRAE FM *See* Jenkins EA
- McDONAGH J, GRAY J, DEIGHTON CM, SYKES H, WALKER DJ. Patient medication does not explain elevated anti-*Proteus* antibodies in rheumatoid arthritis, (A1) 3
- McDONAGH JE. Infrared thermography, what is its place in rheumatology in the 1990s, (L) 857
- McDONAGH J *See also* Deighton CM; Kelly CA
- McDONALD A *See* Crighton A
- McDONALD BR, GOWEN M. Cytokines and bone, 149
- MacFARLANE D *See* Haslock I
- MacFARLANE DG *See* Buckland-Wright JC
- McGILL NW, McGILL VG. Gout management in Sydney. Comparison of practices of varying groups of practitioners, (A2) 144
- McGILL VG *See* McGill NW
- MacGREGOR A *See* Symmons DPM
- MacGREGOR AJ, OLLIER WER, SILMAN AJ. Modification of ARA classification criteria for rheumatoid arthritis for use in population surveys, (A2) 37
- MacGREGOR AJ *See also* Riste L
- McGUIGAN L *See* Smith GM
- McHUGH N *See* Whyte J
- McINTYRE HD *See* Register JY
- McKANE WR *See* Magill M
- McKENNA F. Overlap syndrome of systemic sclerosis and rheumatoid arthritis, (A2) 54
- McKENNA F, COOMBS G, SANDLE L, MATHER H. Urinary D-glucuronic acid in rheumatoid arthritis, (A2) 115
- McKENNA F, WARDROPPER A, ALDERSON DM. Anaemia in rheumatoid arthritis: evaluation of marrow iron stores, serum ferritin and disease activity, (A2) 34
- McKENNA F *See also* Arnold MM; Hayes JH; Mather HC; Ticehurst H; Tracey A
- McKENNA S *See* Tennant A
- McLAREN AM *See* Astbury C
- McLAREN M *See* Lau CS
- McMAHON G *See* Tindall EA
- McMAHON MJ, HILLARBY MC, CLARKSON RWE, HOLLIS S, GRENNAN DM. HLA variants and rheumatoid disease severity, (A2) 8
- McMAHON MJ, SIDEBOTTOM D, ILLINGWORTH KJ, GRENNAN DM, JAYSON MIV. Extra and intradural fibrosis, fibrinolysis and HLA-DR type, (A2) 12
- McMICHAEL A *See* Bowness P
- McMICHAEL AJ *See* Bowness P
- McVIE A *See* Murphy EA
- MACEY M *See* Kaul A
- MACIÁ MA *See* Muñoz-Fernández S
- MACKWORTH-YOUNG CG, ANDREOTTI F, HARMER I, LOIZOU S, POTTINGER BB, PEARSON JD, DAVIES GD, MASERI A, WALPORT MJ. Endothelium-derived haemostatic factors and the antiphospholipid syndrome, (A2) 189

- MACLEOD D, MOWAT AG, WORDSWORTH BP. Correlation of cervical and lumbar spine disease in ankylosing spondylitis, (A2) 73
- MADDISON P See Brennan P; O'Neill T; Will RK
- MADDISON PJ See Stephens CO; Whyte J; Will RK
- MADHOK R See Murphy EA; Porter DR
- Maedi-visna virus-associated synovitis, immunohistological investigation in sheep, (A2) 5
- MAERTENS M See De Clercq L
- MAGEED RA, MOYES S, BROWN CMS, MAINI RN. Analysis of B-lymphocyte repertoire in RA synovia, (A2) 205
- MAGEED RA. See also Sadigh S
- MAGILL KM, IRVINE AE, MCKANE WR, KIRK F, BELL AL. Cytokine interactions in synovial fluid: colony-stimulating factors measured in parallel bioassays and immunoassays, (A2) 190
- Magnetic resonance imaging of rat knee pathology and the effects of treatment: a longitudinal study, (A2) 136
- Magnetotherapy in lumbar syndrome, (A2) 116
- MAGOULAS T, VANCHEESWARAN R, EFRAT G, PENNY R, BLACK CM. Endothelin-1 serum levels in systemic sclerosis, (A2) 13
- MAHEU E See Carraba M
- MAHMOOD IH See Jalal MZ
- MAHMOUD A See O'Neill T
- MAIA C See Vaz C
- MAIN DMG, CHAMBERLAIN MA. Clinical differentiation of oral ulceration in Behçet's disease, 767
- MAINARD D See Pourcel J
- MAINI RN See Adebajo AO; Brennan FM; Brookes SM; Charles PJ; Chu CQ; Cope AP; Deleuran BW; Gibbons DL; Mageed RA; Plater-Zyberk C; Rose LM; Sadigh S; Taylor PC
- MAJKOWSKI RS, ATKINS RM. Fixed flexion deformity treatment of the knee in rheumatoid arthritis using Flowtron intermittent compression stocking, 41
- MÄKI-IKOLA O, HILL JL, LAHESMAA R, TOIVANEN A, GRANFORS K. IgG and IgA antibody responses against porins in *Yersinia*-triggered reactive arthritis, 315
- MÄKI-IKOLA O, YLI-KERTTILA U, SAARIO R, TOIVANEN P, GRANFORS K. *Salmonella* specific antibodies in serum and synovial fluid in patients with reactive arthritis, 25
- MALAVIYA AN See Singh YN
- MALCOLM A See Sadigh S
- MALIA R See Lindsay N
- Malignancy association with SLE: an analysis of 150 patients under long term review, (A2) 215
- MALKOVSKY M See Hylton W
- MALLOY N See Hussain W
- MANI RJ See Smith RW
- MANICOURT DH See Howell DS
- MÄNNSSON B See Geborek P
- MANZANEQUE L, MARIN I, GARCÍA-BRAGADO F, BEIZTEGUI A, DASTIS C, SÁNCHEZ-MATAS P. Osteoarticular tuberculosis of the symphysis pubis presenting as a hypogastric cystic mass in a woman with primary Sjögren's syndrome, 495
- MAPP PI See Walsh DA
- MARAGOU M See Kaskani E
- MARCHANDISE X See Duquesnoy B
- MARCONI A See Brogginì M
- MARCUSON R See Herrick AL
- Marfan syndrome, fibrillin gene mutations in UK Marfan syndrome patients with joint hypermobility, (A2) 87
- MARGUERIE C See Lunardi C
- MARIN I See Manzanque L
- MARINA N See Grlićkov M
- MARINI M See Salaffi F; Zorzin LR
- MARINO A See Bartolone S
- MARK S See Hüge H
- MARKOVIĆ V See Deljanin Ilić M
- MARKOVIĆ Z See Deljanin Ilić M
- MARKS JS See Conway SC
- MARKUSSE HM, HOGEWEG M, SWAAK AJG, VAN HAERINGEN NJ, DE JONG PTVM. Ophthalmological examinations of patients with primary Sjögren's syndrome selected from a rheumatological practice, 473
- MARQUE P See Roques CF
- MARRIOTT A See Hoyland JA
- MARSAL S See Fernandez-Cortijo J; Lima J
- MARSANO S See Galanti A
- MARSHALL DAS See Porter DR
- MARSHALL JM See Gerova Z
- MARSHALL MJ See Ashton IK
- MARTEL-PELLETIER J See Pelletier J-P
- MARTÍN MOLA E See Muñoz-Fernández S
- MARTIN H See Dean MF
- MARTIN M See Foley-Nolan D
- MASARYK P See Drlićková V
- MASCAGNI P See Watson A
- MASEK BA See Landewé RBM
- MASERI A See Mackworth-Young CG
- MASON JC, KAPAH P, WELLCOME SM, LEBRANCHU Y, YARWOOD H, HASKARD DO. Detection of circulating form of VCAM-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus and lack of correlation with levels of circulating ICAM-1, (A2) 90
- MASSARO M See Capone M
- Mast cells in synovium and synovial fluid in osteoarthritis, (A2) 123
- Mastocytosis and osteoporosis, (L) 715
- MAT C See Hamuryudan V
- Maternal antibody detection to RO and LA: prognostic value for foetal outcome, (A2) 186
- Maternal autoantibodies in the fetus, pathogenic effects, (A2) 18
- MATHER H See McKenna F
- MATHER HC, COOPER R, MCKENNA F. Protein S, C4B-binding levels and lupus anticoagulant in systemic lupus erythematosus, (A2) 51
- MATHEWS JA See Buchanan NMM
- MATSUBARA T, KIMURA T, KURODA T, HIROHATA K. Signal transduction in glycosaminoglycan (GAG) synthesis by cultured chondrocytes and its inhibition by inflammatory cell-derived hydrogen peroxide, (S1) 27
- MATSUOKA LY See Varga J
- MATTEY DL, EVANS E, DAWES PT. Tenidap and cytokine effects on fibroblast proliferation, (A2) 25
- MATTEY DL, NIXON N, WYNN-JONES C, DAWES PT. Demonstration of cytokeratin in endothelial cells of the synovial microvasculature *in situ* and *in vitro*, (A2) 14
- MATTEY DL See also Borg AA; Close DR
- MATTHEWS NC, EMERY P, PILLING D, SALMON M. Can depressed cytokine production by rheumatoid synovial helper T cells be attributed to low level CD45RB expression, (A2) 26
- MATTHEWS RC See Donohoe M
- MATUCCI CERINIC M, PIGNONE A, SACERDOTI L. Neutral endopeptidase levels in systemic sclerosis, (A2) 13
- MATUCCI CERINIC M See also Patsch G
- MAURER BJ See Crowley JJ
- MAYEUX D See Kessler M
- MAYMÓ J See Pérez-Edo L
- MAYNARD A. Non-steroidal anti-inflammatory drugs, health economics impact, (A2) 253
- MAZZANTINI M See Riente L
- MAZZONI A See Ferri C
- MEAGER A See Holt I
- Measuring disease progression in rheumatology, (A2) 243
- MEDINA L See Quevedo V
- MEE JB See Hobbs RN
- MEGE JL, DILSEN N, SANGUEDOLCE V, GÜL A, BONGRAND P, ÖCAL L, INANÇ M, CAPO C, ROUX H. Increased TNF α , IL-6 production and superoxide generation in Behçet's disease, (A2) 214
- MEINDERSMA J See Kool J
- MELARANGE R, GENTRY C, DURIE M, BLOWER PR. Nabumetone's differential inhibition of prostanoic acid production may contribute to its lack of gastric irritancy in the rat, (A2) 169
- MELICONI R, UGUCCIONI M, D'ERRICO A, CASSISA A, FRIZZIERO L, FACCHINI A. T-cell receptor gamma-delta positive lymphocytes in synovial membrane, 59
- MELO GOMES JA See Bolten W
- MELONI A See Sorgi ML
- MENEGALE G See Govoni M; La Corte R
- Meningococcal infection: diagnostic and therapeutic pitfalls, (L) 141, (L) 428
- MENKES CJ. DMARDs, steroids and NSAIDs affecting acute phase proteins, (A2) 257
- Extracorporeal photochemotherapy, (L) 789
- MENKES CJ, ANDREU G, HESHMATI F, LAOUSSADI S, HILLIQUIN P, NATAOUR J, WEILL BJ. Treatment of refractory rheumatoid arthritis by extracorporeal photochemotherapy, (A2) 208
- MENKES CJ See also Blanche P; Cormier C; Hilliquin P; Pertuiset E
- MENON S, SNAITH ML, ISENBERG DA. Association of malignancy with SLE: an analysis of 150 patients under long term review, (A2) 215
- MÉRÉTEY K See Szűts I
- MERRY P. Meningococcal infection: diagnostic and therapeutic pitfalls, (L) 141
- Metacarpophalangeal joint evaluation in patients with rheumatoid arthritis by dual photon X-ray (DEXA) scan. Juxtaarticular halisteresis and bone erosions, (A2) 137
- Methotrexate associated Peyronie's disease in the treatment of rheumatoid arthritis, 425
- combination therapy with sulphasalazine in rheumatoid arthritis, (A2) 32
- concentrations in red blood cells of rheumatoid arthritis patients. Correlations with immunological parameters, (A2) 124

- effects of a single weekly dosis on circulating cytokines and cytokine production in patients with rheumatoid arthritis, (A2) 36
- in older patients with rheumatoid arthritis, (L) 860
- Pneumocystis carinii* pneumonia complicating low dose treatment for rheumatoid arthritis, (A2) 34
- pneumonitis in rheumatoid arthritis - a dramatic response to treatment, (L) 356
- short term effects of low dose in rheumatoid arthritis, (A2) 128
- 6-Methoxy-2-naphthylacetic acid, major active metabolite of nabumetone, in vitro effects on polymorphonuclear leukocyte functions, (A2) 170
- Methylprednisolone, intramuscular and oral during induction of chrysotherapy in rheumatoid arthritis, (A2) 35
- Methylprednisolone pulse treatment
- aminoterminal propeptide of collagen type III in rheumatoid arthritis, (A2) 129
- type I collagen metabolism in rheumatoid arthritis, (A2) 129
- MEYER S See Boonsaner K
- MICHAILOVA DM See Boykinov IN
- Microscopic fibrillation measurement in optical sections of hydrated articular cartilage by computer-assisted morphometry, (A2) 202
- MIELANTS H, VEYS EM, CUEVELIER C, DE VOS M. Gut in spondyloarthropathies: recent studies, (A2) 72
- MIELANTS H See also De Clercq L
- MIGLIAU G See De Castro S
- MIGLIORINI P See Riente L
- MILETO G See Bartolone S
- Miliary tuberculosis, disease modifying factor in rheumatoid arthritis, (A2) 186
- MILTENBURG AMM See Kloppenburg M; Landewé RBM
- Minocycline inhibits T cell proliferation and interferon gamma production after stimulation with anti-CD3 monoclonal antibodies, (A2) 41
- MISHRA M, CHAMBERS JBC, JACKSON G, CHILD A, GRAHAME R. Cardiac abnormalities in joint hypermobility syndrome, (A2) 63
- Misoprostol
- de l'action de misoprostol sur la croissance cellulaire et la synthèse de la matrice par des chondrocytes humains, (A2) 130
- prevention of diclofenac-induced gastroduodenal mucosal ulcers by misoprostol: a one year study, (A2) 180
- and ranitidine in prevention of NSAID-induced gastric and duodenal ulcer disease: a multicenter trial, (A2) 180
- treatment of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers in patients with rheumatoid or osteoarthritis, (A2) 177
- vs ranitidine in prevention of NSAID gastroduodenal mucosal injury in cancer patients, (A2) 181
- MITCHELL TJ See Brookes SM; Gibbons DL
- Mitral valve lesions, high prevalence in anti-RNP-positive connective tissue disease patients, (A2) 57
- Mixed connective tissue disease - goodbye to all that, 695
- Mixed cryoglobulinaemia and hepatitis C virus, (A2) 101
- MODY GM. South African Rheumatism and Arthritis Association, report on 13th biennial congress, 565
- MOENS M See Driessens M
- Molecular mimicry in pathogenesis of spondyloarthropathies. Critical appraisal of cross-reactivity between microbial antigens and HLA-B27, 221
- MONCADA S See Farrell AJ
- Monoarthritis, synovial fluid lipid crystal significance, (CC) 183
- Monoclonal anti-IL2 receptor therapy of experimental arthritis, (A2) 103
- MONTANARO M, BIZZARRI F. Non-Hodgkin's lymphoma and subsequent acute lymphoblastic leukaemia in patient with polymyalgia rheumatica, 277
- MONTECUCCO C, CAPORALI R, CAPROTTI P, RONCHETTI A, CAPROTTI M. Sex hormones and bone metabolism in postmenopausal women with rheumatoid arthritis treated with corticosteroids, (A2) 140
- MONTECUCCO C See also Caporali R; Cimmino MA
- MOORE AR, DA SILVA JAP, LARRE J-P, SCOTT DL, WILLOUGHBY DA. Rheumatoid synovial fluids, direct effects on human articular cartilage matrix, (A2) 111
- MOORE DJ See Peel NFA
- MORAL F See Hamuryudan V
- MORENO E See Sanz Frutos P
- MORETTI A See Ferri C
- MORGAN K See John SL; O'Reilly D
- MORLEY BJ See Hohler T
- MORLEY KD See Lau CS
- MOROZUMI K See Yoshida A
- MORRIS IM See Cawley PJ
- MOSCETTI S See Sorgi ML
- MOSS P See Bowness P
- MÖTTÖNEN T See Laheesmaa R
- MOVILIA PG See Pellerin I
- MOWAT A, FITZPATRICK R, ZIEBLAND S, JENKINSON C. Sensitivity to change over time of four health status instruments in rheumatoid arthritis, (A2) 151
- MOWAT A See also Fitzpatrick R
- MOWAT AG See MacLeod D
- MOYES S See Mageed RA
- MRI of the knee joint with measurement of cartilage signal intensity and relaxation times to determine different stages of cartilage hydration - a future aspect to identify human early osteoarthritis, (A2) 139
- MUIR A See Lau CS
- MUKHERJEE M. Anionic phospholipid of the erythrocyte membrane-phosphatidyl serine in collagen disorders, (L) 644
- MULDOON CG, GOULDER MA. Influence of dosing times on clinical response to sustained-release ibuprofen (Brufen Retard) in patients with rheumatoid arthritis, (A2) 159
- MULHERIN D. Methotrexate pneumonitis in rheumatoid arthritis - a dramatic response to treatment, (L) 356
- MULHERIN D, FITZGERALD O, BRESNIHAN B. Lymphoedema of the upper limb in psoriatic arthritis, (A2) 73
- MULHERIN D See also Doherty E
- MULLER F See Howell DS
- MULLER S See Edelsten C; Kalsi J
- MÜLLER-FASSBENDER HR. Open study of efficacy and tolerability of nabumetone (Arthaxan) in extra-articular inflammation, (A2) 163
- MUMFORD D See Helliwell PS
- MUÑOZ-FERNÁNDEZ S, CARDENAL A, MACIÁ MA, Balsa A, MARTÍN MOLA E, PEÑA JM, BARBADO FJ, VÁZQUEZ JJ, GUÓN J. Osteoarticular infection in intravenous drug abusers. A ten years experience, (A2) 79
- MUÑOZ-GÓMEZ J See Cañete JD
- MURPHY E See Belch JFF
- MURPHY EA, KARIM SN, STURROCK RD, GOUDIE RB. T-cell clone PCR analysis in synovial fluid before and after culture in IL-2, (A2) 39
- MURPHY EA, McVIE A, GALBRAITH I, MADHOK R, CAPELL H. Anti-neutrophil cytoplasmic antibodies (ANCA), positive titre in patients with recent infection, 8(A1)
- MURPHY EA, MADHOK R, WARRING R, HUNTER JA, CAPELL HA. Sulphoxidation status and toxicity from sulphasalazine and d penicillamine in rheumatoid arthritis, (A1) 26
- MURRAY K See Chakravarty K
- Muscle strength and inhibition in rheumatoid arthritis patients and following Souter-Strathclyde elbow arthroplasty, (A2) 225
- MUSCOLO V See Capone M
- Muscular involvement in systemic rheumatoid vasculitis, (L) 355
- Musculoskeletal diseases, undergraduate education, 279
- Musculoskeletal pain in Omanis, and relationship to joint mobility and body mass index, 81
- Musicians, instrumental, hand and upper limb problems, 265, (L) 572
- Mustine, review of 89 patients with rheumatoid arthritis treated with oral mustine, (A1) 25
- MUŠKIĆ P See Jevtić V; Rozman B
- Mycobacteria, role of persistent in reactivation of experimental arthritis, (A2) 5
- Mycobacterium tuberculosis* antigen detection in synovial fluid of patients with rheumatoid arthritis, 615
- Myelomatosis, amyloid arthropathy: successful treatment with radiosynovectomy, (L) 718
- MYLES AB. Steroid treatment in giant cell arteritis, (L) 787
- MYLES AB, PERERA T, RIDLEY MG. Blindness prevention in giant cell arteritis by corticosteroid treatment, 103
- Myopathy, idiopathic inflammatory, clinopathological observations in the Indian population, 835
- Myotonic dystrophy, ³¹P NMR spectroscopy in, (A2) 203
- N-terminal peptide from link protein is taken up and degraded by monocytes, B-cells and chondrocytes, (A2) 197
- NABER FB See Kool J
- Nabumetone
- (Arthaxan), open study of efficacy and tolerability in extra-articular inflammation, (A2) 163
- clinical efficacy vs non-steroidal anti-inflammatory drugs pool. An initial experience, (A2) 169
- compared with indomethacin in treatment of osteoarthritis in general practice, (A2) 166
- comparison with indomethacin on human gastric morphology and blood flow, (A2) 166
- differential inhibition of prostanoid production may contribute to its lack of gastric irritancy in the rat, (A2) 169
- double-blind, randomised comparison with naproxen in rheumatoid arthritis, (A2) 167
- double-blind, randomized comparison with aspirin in treatment of patients with rheumatoid arthritis, (A2) 164
- effects of active metabolite on the synthesis of normal canine articular cartilage *in vitro*: comparison with other non-steroidal anti-inflammatory drugs, (A2) 168

- efficacy and tolerability in primary and secondary arthrosis. A 12-week open evaluation, (A2) 163
- ibuprofen and combination of ibuprofen and misoprostol in osteoarthritic patients, comparative, randomized parallel group, endoscopy study of effects, (A2) 165
- and indomethacin effects on human gastric bicarbonate secretion *in vivo*, (A2) 167
- and indomethacin general practice comparison in the treatment of osteoarthritis, (A2) 168
- and naproxen in rheumatoid arthritis, double-blind, randomized comparison, (A2) 165
- open-label treatment of rheumatoid arthritis - efficacy and tolerability, (A2) 164
- in postoperative pain: results of a double-blind randomized placebo-controlled study, (A2) 170
- treatment of joint injuries caused by sporting activities. An open clinical trial of efficacy and tolerability, (A2) 162
- in vitro* effects of 6-methoxy-2-naphthylacetic acid, major active metabolite, on polymorphonuclear leukocyte functions, (A2) 170
- NAESSENS G *See* Driessens M
- NAHIR AM, JABBARIN A, AWAD M, SHOMRAT D. Glucose 6-phosphate dehydrogenase low activity preceding osteoarthritis, (A2) 69
- Naproxen
- double-blind, randomised comparison with nabumetone in rheumatoid arthritis, (A2) 167
- effects on renal function in older patients with mild to moderate renal dysfunction, 163
- and tenidap effects on production of proinflammatory cytokines, (A2) 175
- NASH P *See* Workman E
- NATALE C *See* Pellerin I
- National Health Service, new, Trusts and rheumatology, (E) 361
- NATOUR J *See* Menkes CJ
- Natural killer (NK) cell IgG FcγRIII receptor (CD16) and monocyte CD-14 expression - correlation with IgA-α-1-anti-trypsin (IgA-AAT) in normal and rheumatoid arthritis (RA) sera, (A2) 43
- NAYLOR JR *See* Huston GJ
- NAZHAT NB *See* Fairburn K
- Nefopam hydrochloride effects on human chondrocyte metabolism *in vitro*, (A2) 70
- NEGRI C *See* Caporali R
- Neopterin level reduction in both spontaneous and drug-induced remission in rheumatoid arthritis, (A2) 29
- NETA R *See* Rokita H
- NETTER P *See* Fener P; Kessler M
- NEUMANN V *See* Dearlove SM
- NEURATH F. Efficacy and tolerability of nabumetone in primary and secondary arthrosis. A 12-week open evaluation, (A2) 163
- Neurological involvement in Behçet disease, (A2) 184
- Neutral endopeptidase levels in systemic sclerosis, (A2) 13
- Neutropenic enterocolitis, fatal, associated with sulphasalazine therapy for rheumatoid arthritis, 351
- Neutrophil activation, spontaneous, in patients with primary Raynaud's phenomenon and systemic sclerosis, (L) 856
- NEVILLE E *See* Solanki T
- New genetics, some applications to the investigation of the rheumatic diseases, (A2) 104
- NEWHAM DJ *See* Hurley MV
- NICOLINI P *See* Pourcel J
- NIETFIELD J, DUTIS AJ, DEN OTTER W, CAPEL PJ, BIJLSMA JWJ. Human articular cartilage oligonucleotides inhibiting IL-1- induced synthesis of IL-6 prevent IL-1-induced inhibition of proteoglycan synthesis, (A2) 121
- NIETFIELD JJ *See* Venn G
- NUS J *See* Abdel-Hamid Osman A
- NIKOLIĆ T *See* Krajnc I
- NIKOLIĆ-KOPSA I *See* Krajnc I
- NIKOLOVSKA M *See* Grličkov M
- NISHIKAI M, ITOH K, SATO A. Calcinosi and the anticomplement antibody: its clinical, radiological and immunogenetic aspects, 9
- Nitric oxide synthesis, elevated synovial and serum nitrite suggest increased nitric oxide synthesis in rheumatic diseases, (A2) 20
- Nitrite, elevated synovial and serum suggest increased nitric oxide synthesis in rheumatic diseases, (A2) 20
- NIXON N *See* Close DR; Matthey DL
- NMR imaging - what can it tell us, (A2) 242
- NOBLE DP, LEWTHWAITE JC, DUDHIA J, BLAKE S, HENDERSON B, HARDINGHAM TE. Localisation of decorin mRNA in synovium from rabbits with antigen-induced arthritis, (A2) 197
- NOBLE DP *See also* Hardingham TE
- Nodal generalised osteoarthritis (NGOA), increased DR-positive peripheral blood lymphocytes, (A2) 119
- NOHLMANS MKE *See* Blaauw AAM
- NOLASCO A *See* Ruiz MT
- Non-Hodgkin's lymphoma and subsequent acute lymphoblastic leukaemia in patient with polymyalgia rheumatica, 277
- Noninherited maternal HLA antigens (NIMA) influence occurrence of rheumatoid arthritis. A new approach to study HLA and disease association, (A2) 84
- Non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients, prospective study by gastroscopy of the predictive value of supposed risk factors, (A2) 31
- Non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcer treatment with misoprostol in patients with rheumatoid or osteoarthritis, (A2) 177
- Non-steroidal anti-inflammatory drugs
- blood rates after transdermal application using manual massage, ultrasound therapy and iontophoresis, (A2) 171
- chronic use in arthritic patients, gastric damage and dyspeptic symptoms, (A2) 173
- effect on faecal flora and bacterial antibody levels in rheumatoid arthritis, 443
- effects on glycosyltransferase activity from human osteoarthritic cartilage, (S1) 13
- epidemiology of effects and side effects, (A2) 250
- gastric and duodenal mucosal blood flow in patients - influence of age, smoking, ulceration and *Helicobacter pylori*, (A1) 27
- gastro intestinal effects, (A2) 251
- health assessment questionnaire as predictor of non-steroidal peptic ulceration, (A1) 27
- health economics impact, (A2) 253
- incidence of NSAID induced gastropathy in unselected patients, (A2) 173
- inhibitory influence on the metabolism of polymorphonuclear granulocytes, (A2) 171
- tissue microdissection and quantification of epithelial cell proliferation applied to duodenal mucosa, (A2) 174
- transcutaneous therapy, (A2) 252
- usage and requirement in elderly acute hospital admissions, 45
- Non-steroidal drug-induced peptic ulceration, can we really protect the stomach, (E) 435
- North Humberside osteoporosis screening project - one year review of acceptance of hormone replacement therapy (HRT) and its cost to a general practice, (A1) 19
- NORTON AJ *See* Donnelly S
- Novel treatment for rheumatoid arthritis, (E) 577
- NUKI G *See* Smith GW
- NYMAN U *See* Lundberg I
- O'CONNELL PG, LOHMANN SIEGEL K, STANHOPE S, GERBER LH. Comparative gait analysis in different patterns of foot arthritis, (A2) 29
- O'FLANAGAN SJ *See* Hurley MV
- O'GARA C *See* Hall GM
- O'MAHONEY SA, SIRAJ QH, HILSON AJW, BLACK CM. Systemic sclerosis, oesophageal dysfunction in: scintigraphic study with 99m technetium labelled meal in 159 patients, 6(A1)
- O'MALLEY A *See* Foley-Nolan D
- O'NEILL T, MAHMOUD A, TOOLE A, THOMAS R, MADDISON P. Serologic association with cardiac abnormalities in adults with SLE, (A2) 56
- O'NEILL TW, EVISON G, BHALLA AK. Pseudoarthroplastic hand in arthritis mutilans, 559
- O'NEILL T *See also* Croft PR
- O'REILLY D, HOLT PJJ, COLLINS I, KEEN JH, MORGAN K. Collagen auto-antibodies in juvenile onset arthritis, (A2) 46
- O'TOOLE L *See* Peel NFA
- ÖCAL L *See* Dilşen N; Konıçe M; Mege L
- Occupational rheumatology: are we using the wrong model, (E) 73
- ÖDER A *See* İmeryüz N
- ÖZDOĞAN H *See* İmeryüz N
- ÖZKAN M *See* İmeryüz N
- OZYAGAN Y *See* Hamuryudan V
- OKAWA T *See* Yoshida A
- Oligoarthritis, presenting feature of occult coeliac disease, 349
- OLIVÉ A *See* Juncá J
- OLLIER B *See* Silman AJ
- OLLIER W *See* Pile KD
- OLLIER WER *See* MacGregor AJ; Thomson W; Walport MJ
- OLSEN I *See* Abraham DJ; Tulip GR
- OLSEN N *See* Stephens CO
- OLTHOFF H *See* Franz J
- OM-8980 (Subreum), dose-finding and efficacy studies, (A2) 123
- ONEL D, AKGÜN K. Tenoxicam in 124 osteoarthritic patients. Efficacy and tolerability, (A2) 153
- OOGARAGH P *See* Herrick AL
- Open access bone densitometry - the first 1000 referrals, (A2) 229
- Ophthalmological examinations of patients with primary Sjögren's syndrome selected from a rheumatological practice, 473

- Ophthalmological screening
in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis, 633
in seronegative juvenile chronic arthritis: a personal view, 631
OPPLIGER I See Kalsi J
ORAL A, DİLŞEN G, YALIMAN A, AYDIN R. Bone density values measured by DEXA in patients treated with salmon calcitonin nasal spray and calcium, (A2) 142
ORAL A See also Dilşen G
Oral tolerance and collagen arthritis, (L) 213, (L) 283
Oral ulceration clinical differentiation in Behçet's disease, 767
ORDI-ROS J See Simeon-Aznar CP
Osteo-articular manifestations in diabetes mellitus, (A2) 120
Osteoarthritic and rheumatoid synovial membranes, immunohistological and functional differences, (A1) 10
Osteoarthritis, 132
assessment of crepitus by phonoarthrography, (A2) 202
assessment in a working study group, (A2) 122
chondrocyte collagen metabolism, (A2) 70
cigarette smoking and risk of, (A2) 61
comparative, randomized parallel group, endoscopy study of effects of nabumetone, ibuprofen and combination of ibuprofen and misoprostol, (A2) 165
effects of hormonal change and smoking, (A2) 60
gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol, 753
generalized, hip involvement, 325
genetics, (A2) 236
glucose 6-phosphate dehydrogenase low activity preceding, (A2) 69
intermittent hydrostatic compressive force stimulates exclusively the proteoglycan synthesis of osteoarthritic human cartilage, 437
knee joint space width, quantitative microfocal radiography detects changes in patients on diclofenac sodium vs placebo, (A2) 95
long-term efficacy and safety of arthrotec, (A2) 179
mast cells in synovium and synovial fluid, (A2) 123
nabumetone compared with indomethacin in treatment in general practice, (A2) 166
nodal generalised, dry eye syndrome, (A2) 67
nodal generalized, autoantibodies, immunoglobulins and Gm allotypes in, 605
pathogenesis, (A2) 237
prospects for treatment, (A2) 238
proteoglycan aggregate profiles in the Pond-Nuki dog model of osteoarthritis and in canine disuse atrophy, (S1) 7
ROC analysis of vertebral morphometry, (A2) 118
should weight bearing or non-weight bearing knee radiographs be used in longitudinal studies of knee, (A1) 17
tenascin in normal synovial tissue: variations in osteoarthritis, (A2) 201
tenoxicam in 124 patients. Efficacy and tolerability, (A2) 153
total hip and knee replacement bring long term overall benefit in osteoarthritis and rheumatoid arthritis, (A2) 78
treatment of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers with misoprostol, (A2) 177
urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis, 759
Osteoarthritis of the hip and farming, (A2) 92
influence of sustained-release ibuprofen (Brufen Retard) on mobility of the spine, (A2) 122
and knee, tolerability, efficacy and impact on quality of life of sustained-release flurbiprofen (Cebutid LP): general practice study with 12,005 patients, (A2) 162
and knee, tolerability, efficacy and quality of life evaluation of sustained-release flurbiprofen (Cebutid LP): a study by French rheumatologists, (A2) 161
radiographic patterns, (A1) 18
Osteoarthritis of the knee
efficacy and safety of different dose-schedules of intra-articular injections of hyaluronic acid, (A2) 127
insulin-like growth factor 1: effect of age accounts for apparent correlation with sclerosis and osteophysis, (A2) 213
risk factors, (A2) 119
tenoxicam versus diclofenac (Voltaren) in: a Canadian multicenter study, (A2) 155
therapeutic activity and tolerability of sustained release flurbiprofen (Froben SR) and piroxicam, (A2) 160
Osteoarthrotic cartilage, VLA-integrins in, (A2) 11
Osteoarticular infection in intravenous drug abusers. A ten years experience, (A2) 79
Osteoarticular tuberculosis of the symphysis pubis presenting as a hypogastric cystic mass in a woman with primary Sjögren's syndrome, 495
Osteogenesis imperfecta, bone mineral density by dual energy X-ray absorptiometry in families, (A2) 66
Osteopathic clinics, back pain disability compared in patients attending rheumatology, osteopathic and chiropractic clinics, (A1) 24
Osteopenia
postmenopausal screening, 823
in primary biliary cirrhosis, (A1) 20
Osteoporosis, 206
in anorexia nervosa, (A2) 140
dans la maladie de Crohn, (A2) 141
differential involvement of lumbar and dorsal spine, (A1) 18
evaluation by estimation of volumetric bone mineral density of the lumbar spine, (A2) 67
how should we treat our patients, (A2) 247
and mastocytosis, (L) 715
North Humberide screening project - one year review of acceptance of hormone replacement therapy (HRT) and its cost to a general practice, (A1) 19
ROC analysis of vertebral morphometry, (A2) 118
in systemic sclerosis: preliminary considerations, (A2) 139
vertebral in rheumatoid arthritis patients: effect of low dose prednisone therapy, 91, (L) 573
who are we treating, (A2) 246
who should we treat, (A2) 245
Osteoporotic outpatients, plasma ascorbic acid concentrations, (L) 141
OSTUNI PA, GUSI R, RIGA B, PRESACCO D, GAZZETTO G, GAMBARI PF. Ultrasonography in the evaluation of hip involvement in rheumatoid arthritis, (A2) 225
Outcome
audit in rheumatology, (A2) 77
definition of medium-term of rheumatoid arthritis, (A2) 144
Outpatient
clinic, satisfaction, knowledge and compliance in, (A2) 149
education programme evaluation for people with rheumatoid arthritis, (A2) 77
Overlap syndrome
evolution of case with systemic sclerosis, rheumatoid arthritis and systemic lupus erythematosus, 783
of systemic sclerosis and rheumatoid arthritis, (A2) 54
OWEN JP See Kelly CA
Oxidising species detection in synovial fluid by electron spin resonance spectroscopy: evidence for *in vivo* production of reactive oxygen species, (A2) 19
Oxygen partial pressure, novel technique to measure in the rheumatoid knee, (A2) 18
31 PNMN spectroscopy in myotonic dystrophy, (A2) 203
PACIUCCI A See Luziatelli S
Paediatric rheumatology, 627
advances in: report of American College of Rheumatology Meeting, Boston 1991, 628
district clinics: the requirements for supporting services, (A1) 17
Paf-acether and T lymphocyte functions in rheumatoid arthritis, (A2) 209
Paget's disease
of bone, nasal hCT effects on bone turnover - implications for treatment of other metabolic bone diseases, 35
refractory, effects of intravenous aminopropylidene diphosphonate, (A2) 65
treatment by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (ADP), 97
Pain centre existence, (E) 290
PALACIOS I See Gutierrez S
PALLA P See Ferri C
PALMARES J See Costa L
PALMER RG See Hylton W
PALMER RMJ See Farrell AJ
Panarthritis nodosa and polymyalgia rheumatica, (L) 431
PANAYI GS See Chicco-Bianchi F; Chikanza IC; Choy EHS; Corrigan V; Farahat MNMR: Iannone F
Pancreatic function in patients with primary Sjögren's syndrome, (A1) 5
PANDOLFI A, LUZIATELLI S, CASTAGNOLI M, DAINOTTO F. Study of rheumatoid knee by arthro-CT, (A2) 137
PANDOLFI A See also Luziatelli S
PANDOLFINO YA See Brookes SM
PAPAGEORGIOU AC See Williams GH
PAPAIOANOU D See Galatas ID
PAPAPOULOS SE See Eggemeijer F
Papular mucinosis (scleromyxoedema) complicating diffuse systemic sclerosis: clinical features and electron microscope observations, 779
Paradiscal injection technique, new, for relief of back spasm after chemo-nucleolysis, 491
PARESC E See Carraba M; Galanti A
PARTSCH G, MATUCCI-CERINIC M. Galactosaminoglycuronoglycan-sulfate

- influence on the action of PMN cell migration in the presence of chemotactants, (A2) 109
- PASCUAL E.
Phagocytosis of urate crystals in synovial fluid obtained from asymptomatic knees of patients with gout, (A2) 20
Synovial fluid analysis from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout, (A2) 219
- PASCUAL E, CASTELLANO JA, LÓPEZ E. Costovertebral joint changes in ankylosing spondylitis with thoracic pain, 413
- PASCUAL E See Ruiz MT
- PASMA HR See Houtman PM
- Pathogenetic and diagnostic role of anti-DNAase autoantibodies at diffuse diseases of connective tissue, (A2) 182
- Patient
care, who should be involved, (A2) 249
education, do patients hear what they are told, (A2) 148
medication does not explain elevated anti-*Proteus* antibodies in rheumatoid arthritis, (A1) 3
satisfaction index comparison with the arthritis impact measurement scales, (A2) 75, (A2) 94
- PATRICK MR. Short of a length: *Streptococcus sanguis* knee infection from dental source, (L) 569
- PATRIKOS D See Kaskani E
- PATTERSON D See Hay EM
- PATRICK M See Jones A
- PAUWELS EKJ See Eggelmeijer F
- PAVELKA JR K, PAVELKA SEN K. Tiaprofenic acid (Surgam SR[®]) in the long term treatment of active rheumatoid arthritis, (A2) 152
- PAVONI P See Sorgi ML
- PAYTON T See Thomson W
- PAZARLI H See Hamuryudan V
- PAZZI P See Canazza S; La Corte R
- PEARCY MJ See Russell P
- PEARSE MF See Ismaiel S
- PEARSON JD See Mackworth-Young CG
- PEASE CT See Charles PJ
- PEDERSEN BK See Lyngberg K
- PEEL N See Gough A
- PEEL NFA, EASTELL R. Evaluation of osteoporosis by estimation of volumetric bone mineral density of the lumbar spine, (A2) 67
- PEEL NFA, O'TOOLE L, BAX DE, TRIGER DR, MOORE DJ, EASTELL R. Osteopenia in primary biliary cirrhosis, (A1) 20
- Peer and family relationships in adult patients with chronic arthritis since childhood, (A2) 79
- PEERS SH See Da Silva JAP
- PEETERS AJ. Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study, (L) 502
- PEETERS R See Landewé RBM
- PELL P See Sheldon P
- PELLERIN I, RESTELLI L, VAIANI G, NATALE C, MOIVILIA PG. Nabumetone in postoperative pain: results of a double-blind randomized placebo-controlled study, (A2) 170
- PELLETIER J-P, MCCOLLUM R, CLOUTIER J-M, MARTEL-PELLETIER J. Tiaprofenic acid effects on plasminogen activators and inhibitors in human OA and RA synovium, (S1) 19
- PELSTER B. Etofenamate in oily solution: new facilities for treatment of severe inflammatory pain, (A2) 157
- PELSTER B, BILLIGMANN PW. Topical treatment of ankle dislocations with an etofenamate containing gel. Results of a randomized, placebo-controlled double-blind study, (A2) 157
- PELSTER B See also Bernard I
- PELTON BK See Hylton W
- PELTONEN L See Child A
- d-Penicillamine
longitudinal study of pulmonary function in patients with rheumatoid arthritis, 829
sulphoxidation status and toxicity from in rheumatoid arthritis, (A1) 26
- PENNY R See Magoulas T
- PEÑA JM See Muñoz-Fernández S
- Pentraxins, CRP and SAP interactions with cell nuclei: a role in lupus, (A2) 102
- Peptic ulceration, non-steroidal drug-induced, can we really protect the stomach, (E) 435
- PEPYS MB, BOOTH S, TENNETT G, BUTLER PJG. Interactions of pentraxins, CRP and SAP with cell nuclei: a role in lupus, (A2) 102
- PEPYS MB See also Vigushin DM
- PERBELLINI A See Carraba M
- PERČINKOVA S See Gričkov M
- PERE P See Kessler M
- PERERA T See Myles AB
- PEREZ A. Adjuvant treatment of recent onset rheumatoid arthritis by selenium supplementation: preliminary observations, (L) 281
- PÉREZ-EDO L, MAYMÓ J, ROTÉS-SALA D, LAFONT A, BOQUET D, CARBONELL J. Bone study in patients with rheumatoid arthritis, (A2) 141
- Performing arts medicine, (E) 795
- Pericardial involvement in rheumatoid arthritis in Turkey, (A2) 223
- PERKINS C See Herrick AL
- PERONI M See Allegrezza-Giulietti A; Salaffi F
- PERRET P See Larbre J-P
- PERRETT D See James IT
- PERTUISSET E, MENKES CJ, LENOIR G, JEHANNE M, DOUCHAIN F, GUILLOT M. Cystic fibrosis arthritis. A report of five cases, 535
- PESCHARD MJ See David MJ
- PETERS L See Visser GJ
- PETERSEN AK See Krüer K
- PETERSSON I See Lundberg I
- PETIT P See Eggelmeijer F
- PETRIE JP See Ching DWT
- PETROU P See Chikanza IC
- Peytonic's disease, methotrexate associated, in the treatment of rheumatoid arthritis, 425
- Phagocytosis of urate crystals in synovial fluid obtained from asymptomatic knees of patients with gout, (A2) 20
- PHAROAH PGP See Chakravarty K
- PHELAN M, WHITTAKER T, RILEY P, LYNCH M. Cancelled joint replacements: the multidisciplinary approach to closing the audit loop, (A1) 16
- PHELAN MJ. Rheumatology nurse specialist in the United Kingdom, profile, (L) 858
- PHELAN MJ, RILEY PL, LYNCH MP. Methotrexate associated Peyronie's disease in the treatment of rheumatoid arthritis, 425
- Phenotypic characterization of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis by cytofluorimetric analysis, (A2) 193
- Phonoarthography, assessment of crepitus in osteoarthritis, (A2) 202
- Phospholipase A₂, secretory, controlling mechanisms of synthesis and release, (A2) 109
- Phthalylsulphathiazole in rheumatoid arthritis, 461
- PIGNONE A See Matucci Cernic M
- PILE KD, WORDSWORTH BP, BELL JI. Particular genetic variants of type II collagen are not associated with rheumatoid arthritis, (A2) 86
- PILE KD, WORDSWORTH BP, HYER RN, BELL JI. Gene interactive with HLA-DR4 in susceptibility to type I diabetes is not involved in rheumatoid arthritis, (A2) 6
- PILE KD, WORDSWORTH BP, LANCHBURY JSS, OLLIER W, BELL JI. HLA-DR heterozygosity contributes susceptibility to severe rheumatoid arthritis, (A2) 209
- PILLING D See Matthews NC
- PIMM TJ, AMOS M, BYRON MA. Evaluation of an out-patient education programme for people with rheumatoid arthritis, (A2) 77
- PINEDA M See Collantes E
- PINTO MJ, CARDOSO L, FERNANDES M, COSTA L, VAZ C, LOPES VAZ A. Cardiovascular abnormalities in connective tissue diseases, (A2) 232
- PIRANI O See Cervini C
- PIROSKA E See Szűts I
- PITCHER O See Fordham JW
- PITSILLIDES AA, WILL R, BAYLISS MT, EDWARDS JCW. Effect of intra-articular corticosteroid on hyaluronan concentration in synovial fluid, (A2) 21
- PITSILLIDES AA See also Worrall JG
- PITT T See Salih H
- Plasma fibrinolysis, baseline, in 164 patients with Raynaud's phenomenon, (A1) 20
- Plasminogen activators and inhibitors, tiaprofenic acid effects in human OA and RA synovium, (S1) 19
- Platelet activating factor and tumour necrosis factor involvement in pathogenesis of joint inflammation in rabbits, (A2) 24
- PLATER-ZYBERK C, CARAPETI M, TAYLOR PC, MAINI RN. CD5+B cells: possible target for action of disease-modifying anti-rheumatic drugs in rheumatoid arthritis, (A2) 191
- PLATT D, BAYLISS MT, HARDINGHAM TE. Effects of IL-1beta on proteoglycan metabolism in mature equine cartilage *in-vitro*, (A2) 117
- Pneumocystis carinii*
infection complicating cytotoxic therapy in two patients with lymphopenia, but a normal total white cell count, 71
pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis, (A2) 34
pneumonia following immunosuppressive therapy in systemic lupus erythematosus, (L) 643
- Pocket computers in clinical rheumatology, (L) 645
- PØDENPHANT J, FLORESCU A, THAMSBORG G, SCHIØER H, ANDERSEN V. Evaluation of metacarpophalangeal joints in patients with rheumatoid arthritis by dual photon X-ray (DEXA) scan. Juxtaarticular halisteresis and bone erosions, (A2) 137
- PODRAŽKY V, SKŘIVÁNKOVÁ B, JULIŠ I, TRNAVSKÝ K. Effects of antirheumatic drugs and chondroprotective drugs on experimental papain arthropathy, (A2) 131

- POET JL, GALINIER-PUJOL A, CONTE-DEVOLX B, ROUX H. Osteoporosis in anorexia nervosa, (A2) 140
- POLAK JM See Walsh DA
- POLE KD, TIKLY M, WORDSWORTH BP. HLA-DR association with rheumatoid arthritis in three black South African groups, (A1) 12
- POLITO R See Zorzin LR
- Polyarthritis
 Bewirkt eine Enzym- oder Goldtherapie bei chronischer Polyarthrit-
 is Veränderungen immunologischer Parameter, (A2) 132
 chronic, cervical vertebral column affection: incidence, correlations,
 complications, (A2) 226
 Ergebnisse einer randomisierten, doppelblinden 1- Jahresstudie mit
 oralen Enzymen im Vergleich zur oralen Goldtherapie bei
 Patienten mit chronischer Polyarthrit, (A2) 133
 Polyclonal origin of rheumatoid synovial T-lymphocytes, 55
 Polymerase chain reaction technique amplification of synovial compart-
 ment cytokine mRNA, (A2) 23
- Polymorphonuclear cells, further evidence of increased activity in
 patients with Raynaud's phenomenon, 375
- Polymorphonuclear granulocytes, inhibitory influence of non- steroidal
 anti-inflammatory drugs on the metabolism, (A2) 171
- Polymyalgia rheumatica
 delayed sequelae of *Borrelia* infection, (L) 647
 hypothyroidism and thyroid antibodies in polymyalgia rheumatica,
 (L) 214
 interleukin 6 production: comparison of serum levels and production
 by peripheral blood lymphocytes, (A2) 212
 and its treatment in general practice, (A2) 143
 non-Hodgkin's lymphoma and subsequent acute lymphoblastic leu-
 kaemia, 277
 and panarteritis nodosa, (L) 431
 sun exposure, (A2) 217
 synovitis in: an immunogenetic study, (L) 718
 ultrasonographic evidence of synovitis in axial joints, 201
 value of CD8+ T lymphocyte levels in distinguishing polymyalgia
 rheumatica from early rheumatoid arthritis, (A2) 91
- Polymyalgia rheumatica and giant cell arteritis (PMR/GCA)
 α -1-antichymotrypsin levels in, (A2) 38
 soluble IL2 receptors, (A1) 7
- Polymyositis
 presenting as groin pain, (L) 283
 total body irradiation failure: report of three cases, (L) 282
- PONASSI M See Cutolo M
- PONSEL O See Glückert K
- POOLE ES, HIGHTON J, WILKINS RJ, LAMONT IL. *Chlamydia trachomatis*,
 search for in synovial fluids from patients with reactive arthritis using
 the polymerase chain reaction and antigen detection methods, 31
- POOLE P. Methotrexate in older patients with rheumatoid arthritis, (L) 860
- POPE D See Croft PR
- POPE FM See Child A
- POPERT AJ See Pugh MT
- PORTER DR, MARSHALL DAS, MADHOK R, CAPELL H, STURROCK RD.
Pneumocystis carinii infection complicating cytotoxic therapy in two
 patients with lymphopenia, but a normal total white cell count, 71
- Postmenopausal screening for osteopenia, 823
- POSTON R See Farahat MNMR
- POSTON RN See Wilkinson LS
- Post-streptococcal arthropathy, spectrum of, (A2) 227
- POTTER EM. Psoriatic arthritis, clinical features with particular reference
 to distal interphalangeal joint involvement, (L) 646
- POTTER PJ. Hand and upper limb problems of instrumental musicians, (L)
 572
- POTTINGER BB See Mackworth-Young CG
- POUNCEY L See Jeddi PA
- POUNTAIN G. Musculoskeletal pain in Omanis, and relationship to joint
 mobility and body mass index, 81
- POUNTAIN G, CALVIN J, HAZLEMAN BL. α -1-Antichymotrypsin levels in
 polymyalgia rheumatica and giant cell arteritis (PMR/GCA), (A2)
 38
- POUNTAIN G, HAZLEMAN BL. IL2 receptors, soluble in polymyalgia rheu-
 matica and giant cell arteritis (PMR/GCAG), and during predniso-
 lone treatment per se, (A1) 7
- POUREL J, JAULHAC B, FENER P, MAINARD D, NICOLINI P, VALCKENAERE I,
 GUILLEMIN F. Detection of *Borrelia burgdorferi* in synovial tissue
 using the polymerase chain reaction, (A2) 88
- POUREL J See also Fener P: Kaminsky P
- POWELL R See Regan M: Spector TD
- POWELL RJ See Hemsley AG: Hopkinson ND: Jones DRE: Lim KL
- PRASAD ML, SARKAR C, ROY S, BAGCHI U, SINGH RR, SINGH YN, SHARMA S.
 Idiopathic inflammatory myopathy: clinopathological observations
 in the Indian population, 835
- Prednisolone acetate, erythema multiforme after intradural injection, (L)
 717
- Prednisolone treatment, soluble IL2 receptors, (A1) 7
- Prednisone
 low dose therapy effects in vertebral osteoporosis in rheumatoid
 arthritis, 91
 short term effect of low dose therapy on bone metabolism and lum-
 bar mineral density in patients with rheumatoid arthritis, (A2)
 33
 short term effect of low dose therapy on disease activity and func-
 tional capacity in patients with rheumatoid arthritis, (A2) 32
 vertebral osteoporosis in rheumatoid arthritis patients: effects of low
 dose therapy, (L) 573
- Pregnancy and female hormones, examination of role as risk factors for
 rheumatoid arthritis using male population as control group, 395
- PRESACCO D See Ostuni PA
- PRESENIK M See Rozman B
- PRESTON B See Ledingham J
- Prevalence
 low, of rheumatoid arthritis in urbanised Chinese people of Hong
 Kong, (A2) 93
 of rheumatoid arthritis and rheumatoid factor in females: the Ching-
 ford study, (A2) 93
 of vertebral fractures in females with rheumatoid arthritis, (A2) 94
- PREVOO M See van Riel P
- PRITCHARD MH. Female hormones and pregnancy, examination of role as
 risk factors for rheumatoid arthritis using male population as control
 group, 395
- PROCKOP DJ. Osteoarthritis genetics, (A2) 236
- Progesterone inadequate production in women with systemic lupus
 erythematosus, 247
- Prognostic factors for radiographic damage and physical disability in
 early rheumatoid arthritis. A prospective follow-up study of 147
 patients, 519
- Proprioception, impaired, of the proximal interphalangeal joints of the
 hand in rheumatoid arthritis, (A1) 16
- Prostacyclin release, thrombin-induced, produced by anticardiolipin anti-
 bodies, serum masking inhibition, 179
- Prostacyclin-thromboxane unbalance in systemic sclerosis patients: a
 possible role in endothelial damage, (A2) 15
- Prostaglandin E production, tumour necrosis factor alpha and extracel-
 lular ATP interact in stimulating production by human articular
 chondrocytes, (A2) 22
- Protein S, C4B-binding levels and lupus anticoagulant in systemic lupus
 erythematosus, (A2) 51
- Proteinuria, serial measurement using spot creatinine index in rheu-
 matoid patients, (A2) 218
- Proteoglycan
 aggregate profiles in the Pond-Nuki dog model of osteoarthritis and
 in canine disuse atrophy, (S1) 7
 biosynthesis in human articular cartilage, (A2) 118
 metabolism, effects of IL-1beta on in mature equine cartilage *in*-
vitro, (A2) 117
 turnover, growth factor and cytokine effects in articular cartilage,
 (S1) 1
- Proteoglycan synthesis
 human articular cartilage oligonucleotides inhibiting IL-1- induced
 synthesis of IL-6 prevent IL-1-induced inhibition, (A2) 121
 intermittent hydrostatic compressive force stimulates exclusively the
 proteoglycan synthesis of osteoarthritic human cartilage, 437
 is induced by azapropalone and inhibited by indomethacin in
 patients with osteoarthritis of the knee, (A2) 201
- PRUZANSKI W, VADAS P. Controlling mechanisms of synthesis and release
 of secretory phospholipase A₂, (A2) 109
- Pseudoarthroplastic hand in arthritis mutilans, 559
- Pseudosepsis in rheumatoid arthritis due to cellular and lipid abnormal-
 ities in synovial fluid, 625
- Psoriatic arthritis
 clinical features with particular reference to distal interphalangeal
 joint involvement, (L) 646
 clinical subsets in: is there a need to re-classify, (A2) 92 cyclosporin A
 - long-term assessment of tolerability, (A1) 25
 DIP or not DIP, that is the question, (L) 430
 fumaric acid therapy. A randomized, double-blind, placebo-control-
 led study, (L) 502
 harmless disease, (L) 210
 immunolocalisation of adhesion molecules in synovium and skin,
 (A2) 89
 lymphoedema of the upper limb, (A2) 73
 phenotypic characteristics of synovial cell populations, (A2) 183
- Psychotherapy, existentially-humanistic in rheumatological rehabili-
 tation, (A2) 150
- PUCCELLI L, CIOMPI ML. Tenoxicam (TILCOTIL) versus ketoprofen
 (FLEXEN): a double-blind study in the treatment of active rheu-
 matoid arthritis, (A2) 156
- PUGH MT. Adult dermatomyositis treated with cyclosporin A, (L) 855

- PUGH MT, COPPOCK JS, POPERT AJ. Review of 89 patients with rheumatoid arthritis treated with oral mustine, (A1) 25
- PUGH MT, JONES S, COPPOCK JS, DAWES PT. Comparison of the use of inpatient facilities between two similar rheumatology units, (A2) 74
- PUGH MT, KENT C, COLLINS NA, RAI A, COPPOCK JS, HOLLINRAKE K. Factor VIII related antigen acts a marker of disease activity in adult dermatomyositis treated with cyclosporin A, (A2) 231
- PULLAR T *See* Kay EA
- Pulmonary artery aneurysms in Behçet's syndrome: report of 22 cases, (A2) 199
- PURDIE DW *See* Wilkinson M
- Purine enzyme levels and response to azathioprine association in rheumatoid arthritis, (A2) 207
- PUŠEVSKI A *See* Grlićkov M
- Pustulose arthroostopathy with exocrinopathy, (A2) 232
- PUXEDDU A *See* Coaccioli S
- PVELKA JR K *See* Pavelka Sen K
- Pyridinolone and deoxypyridinolone urinary excretion correlate with disease activities in first year of early rheumatoid arthritis, (A2) 30
- QUAILE A, REEKIE RM. Effects of flurbiprofen on the intra-articular environment in patients with traumatic effusions, (A2) 158
- Quality of life, audit in rheumatology, (A2) 77
- Quantitative microfocal radiography
detects changes in OA knee joint space width in patients on diclofenac sodium vs placebo, (A2) 95
detects the onset of erosion repair in patients with RA treated early with mycristin, (A2) 96
- QUEIROZ MV *See* Branco JC
- QUERCI G *See* Cimmino MA
- QUEVEDO V, ALCINO S, COSTA L, BRITO I, VAZ C, BRAVO T, ARAUJO D, ALMEIDA G, MEDINA L, LOPES VAZ A. Osteo-articular manifestations in diabetes mellitus, (A2) 120
- QUI LIANQUN *See* Chen Jifan
- QUIGLEY PJ *See* Crowley JJ
- Radiographic demonstration of paraspinal muscle wasting in patients with chronic low back pain, 389
- Radiographic progression of hip osteoarthritis, (A2) 95
- Radioiodinated C-reactive protein, *in vivo* turnover studies in man, (A2) 100
- RAGNO S *See* Watson A
- RAI A, FARNDON P, KILPATRICK M, FETHERSTON TJ, STRUTHERS G. Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene, (A2) 86
- RAI A *See also* Pugh MT
- RAJKOVIC IA *See* Smith GM
- RAMESAR R *See* Beighton P
- Ranitidine
and misoprostol in prevention of NSAID-induced gastric and duodenal ulcer disease: a multicenter trial, (A2) 180
vs misoprostol in prevention of NSAID gastroduodenal mucosal injury in cancer patients, (A2) 181
- RASKER JJ *See* Taal E; Visser GJ
- RASKIN JB *See* White R
- RAUH G, LANDTHALER M, KAMILI I, GRESSER U, RIEDEL KG, ZOLLNER N. Relapsing poly(peri)chondritis associated with periarteritis nodosa, (A2) 232
- RAVIRAJAN C *See* Blanco F; Kalsi J; Longhurst C
- RAYAN V *See* Hardingham TE
- Raynaud's phenomenon
baseline plasma fibrinolysis in 164 patients, (A1) 20
further evidence of increased polymorphonuclear cell activity, 375
pilot study with oral iloprost, a prostacyclin analogue, (A2) 55
primary, heat distribution pattern and nailfold capillary damage, (A2) 54
primary, peripheral vascular changes evoked by emotional stress in patients, (A1) 21
primary and secondary, anxiety levels in patients, (A1) 21
spontaneous neutrophil activation, (L) 856
- Reactive arthritis
bacterial superantigens in pathogenesis, (A2) 41
gastrointestinal accumulation of indium-111 labelled granulocytes, 543
Salmonella specific antibodies in serum and synovial fluid, 25
search for *Chlamydia trachomatis* in synovial fluids from patients with reactive arthritis using the polymerase chain reaction and antigen detection methods, 31
T cell receptor usage of synovial lymphocytes, (A2) 40
Yersinia-triggered, IgG and IgA antibody responses against porins, 315
- REARDON PM *See* Smith PL
- Red cell membrane essential fatty acid concentration, lack of correlation with disease activity variables in patients with rheumatoid arthritis, (A1) 28
- REEKIE RM *See* Quaille A
- REES WDW *See* Shorrock CJ
- Reflex sympathetic dystrophy stage I, use of intranasal synthetic salmon calcitonin in treatment, (A2) 80
- REGAN M, DOHERTY M, POWELL R. Increased DR-positive peripheral blood lymphocytes in nodal generalised osteoarthritis, (A2) 119
- REGAN M, HUGKULSTONE C, VERNON S, DOHERTY M. Dry eye syndrome in nodal generalised osteoarthritis, (A2) 67
- REGAN M *See also* McCarthy CJ; Samanta A
- REGINSTER JY, JEUGMANS-HUYENEN AM, WOUTERS M, SARLET N, MCINTYRE HD, FRANCHIMONT P. Human calcitonin (hCT), nasal, effects on bone turnover in Paget's disease of bone - implications for treatment of other metabolic bone diseases, 35
- Rehabilitation, existentially-humanistic psychotherapy in, (A2) 150
- REID DM *See* Garton MJ
- REILLY KM *See* Ahmed K
- REILLY PA, KHALIL Z, HELME RD, LITTLEJOHN GO. Axon reflex flare responses in patients with fibromyalgia syndrome, (A2) 203
- REILLY PA, LITTLEJOHN GO. Sleep disturbance and lumbar hyperlordosis and their influence on the aetiology of fibromyalgia syndrome, (A2) 221
- Relapsing polychondritis or Coxsackie infection, (A2) 231
- Relapsing poly(peri)chondritis associated with periarteritis nodosa, (A2) 232
- Renal dysfunction, mild to moderate in elderly, naproxen effects on renal function, 163
- Renal vein thrombosis in Chinese systemic lupus erythematosus with high titre anticardiolipin antibody, (L) 787
- RENNIE JAN *See* Garton MJ
- Repetitive strain injury, analysis of the contribution of physical and psychological factors to the pain and disability experienced, (A1) 22
- Research funding, what should the Arthritis and Rheumatism Council be funding? (E) 649
- Research priorities in rheumatology, 193, (E) 505
- RESTELLI L *See* Pellerin I
- Restricted T-cell receptor beta-chain heterogeneity and clonal expression in rheumatoid synovitis, (A2) 104
- Retroviral gag sequences, immune response to and expression of in autoimmune disease, 735
- Retroviruses
potential aetiological agents in autoimmune rheumatic disease, 841
seminar, 135
- REVELL P *See* Axford JS
- REVICZYKY A *See* Kurth G
- Rheumatic disease and disability: who sees the specialist, (A2) 75
- Rheumatic findings in thalassaemia minor, frequency and features: a blind controlled study, 197
- Rheumatic symptoms in the general population - physical and psychosocial impact, (A2) 78
- Rheumatoid arthritis
a 12 weeks clinical trial to the effect of hydrotherapy in a thermomineral institution compared with hydrotherapy in a hospital-exercise-bath, (A2) 31
adjuvant treatment of recent onset by selenium supplementation: preliminary observations, (L) 281
alpha-1-antitrypsin: is all API in these patients functionally active, (A1) 10
alpha-interferon treatment, preliminary study on effect on joint inflammation and serum calcium, 405
alteration in normal glycosylation control mechanisms, (A2) 88
aminoterminal propeptide of collagen type III. Pulse treatment with methylprednisolone, (A2) 129
anaemia in: evaluation of marrow iron stores, serum ferritin and disease activity, (A2) 34
analysis of B-lymphocyte repertoire in RA synovial, (A2) 205
ANCA in, (A2) 206
androgen receptor identification in synovial macrophage-like cells, (A2) 16
anti-CD4 chimaeric monoclonal antibody in, (A2) 102
anti-galactosyltransferase antibody: an integral part of a glycosylation control system, (A2) 115
anti-*Proteus* antibodies in same-sexed sibships, 241
anti-*Proteus* antibody response specificity, (A1) 3
antiarthritis efficacy of arthrocare: subgroup analysis of the effects of disease duration and functional capacity, (A2) 179
antibodies to cytokeratin-18, (A2) 14
antiviral antibodies in discordant HLA-identical same-sexed sibling pairs, (L) 357
articular indices in - the Trafford index correlates with the acute phase response, (A2) 76
auditing long-term progression, (A2) 145
autogenic training in - a pilot study, (A1) 15

- axial bone mass in: comparison of dual-photon and dual-energy X-ray absorptiometry, (A2) 65
- azathioprine daily and alternate-day treatment: a twelve-week controlled clinical trial, (L) 501
- bicycle training improved subjective scores, (A2) 217
- bone mineral density loss in early rheumatoid arthritis, (A2) 97
- bone mineral density in men: effect of low dose corticosteroids, (A1) 19
- bone study, (A2) 141
- CD3+CD4-CD8- and CD3+CD4+CD8+ lymphocyte analysis in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease, (A2) 42
- CD5+B cells: possible target for action of disease-modifying anti-rheumatic drugs, (A2) 191
- cervical spine involvement: a clinical, neurological and radiological evaluation, (A2) 226
- change over time sensitivity of four health status instruments, (A2) 151
- clinical and laboratory outcomes of L-fucose treatment, (A2) 205
- clinical study of older age onset with comparison to an early onset group, (A2) 216
- clinical trials, correlation among variables, (A2) 143
- clinopathological findings of bucillamine-induced nephropathy in patients, (A2) 134
- combination therapy in: sulphasalazine and methotrexate, (A2) 32
- comparative clinical trial of indomethacin and diclofenac, (A2) 172
- comparison of two articular indices in rheumatoid arthritis, (A2) 229
- complement C4 null alleles as marker of gold or D-penicillamine toxicity in treatment, 53
- corticosteroid pulse therapy complications in, (A2) 125
- cyclosporine A in therapy, (A2) 130
- cytokine detection at the cartilage/pannus junction: implications for the role of cytokines in cartilage destruction and repair, 653
- debrisoquine (DBQ) oxidation polymorphisms do not predispose to, (A2) 7
- definition of medium-term outcome, (A2) 144
- detection of circulating form of VCAM-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus and lack of correlation with levels of circulating ICAM-1, (A2) 90
- difficulties with drug containers and domestic containers in elderly and patients with rheumatoid arthritis, (A2) 145
- disease modifying factor, miliary tuberculosis in, (A2) 186
- dominance effect on severity, 77
- double-blind, randomised comparison of nabumetone and naproxen, (A2) 165, (A2) 167
- double-blind randomized comparison of nabumetone and aspirin in treatment, (A2) 164
- early, increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker, 593
- effects of a single weekly dose of methotrexate on circulating cytokines and cytokine production, (A2) 36
- efficacy and tolerability of auranofin in: two years follow-up, (A2) 126
- elemental diet use and subsequent food reintroduction, (A2) 80
- evaluation of an out-patient education programme, (A2) 77
- exercise causes a rise in plasma endothelin concentration, (A2) 16
- exercise induces rises in plasma von Willebrand factor, (A2) 110
- extraarticular manifestations in Turkey based on analysis of 110 cases, (A2) 224
- failure to detect lentiviral sequences, (A2) 204
- failure to detect urinary anti-Protein antibodies more frequently in rheumatoid arthritis patients compared with controls, (A1) 4
- female hormones and pregnancy, examination of role as risk factors using male population as control group, 395
- fixed flexion deformity treatment of the knee using Flowtron intermittent compression stocking, 41
- frequency of DR4 and DR1 in newly diagnosed cases of rheumatoid arthritis and inflammatory arthritis found in a population survey, (A2) 84
- gastrointestinal safety of arthroctec: subgroup analyses of the effects of age and gender, (A2) 178
- gene interactive with HLA-DR4 in susceptibility to type I diabetes is not involved, (A2) 6
- generic health status instrument in assessment, 87
- gold treatment diminishes IL-8 expression and monocyte numbers at two weeks, (A2) 89
- greater disease severity predicts concordance in same-sexed siblings, (A1) 13
- health status, self-efficacy, social support and adherence with health guidelines, (A2) 148
- high resolution computed tomography (HRCT) of the thorax in patients with rheumatoid arthritis and interstitial lung disease, (A2) 96
- HLA class I, class II determinants in patients in Turkey, (A2) 222
- HLA DR locus has no association with early, (A2) 85
- HLA genes are unimportant in clinically mild rheumatoid arthritis, (A2) 85
- and HLA-DR1 in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1-subtype, (A2) 7
- HLA-DR3, C4A*QO and toxicity from gold, (L) 645
- HLA-DR association with in three black South African groups, (A1) 12
- HLA-DR heterozygosity contributes susceptibility, (A2) 209
- HLA-DR phenotypes in disease expression and familiarity, (A2) 189
- human phospholipase A₂ measurement in arthritis plasma using newly developed sandwich ELISA, 175
- hypothalamic-pituitary-adrenal (HPA) axis defective regulation is not a consequence of chronic inflammation per se, (A2) 28
- IgG, IgA and IgM glycosylation in immunoglobulin heavy and light chains and immune complexes, (A2) 52
- IL-1 secreting cell assay and its application to cells, 19
- immunogenetics of and the Arthritis and Rheumatism Council's National Repository, 701
- impaired proprioception of the proximal interphalangeal joints of the hand, (A1) 16
- impaired suppressor cell activity due to surface sulphhydryl oxidation, 599
- incidence in a genetically predisposed population, 365
- increased levels of urinary collagen cross links in females with rheumatoid arthritis, (A2) 27
- inflammatory activity evaluation: comparison of MR contrast enhanced imaging with clinical findings, (A2) 210
- influence of disease activity steroid hormone levels in peripheral blood, (A2) 28
- influence of dosing times on clinical response to sustained-release ibuprofen (Brufen Retard), (A2) 159
- influence of psychological and social factors on self-reported functional status in early stage, (A2) 206
- interleukin-1 α , type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction, 801
- intramuscular and oral methylprednisolone during induction of chrysotherapy in rheumatoid arthritis, (A2) 35
- is onset triggered by life events, (A2) 30
- lack of correlation between red cell membrane essential fatty acid concentration and disease activity variables, (A1) 28
- long-term efficacy and safety of arthroctec, (A2) 179
- long-term prospective study of sulphasalazine, (A2) 83
- long-term second-line treatment: prospective drug survival study, 253
- long-term treatment with cyclosporin A, (A2) 128
- longitudinal study of pulmonary function in patients treated with gold and D-penicillamine, 829
- low powered laser therapy for rheumatoid arthritis, (A2) 81
- low prevalence in urbanised Chinese people of Hong Kong, (A2) 93
- and lymphoma, patient with, 107
- measurement of hand bone mineral content by dual energy X-ray absorptiometry: development of the method, (A2) 68
- metacarpophalangeal joint evaluation by dual photon X-ray (DEXA) scan. Juxtaarticular halitresis and bone erosions, (A2) 137
- methotrexate concentrations in red blood cells of patients. Correlations with immunological parameters, (A2) 124
- methotrexate in older patients with rheumatoid arthritis, (L) 860
- methotrexate pneumonitis in rheumatoid arthritis - a dramatic response to treatment, (L) 356
- modification of ARA classification criteria for rheumatoid arthritis for use in population surveys, (A2) 37
- mononuclear cells, IL2 receptor P75 chain quantitation, (A2) 208
- muscle strength and inhibition in patients and following Souter-Strathclyde elbow arthroplasty, (A2) 225
- Mycobacterium tuberculosis* antigen detection in synovial fluid, 615
- neopterin level reduction in both spontaneous and drug-induced remission, (A2) 29
- nodules as result of manual work, (L) 143
- non-steroidal anti-inflammatory drug effect on faecal flora and bacterial antibody levels, 443
- noninherited maternal HLA antigens (NIMA) influence occurrence, (A2) 84
- novel treatment, (E) 577
- open-label treatment - efficacy and tolerability nabumetone, (A2) 164
- overlap syndrome with systemic sclerosis, (A2) 54
- paf-acether and T lymphocyte functions, (A2) 209
- particular genetic variants of type II collagen are not associated, (A2) 86

- patient satisfaction with function, (A1) 13
 pericardial involvement in Turkey, (A2) 223
 phenotypic characterization of peripheral blood and synovial fluid lymphocytes by cytofluorimetric analysis, (A2) 193
 phthalylsulphathiazole in, 461
 pivotal role for TNF α , 293
 population of West Africa, anti-type II collagen and anti-keratin antibodies in, 8(A1)
 possible downregulating effects of increased iron stores on erythropoietin responsiveness, (L) 212
 prevalence in an urban black population, (A2) 38
 prevalence in females: the Chingford study, (A2) 93
 prevalence of vertebral fractures in females, (A2) 94
 prognostic factors for radiographic damage and physical disability. A prospective follow-up study of 147 patients, 519
 prospective study by gastroscopy of the predictive value of supposed risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease, (A2) 31
 provisional guidelines for measuring disease activity in clinical trials, (E) 793
 pseudosepsis due to cellular and lipid abnormalities in synovial fluid, 625
 purine enzyme levels and response to azathioprine association, (A2) 207
 pyridinoline and deoxypyridinoline urinary excretion correlate with disease activities in first year, (A2) 30
 quantitative microfocal radiography detects the onset of erosion repair in patients treated early with mycristin, (A2) 96
 review of 89 patients treated with oral mustine, (A1) 25
 rheumatoid factor clinical significance in early rheumatoid arthritis: results of a follow-up study, (A2) 220
 rifampicin in, (A2) 124
 risk factors for the discontinuation of second-line antirheumatic drugs: a prospective analysis, (A2) 207
 serological and pathological features of transferred to severe combined immunodeficient (SCID) mice, (A2) 6
 serum angiotensin converting enzyme activity is lower in patients than age and sex matched controls, (A2) 110
 sex hormones and bone metabolism in postmenopausal women treated with corticosteroids, (A2) 140
 short term effect of low dose prednisone therapy on bone metabolism and lumbar mineral density, (A2) 33
 short term effect of low dose prednisone therapy on disease activity and functional capacity, (A2) 32
 short term effects of low dose methotrexate, (A2) 128
 sibship size does not increase the risk of developing, 763
 sonography of metacarpophalangeal joints by 13MHz transducer, (A2) 224
 steroid hormone influence on proliferation of peripheral blood mononuclear cell, 663
 stroke index (SI) use to distinguish between non-steroidal anti-inflammatory drugs and SAARDS, (A2) 36
 sulphydryl compound toxicity in: results of meta-analysis, (A2) 132
 sulphasalazine effect on urinary excretion of pyridinium cross-links, (A1) 26
 sulphasalazine therapy: qualitative changes in lymphocytes and correlation with clinical response, 259
 sulphoxidation status and toxicity from sulphasalazine and d penicillamine, (A1) 26
 symmetry in hands, (A1) 15
 synovial fluid analysis from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout, (A2) 219
 and systemic sclerosis, clinical and immunological parallels, (A2) 183
 tenoxicam (TILCOTIL) versus ketoprofen (FLEXEN): a double-blind study in the treatment of active rheumatoid arthritis, (A2) 156
 Tgammadelta cells and their subsets in blood and synovial fluid, 527
 in thyroid disease positive and negative same-sexed sibships, 13
 tiaprofenic acid (Surgam SR^R) in the long term treatment, (A2) 152
 tolfenamic acid (Gantil): effect on the immunologic profile, (A2) 174
 total hip and knee replacement bring long term overall benefit in osteoarthritis and rheumatoid arthritis, (A2) 78
 treatment with essential fatty acids, (A2) 37
 treatment with humanised anti-lymphocyte antibody CAM-PATH-1H, (A2) 103
 treatment of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers with misoprostol, (A2) 177
 treatment of refractory by extracorporeal photochemotherapy, (A2) 208
 tumour necrosis factor receptors increased expression on cells isolated from synovial joints, (A2) 211
 type I collagen metabolism in. Effects of pulse treatment with methylprednisolone, (A2) 129
 type III procollagen peptide levels, (A2) 227
 ultrasonography in the evaluation of hip involvement, (A2) 225
 urinary D-glucuric acid in, (A2) 115
 validation of electronic method for measuring joint tenderness, (A2) 76
 vertebral osteoporosis: effects of low dose prednisone therapy, (L) 573
 vertebral osteoporosis and effect of low dose prednisone therapy, 91
 whole body bone density in postmenopausal, (A2) 97
Rheumatoid factor
 clinical significance in early rheumatoid arthritis: results of a follow-up study, (A2) 220
 prevalence in females: the Chingford study, (A2) 93
 Rheumatoid hand synovitis treatment with hydrocortisone using a regional block technique, (A1) 29
 Rheumatoid nodules, superficial, injection therapy, 775
 Rheumatoid and osteoarthritic synovial membranes, immunohistological and functional differences, (A1) 10
 Rheumatoid synovial fluids, direct effects on human articular cartilage matrix, (A2) 111
 Rheumatoid synovitis, absence of flares after intravenous iron administration, (A2) 33
 Rheumatological disability, difference from other types, (A1) 14
 Rheumatological research and rheumatology, a mismatch, (E) 145
 Rheumatologist in India, 113
 Rheumatologists and their patients who seek alternative care: an agreement to disagree, 485
Rheumatology
 in Australia, 273
 clinics, back pain disability compared in patients attending rheumatology, osteopathic and chiropractic clinics, (A1) 24
 nurse specialist in the United Kingdom, profile, (L) 858
 and rheumatological research, a mismatch, (E) 145
 in Russia: an opportunity to help, 849
 units, comparison of the use of inpatient facilities, (A2) 74
 ward, what happens on, (A2) 147
 Rheumatology/general practitioner interface. Proceedings of meeting held between general practitioners and rheumatologists, (L) 209
RIBOLDI L See Broggin M
RICARD-BLUM S See Fener P
RICCIERI V, SPADARO A, TACCARI E. Phenotypic characteristics of synovial cell populations in early psoriatic arthritis, (A2) 183
RICCIERI V See also Spadaro A
RICHARD M See David MJ
RICHARDS NP See Jones DRE
RICHARDSON K See Gordon C
RICHTER B See Langer M
RIDGWAY GL See Dhillon VB
RIDLEY MG See Myles AB
RIEDEL KG See Rauh G
RIENTE L, MIGLIORINI P, FERRI C, MAZZANTINI M. Anti-collagen antibodies in connective tissue disorders, (A2) 199
 Rifampicin in early rheumatoid arthritis, (A2) 124
RIGA B See Ostuni PA
RIGBY AS, HANNAFORD PC, CROFT PR. Risk factors for low back pain in women, (A2) 62
RIGBY AS See also Croft PR: Williams GH
RILEY P See Phelan M
RILEY PL See Phelan MJ
RING EFJ See Will RK
Risk factors
 associated to hyperuricaemia: a case control study, (A2) 222
 for the discontinuation of second-line antirheumatic drugs in rheumatoid arthritis: a prospective analysis, (A2) 207
 of osteoarthritis of the knee, (A2) 119
RISTE L, MACGREGOR AJ, HAZES JMW, SILMAN AJ. Prevalence of rheumatoid arthritis in an urban black population, (A2) 38
RISTELI J See Hansen M
RISTELI L See Hansen M
RISTIC M, SMILIC LJ, GLASNOVIC M. T rheumatoid rosettes, (A2) 232
RÖNNINGEN KS See de Vries N
RÓNA K See Szüts I
ROBERTS DF See Deighton CM
ROBERTSON JF See Jones MG
ROBIN-L'HERBIER B See Kaminsky P
ROBINS SP See Astbury C
ROBINSON DR See Simon LS
ROBINSON M See Gordon C
 ROC analysis of vertebral morphometry in osteoarthritis and osteoporosis, (A2) 118
ROCHE NE, WEYAND CM, HUNTER GG, GORONZY JJ. Interleukin 6 pro-

- duction in patients with giant cell arteritis and polymyalgia rheumatica: comparison of serum levels and production by peripheral blood lymphocytes, (A2) 212
- RODDY J See Vecchio P
- RODRIGUEZ DE LA SERNA A, SANCHEZ JC, BARTLETT A, COSTA A, FRESQUET A. Correlation among variables in rheumatoid arthritis clinical trials, (A2) 143
- RODRIGUEZ V See Savineau C
- ROELOFSE JA, DE JOUBERT JJ, KOTZE TJ. Tenoxicam (TILCOTIL) in maxillo-facial surgery: an open comparative trial versus diclofenac sodium following single parenteral administration, (A2) 154
- ROGERS S See Veale D
- ROHATINER AZS See Donnelly S
- ROJKOVICH B See Szüts I
- ROKITA H, NETA R, LOOSE LD, BARTLE LM, SIPE JD. Interleukin-1 receptor antagonist (IRAP) differentially regulates both *in vivo* and *in vitro* serum amyloid and fibrinogen expression, (A2) 213
- ROLAND L See Thompson P
- ROMBOUTS A See de Vries N
- RONCHETTI A See Montecucco C
- RONDGOIANNI PH See Kaskani E
- ROONEY M. Is there a disease-modifying drug for juvenile chronic arthritis, 635
- ROQUES CF, COTONAT J, MARQUE P, CHATAIN M, FELLEZ A. Non-steroidal anti-inflammatory drug blood rates after transdermal application using manual massage, ultrasound therapy and iontophoresis, (A2) 171
- ROSE LM, HORSFALL AC, MAINI RN. Detection of maternal antibodies to RO and LA: prognostic value for foetal outcome, (A2) 186
- ROSE LM See also Horsfall AC
- ROSELLÓ J See Lima J
- ROSSI S See Caporali R
- Rotator cuff lesions, suprascapular nerve block, (A1) 23
- Rotator cuff tendinitis, laser treatment, (A2) 61
- ROTÉS-SALA D See Pérez-Edo L
- ROTH H See Tindall EA
- ROTHERHAM NE, BRATTY JR. Tolerability of Brufen Retard, (A2) 231
- ROTHERHAM NE, BRATTY JR, WRIGHT RF, BYROM WD, CRAMPTON EL, GLASS RC. Brufen: extent of isomeric conversion of R-ibuprofen to S+ ibuprofen, (A2) 152
- ROTHSCHILD BM. Oral tolerance and collagen arthritis, (L) 213
- ROUSSOU E, GORDON C, SYKES C, FARR M, BACON PA. Elevated soluble CD23 representing disease activity in SLE, (A2) 91
- ROUTIER R See Hohler T
- ROUX H See Mege L, Poet JL
- ROWBOTHAM D See Foley-Nolan D
- ROWE IF See Hughes RA
- ROY S See Prasad ML; Samanta A
- ROZMAN B, JEVIĆ V, KOS-GOLJA M, RUPENOVIC S, LOGAR D, PRESETNIK M, JARH O, MUSIČIĆ P, CAMPION G, WAIT I. Evaluation of inflammatory activity in rheumatoid arthritis: comparison of MR contrast enhanced imaging with clinical findings, (A2) 210
- ROZMAN B See also Jević V
- RUBINSTEIN P See ten Wolde S
- RUDGE SR See Wedderburn LR
- RUUS S See Laan R
- RUUS SHJ See Laan RFJM
- RUIZ MT, VIOQUE J, NOLASCO A, PASCUAL E. Risk factors associated to hyperuricaemia: a case control study, (A2) 222
- RUPENOVIC S See Rozman B
- RUSSELL AS See Juby A
- RUSSELL P, WELD A, PEARCY MJ, HOGG R, UNSWORTH A. Lumbar spine mobility variation measured over a 24-hour period, 329
- RUSSELL RGG See Leong WS
- RUSSELL RI See Taha AS
- Russia, rheumatology in: an opportunity to help, 849
- RYAN PJ, BLAKE GM, FOGELMAN I. Postmenopausal screening for osteopenia, 823
- RYAN PJ, FOGELMAN I, CHILD A, GRAHAME R. Bone mineral density in joint hypermobility syndrome, (A2) 64
- RYAN PJ, SHERRY M, GIBSON T, FOGELMAN I. Paget's disease treatment by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (ADP), 97
- RYDER CAJ See Southwood TR
- SAADALLA-NAZHAT RA See Fairburn K
- SAAL JG, GALL H, FRITZ P, ZACHER J, ALBERT K. ¹H- and ¹³C-NMR spectroscopy can be used to record both biochemical and biophysical properties of synovial fluid, (A2) 210
- SAAL JG See also Dürk H
- SÁNCHEZ JC See Rodríguez de la Serna A
- SÁNCHEZ P See Collantes E
- SÁNCHEZ-MATAS P See Manzaneque L
- SAARIO R See Lahesmaa R; Mäki-Ikola O
- SABER S See Capone M
- SACERDOTI L See Matucci Cerinic M
- SACHS J See Chikanza IC
- SADIGH S, SCOTT BB, ANDREW E, MAGEED RA, MAINI RN, MALCOLM A. Antigen induced immunoglobulin isotype switch and somatic mutation in the variable region genes of CD5+ B-lymphocytes, (A2) 187
- SAFIEH-GARABEDIAN B See Ahmed K
- SAHINOGLU T See Smith EC
- SAILE R See Duquesnoy B
- SALITA A See Bartolone S
- SALAFFI F, BLASETTI P, MARINI M, SARTINI A, CERVINI C. Short term effects of low dose methotrexate in rheumatoid arthritis, (A2) 128
- SALAFFI F, PERONI M, MARINI M, CERVINI C. Comparison of two articular indices in rheumatoid arthritis, (A2) 229
- SALIH A, AUCKEN H, PITT T, HUGHES R, HYDER E, KEAT A. Detection of bacterial lipopolysaccharide in synovial fluid using an amplified ELISA assay, (A1) 2
- Salivary gland epithelial cell cultures as model of autoimmunity in Sjögren's syndrome, (A2) 188
- Salmon calcitonin nasal spray and calcium, bone density values measured by DEXA in patients treated with, (A2) 142
- SALMON M See Gough A; Matthews NC
- Salmonella specific antibodies in serum and synovial fluid in patients with reactive arthritis, 25
- SALTER DM, HUGHES DE, SIMPSON R, GARDNER DL. Integrin expression by human articular chondrocytes, 231
- SALTER DM, HUGHES DE, SIMPSON R. VLA-integrins in osteoarthrotic cartilage, (A2) 11
- SALTER DM See also Hughes DE
- SALVARANI C. Synovitis in polymyalgia rheumatica: an immunogenetic study, (L) 718
- SAMANTA A, REGAN M, JONES A, WILSON S, DOHERTY M. Osteoarthritis: effects of hormonal change and smoking, (A2) 60
- SAMANTA A, ROY S, FEEHALLY J, SYMONS DPM. Prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester city, UK, 679
- SAMANTA A, WEBB C, GRINDULIS KA, FLEMING J, SHELDON PJ. Sulphasalazine therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response, 259
- SAMBROOK P. Vertebral osteoporosis in rheumatoid arthritis patients: effects of low dose prednisone therapy, (L) 573
- SANDERS ME See Choy EHS
- SANDERS PA See Clarkson RWE
- SANDLE L See McKenna F
- SANGUEDOLCE V See Mege L
- SANMARTÍ R See Cañete JD
- SANTOPADRE P See De Castro S
- SANZ FRUTOS P, MORENO E, TEBBS VM. Therapeutic activity and tolerability of sustained release flurbiprofen (Froben SR) and piroxicam in osteoarthritis of the knee, (A2) 160
- SARAUX A See Blanche P
- Sarcoid synovitis and synovial cysts, 497
- SARKAR C See Prasad ML
- SARLET N See Register JY
- SARTINI A See Salaffi F
- Satisfaction, knowledge and compliance in a rheumatology outpatient clinic, (A2) 149
- SAUERWEIN RW See Barrera P
- SAUNDERS A See Clarke GS
- SAVINEAU C, RODRIGUEZ V, CAPRON MH, HARMOND M-F. De l'action de misoprostol sur la croissance cellulaire et la synthèse de la matrice par des chondrocytes humains, (A2) 130
- SAXNE P See Geborek P
- SAXNE T, HEINIGÅRD D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood, 583
- SAXNE T See also Forslind K
- SCAGLIARINI G See La Corte R
- SCAGLIARINI R See Canazza S
- SCAGLIUSI P, TORTORELLI E, INGLESE P, SERAFINO L, BELLO S. Eosinophilic fasciitis: an atypical case, (A2) 231
- SCARDOUTSOU A See Vougiouka O
- SCARPA R. Psoriatic arthritis, harmless disease, (L) 210
- SCELSA MG See Sorgi ML
- SCHADEN W See Lanyi E
- SCHARDUN GHC See Haanen HCM
- SCHATTENKIRCHNER M See Krieter K
- SCHWE S. Expert system 'Rheuma' on a PC in clinical validation, (A2) 150
- SCHIBLER H See Pödenphant J
- SCHLABACH P, BEYELER CH, GERBER NJ, VAN DER LINDEN SJ, BÜRG U, FUCHS WA, EHRENGRUBER H. Prevalence of palpable finger joint nodules in diffuse idiopathic skeletal hyperostosis (DISH). A controlled study, 531

- SCHLAPBACH P *See also* Beyeler Ch
 SCHMIDT P *See* Gresser U
 SCHNEIDER M *See* D'Cruz D
 SCHNEIDER W *See* Hüge H
 SCHOLLUM J *See* Croft PR
 SCHREUDER I *See* ten Wolde S
 SCHRODER H *See* Gromnica-Ihle E
 SCHULZER M *See* Atkins CJ
 SCHUMACHER JR Hr *See* Boonsaner K
 Scleroderma
 clinically normal skin becomes sclerodermatous when transplanted into a sclerodermatous area, 707
 familial, evidence of genetic or environmental trigger, 7(A1)
 quantification of skin elasticity and tethering, (A2) 53
 skin involvement measure reliability, 457
 SCOTCHFORD CA *See* Yousuf Ali S
 SCOTT BB *See* Sadigh S
 SCOTT DGI *See* Chakravarty K
 SCOTT DL *Imaging*, 129
 SCOTT DL *See also* Agambar L; Byrne JM; Da Silva JAP; Donnelly S; Griffiths ID; Hammond A; Moore AR; Waller A
 SCOTT KF *See* Smith GM
 SCOTT N *See* Lau CH
 SEÇKIN B *See* Tuncer S
 SEEDHOM BB, SWANN AC. Mechanical properties of articular cartilage: do they adapt to the prevalent stress, (A2) 100
 SEGAL R *See de* Vries N
 Selenium supplementation, adjuvant treatment of recent onset rheumatoid arthritis: preliminary observations, (L) 281
 Self-reported functional status, influence of psychological and social factors in early stage rheumatoid arthritis, (A2) 206
 Sensorineural hearing loss in juvenile chronic arthritis, 711
 SEPICI V *See* Dilşen G
 Septic bone, joint and muscle lesions associated with human immunodeficiency virus infection, 381
 SERAFI T *See* Kamel M
 SERAFINO L *See* Scagliusi P
 SERIOLO B *See* Cutolo M
 Seronegative arthritis, 771
 SERRETTI R *See* Allegrezza-Giulietti A
 Serum amyloid expression, interleukin-1 receptor antagonist (IRAP) regulation, (A2) 213
 Serum masks inhibition of thrombin-induced prostacyclin release produced by anticardiolipin antibodies, 179
 Sex hormones
 in autoimmune disease, (A2) 196
 and bone metabolism in postmenopausal women with rheumatoid arthritis treated with corticosteroids, (A2) 140
 influence the HPA axis anti-inflammatory response, (A2) 111
 protect cartilage from inflammation-induced degradation, (A2) 112
 SEYDEL ER *See* Taal E
 SHADFORTH MF *See* Borg AA
 SHANAHAN WR *See* Loose LD
 SHAND N *See* Krüer K
 SHANSON D *See* Hughes RA
 SHARMA S *See* Prasad ML
 SHATTLES W *See* Charles PJ
 SHATTLES WG *See* Brookes SM
 SHEERAN T, LUQMANI RA, KUMARATNE DS, SPECULAND B, LUESLEY D, CONNOLLY P, SITUNAYAKE D. Chronic dyspareunia: Sjögren's syndrome. Another clinical presentation, (A2) 57
 SHEERAN T *See also* Brennan P
 SHEERAN TP *See* Cotzias T; Gerova Z
 SHEIKH A *See* Al-Dalaan AN
 SHELDON P, PELL P, MCBURNEY A. Sulphasalazine effects on antibody response to oral antigen, 819
 SHELDON P, PELL P. Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen-in-vivo, (A2) 39
 SHELDON PA *See* Samanta A
 SHERLAW-JOHNSON C *See* Gallivan S
 SHERRY M *See* Ryan PJ
 SHIOZAWA K *See* Shiozawa S
 SHIOZAWA S, SHIOZAWA K, KITA M, KISHIDA T, FUJITA T, IMURA S. Alpha-interferon treatment, preliminary study on effect on joint inflammation and serum calcium in rheumatoid arthritis, 405
 SHOMRAT D *See* Nahir AM
 SHORROCK CJ, REES WDW.
 Comparison of indomethacin and nabumetone on human gastric morphology and blood flow, (A2) 166
 Effects of indomethacin and nabumetone on human gastric bicarbonate secretion in vivo, (A2) 167
 SHORTER J *See* Byrne JM
 Shoulder
 disorders in elderly, follow-up of a community survey, (A1) 23
 pain, suprascapular nerve block (SSNB) for. When to use it, (A2) 82
 problems, disability associated with in the community, (A2) 62
 soft tissue lesions in the African, 275
 Sibship size does not increase the risk of developing rheumatoid arthritis, 763
 SICARD D *See* Blanche P
 SIDEBOTTOM D *See* McMahon MJ
 Signal transduction in glycosaminoglycan (GAG) synthesis by cultures chondrocytes and its inhibition by inflammatory cell-derived hydrogen peroxide, (S1) 27
 Silastic metacarpophalangeal and proximal interphalangeal joint replacement, long term follow-up results, (CC) 839
 SILI SCAVALLI A *See* Sorgi ML; Spadaro A
 SILLS JA. British Paediatric Rheumatology Group news, 627
 SILMAN A *See* Brennan P
 SILMAN AJ, HENNESSY E, OLLIER B. Rheumatoid arthritis, incidence in a genetically predisposed population, 365
 SILMAN AJ *See also* Birrell F; Croft PR; MacGregor AJ; Riste L; Spector TD; Symmons DPM; Thomson W
 SIM AK *See* McCormick JN
 SIM E *See* di Giovine FS
 SIMEON C *See* Lima J
 SIMEON-AZMAR CP, TOLOSA-VILELLA C, CUENCA-LUQUE R, JORDANA-COMAJUNCOSA R, ORDÍ-ROS J, BOSCH-GIL JA. Transverse myelitis in systemic lupus erythematosus: two cases with magnetic resonance imaging, 555
 SIMOES M. Juvenile arthritis and coeliac disease, (L) 791
 SIMON LS, BASCH CM, YOUNG DY, ROBINSON DR. Naproxen effects on renal function in older patients with mild to moderate renal dysfunction, 163
 SIMPSON D *See* Fordham JW
 SIMPSON JB *See* Deodhar AA
 SIMPSON R *See* Hughes DE; Salter DM
 SINANIOTIS C *See* Vougiouka O
 SINGER P *See* Eckernäs S
 Singh index in postmenopausal women at risk of fracture, (A2) 66
 SINGH RR *See* Prasad ML
 SINGH YN, ADYA CM, KUMAR A, MALAVIYA AN. Adult-onset Still's disease in India, 417
 SINGH YN *See also* Prasad ML
 SIPE J *See* Loose LD
 SIPE JD, BARTLE LM, LOOSE LD. Tenidap and naproxen effects on production of proinflammatory cytokines, (A2) 175
 SIPE JD *See also* Loose LD; Rokita H
 SIRAJ QH *See* O'Mahoney SA
 SITUNAYAKE RD *See* Hussain W; McCormick JN; Sheeran T
 Sjögren's syndrome
 chronic dyspareunia. Another clinical presentation, (A2) 57
 drug hypersensitivity occurrence in patients, (A2) 127
 extraglandular primary, serology and immunogenetics, (A2) 47
 histopathologic and immunopathologic investigations in primary and secondary, (A2) 192
 and inflammatory bowel diseases, (L) 429
 primären und sekundären, (A2) 194
 Sjögren's syndrome, primary
 central neurological manifestations, (L) 787
 development of Hodgkin's disease, 561
 DR3 association with susceptibility to and severity of in a family study, 309
 ophthalmological examinations of patients selected from a rheumatological practice, 473
 osteoarticular tuberculosis of the symphysis pubis presenting as a hypogastric cystic mass, 495
 pancreatic function, (A1) 5
 review of extraglandular manifestations, 6(A1)
 salivary gland epithelial cell cultures as model of autoimmunity, (A2) 188
 Skeletal tuberculosis, (A2) 221
 Skin
 blood flow without temperature recovery of the fingers following cold challenge, (A2) 55
 elasticity and tethering quantification in scleroderma, (A2) 53
 involvement measure reliability in scleroderma, 457
 preparation prior to joint injection, study to compare efficacy of two methods, 847
 SKŘIVÁNKOVÁ B *See* Podrázský V
 SKURNIK M *See* Lahesmaa R
 Sleep disturbance and lumbar hyperlordosis and their influence on the aetiology of fibromyalgia syndrome, (A2) 221
 SMEATHERS JE *See* Helliwell PS
 SMILIC LJ *See* Ristic M
 SMITH EC, SAHINOGLU T, STEVENS CR, BLAKE DR. Plasma xanthine oxidase activity increases on exercise of a chronically inflamed knee joint, (A2) 220

- SMITH EC *See also* Asmar G
- SMITH GM, WARD RL, MCGUIGAN L, RAJKOVIC IA, SCOTT KF. Human phospholipase A₂ measurement in arthritis plasma using newly developed sandwich ELISA, 175
- SMITH GW, STEWART J, NUKI G. Total immunoglobulins and specific antibodies to self gut bacteria in ankylosing spondylitis, (A2) 48
- SMITH M *See* Workman E
- SMITH PL, REARDON PM, WALL DA, HART TK, GOCHOCO CH. Investigation of the utility of ovine nasal mucosa in vitro for evaluating the elcatonin formulation component ammonium glycyrrhizate, (A2) 231
- SMITH RW, ARMSTRONG RD. Spectrum of post-streptococcal arthropathy, (A2) 227
- SMITH RW, MANI RJ, CAWLEY MID. Use of laser Doppler flowmetry and transcutaneous oxygen tension electrodes to assess local autonomic dysfunction in epicondylitis, (A1) 22
- SMITH W *See* Billingham MEJ
- SMITH-BURCHINELL C *See* Hylton W
- Smoking
cigarette and risk of osteoarthritis: the Chingford study, (A2) 61
effects on osteoarthritis, (A2) 60
- SMOLEN JS. EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT), work of, (E) 219
- SNAITH ML *See* Bourke ME; Dhillon VB; Menon S
- Snake oil, (L) 788
- SNOW S *See* Kirwan JR
- So AK *See* Lunardi C
- So AKL *See* Lunardi C; Vyse T
- Social status impact on outcome and employability in ankylosing spondylitis, (A1) 1
- Soft tissue
rheumatism, 135
shoulder lesions in the African, 275
- SOLANKI T, NEVILLE E. Bronchiectasis and rheumatoid disease: is there an association, 691
- SOLANS R *See* Fernandez-Cortijo J
- Sonographic study of Baker's cysts in 948 knees, (A2) 134
- Sonography of metacarpophalangeal joints in rheumatoid arthritis by 13MHz transducer, (A2) 224
- SORGI ML, IASCONC C, IAGNOCO A, MELONI A, MOSCETTI S, COARI G. Evaluation of esophageal disorders in 32 patients with connective tissue diseases, (A2) 181
- SORGI ML, SCIELSA MG, SILI SCAVALLI A, TERRACINA S, PAVONI P. Bone turnover markers in systemic sclerosis: a preliminary study, (A2) 216
- SORGI ML, SILI SCAVALLI A, SCIELSA MG, TERRACINA S, PAVONI P. Osteoporosis, in systemic sclerosis: preliminary considerations, (A2) 139
- SORGI ML *See also* De Castro S
- SORIGUER F *See* Collantes E
- Souter-Strathclyde elbow arthroplasty, muscle strength and inhibition, (A2) 225
- South African Rheumatism and Arthritis Association, report on 13th biennial congress, 565
- SOUTHWOOD T. Advances in paediatric rheumatology: report of American College of Rheumatology Meeting, Boston 1991, 628
- SOUTHWOOD TR, RYDER CAJ. Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis, 633
- SOZZI M *See* Valentini M
- SPADARO A, RICCIERI V, SILI SCAVALLI A, TACCARI E. Methotrexate concentrations in red blood cells of rheumatoid arthritis patients. Correlations with immunological parameters, (A2) 124
- SPADARO A *See also* Riccieri V
- SPECTOR TD, HALL GM, MCCLOSKEY EV. Prevalence of vertebral fractures in females with rheumatoid arthritis, (A2) 94
- SPECTOR TD, HART DJ, POWELL R, HARRIS P. Prevalence of rheumatoid arthritis and rheumatoid factor in females: the Chingford study, (A2) 93
- SPECTOR TD, SILMAN AJ. Sibship size does not increase the risk of developing rheumatoid arthritis, 763
- SPECTOR TD *See also* Hall GM; Hart DJ; Thompson PW
- SPECULAND B *See* Sheeran T
- Spinal cord compression revealing destructive arthropathy of atlanto-occipital joint associated with beta-2 microglobulin amyloidosis in a haemodialysed patient, (L) 427
- SPOELSTRA P *See* Houtman PM
- Spondyloarthropathies, molecular mimicry in pathogenesis. Critical appraisal of cross-reactivity between microbial antigens and HLA-B27, 221
- Spondyloarthropathies, gut in: recent studies, (A2) 72
- SPEKELER R. Open-label treatment of rheumatoid arthritis - efficacy and tolerability nabumetone, (A2) 164
- ST CLAIR FORBES W *See* Cooper RG
- STAINES NA. Oral tolerance and collagen arthritis, (L) 283
- STAMP J *See* Baillie K
- Stanford Health Assessment Questionnaire (HAQ) as tool for audit, (A2) 146
- STANHOPE S *See* O'Connell PG
- STANKOVIC A *See* Deljanin Ilic M
- STANLEY JK, EVANS RA. Silastic metacarpophalangeal and proximal interphalangeal joint replacement, long term follow-up results, (CC) 839
- STANWORTH DR *See* Close DR
- STARK W *See* Herrmann J
- STEAD H, GEIS GS.
Gastroduodenal safety of arthrotec in osteoarthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
Gastroduodenal safety of arthrotec in rheumatoid arthritis patients: subgroup analyses of the effects of age and gender, (A2) 178
Treatment of non-steroidal anti-inflammatory drug-induced gastric and duodenal ulcers with misoprostol in patients with rheumatoid or osteoarthritis, (A2) 177
- STEAD H *See also* Bolten W; Geis GS; Kochman RL
- STEIN M *See* Chikanza IC
- STENGER AAME *See* Houtman PM
- STEPHENS CO, BRIGGS DC, OLSEN N, GUSSEVA NG, MADDISON PJ, WELSH KI, BLACK CM. Scleroderma, familial, evidence of genetic or environmental trigger, 7(A1)
- STEPHENS CO *See also* Whyte J
- Steroid hormone influence on proliferation of peripheral blood mononuclear cell in patients with rheumatoid arthritis, 663
- Steroid treatment in giant cell arteritis, (L) 431, (L) 787
- STEVENS C *See* Brennan P
- STEVENS CR, THORNE SA, HARLEY SL, ABBOT SE, BLAKE DR. Vascularity assessment and angiogenesis in the synovial lining of human rheumatoid knees, (A2) 9
- STEVENS CR *See also* Farrell A; Kaul A; Smith EC
- STEVENS TRJ. Neutrophil activation, spontaneous, in patients with primary Raynaud's phenomenon and systemic sclerosis, (L) 856
- STEVENS W, VANCHEESWARAN R, BLACK CM. UK SYSTEMIC SCLEROSIS STUDY GROUP. Alpha interferon-2a (Roferon-A) in treatment of diffuse cutaneous systemic sclerosis: a pilot study, 683
- STEVENSON FK *See* Cook NJ
- STEWART I. Hypothyroidism and thyroid antibodies in polymyalgia rheumatica, (L) 214
- STEWART J *See* Smith GW
- STOLTENBERG M, HANSEN M, HØRSLEV-PETERSEN K, LORENZEN I. Amino-terminal propeptide of collagen type III in rheumatoid arthritis. Pulse treatment with methylprednisolone, (A2) 129
- STOLTENBERG M *See also* Hansen M
- STRAUGHAI S. Independence in young people with arthritis, (A2) 149
- STRAUSS K *See* Erkeller-Yuksel FM
- Streptococcus sanguis* knee infection from dental source, 59
- Stroke index (SI) use to distinguish between non-steroidal anti-inflammatory drugs and SAARDS in rheumatoid arthritis, 5
- Structure/function studies on the extracellular domain of the human P55 TNF receptor, (A2) 112
- STRUTHERS G *See* Rai A
- STRUTHERS GR *See* Farrell AJ
- STURROCK RD. Non-steroidal drug-induced peptic ulceration, can we really protect the stomach, (E) 435
- STURROCK RD *See also* Brighton A; Field M; Murphy EA; Porter DR; Taha AS
- Subchondral bone change sequences which may lead to degenerative joint disease in the knee, (A2) 120
- SUE SO *See* White R
- SUGITO K *See* Yoshida A
- Sulphydryl compound toxicity in rheumatoid arthritis: results of meta-analysis, (A2) 132
- Sulphapyridine, sulphasalazine and 5-amino-salicylic acid comparison on the humoral response to antigen in-vivo, (A2) 39
- Sulphasalazine
5-amino-salicylic acid and sulphapyridine comparison on the humoral response to antigen in-vivo, (A2) 39
combination therapy with methotrexate in rheumatoid arthritis, (A2) 32
and course of established ankylosing spondylitis over 3 years, (A2) 82
effect on urinary excretion of pyridinium cross-links in patients with rheumatoid arthritis, (A1) 26
effects on antibody response to oral antigen, 819
fatal neutropenic enterocolitis associated with therapy for rheumatoid arthritis, 351
induced autoimmune syndrome, 115
long term prospective study in rheumatoid arthritis, (A2) 83
sulphoxidation status and toxicity from in rheumatoid arthritis, (A1) 26
therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response, 259

- Sulphoxidation status
genetic factors influencing the outcome of early arthritis, 449
and toxicity from sulphasalazine and d penicillamine in rheumatoid arthritis, (A1) 26
- SUMAR N See Jeddi PA
- SUMMER H See Tulip GR
- Sun exposure and polymyalgia rheumatica, (A2) 217
- SUN K-H See Yu C-L
- SUN MZ See Cutoio M
- Suppressor cell impaired activity due to surface sulphhydryl oxidation in rheumatoid arthritis, 599
- Suprascapular nerve block
in lesions of rotator cuff, (A1) 23
for shoulder pain. When to use it, (A2) 82
- Surrogate marker validity in rheumatic disease and the role of APPs in inflammation, (A2) 256
- SWAAK AJG See Markusse HM
- SWALLOW R See Field M
- SWANA M See Ehrenstein MR
- SWANN AC See Seedhom BB
- SWEETMAN BJ. Viruses and rheumatic disease, (L) 716
- SYKES C See Roussou E
- SYKES H See McDonagh J
- SYMONS DPM, DAWES PT. Clinical terms project, (E) 723
- SYMONS DPM, LAU EMC, MACGREGOR A, BANKHEAD C, DONNAN SJ, SILMAN AJ. Low prevalence of rheumatoid arthritis in urbanised Chinese people of Hong Kong, (A2) 93
- SYMONS DPM See also Chakravorty K; Conway SC; Donnelly S; Samanta A; Thomson W
- Synovial cell population phenotypic characteristics in early psoriatic arthritis, (A2) 183
- Synovial cysts and sarcoid synovitis, 497
- Synovial expression of the chondroitin sulphate proteoglycans decorin and biglycan, (A2) 68
- Synovial fibroblast proliferation, Tenidap and cytokine effects, (A2) 25
- Synovial fluid
analysis from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout, (A2) 219
cell cartilage degradation capacity measurement with ^{35}S , (A2) 113
cells, haem oxygenase (HO-1) in, (A2) 19
1H- and 13C-NMR spectroscopy can be used to record both biochemical and biophysical properties, (A2) 210
inflammatory, cytidine deaminase and lactoferrin in. Indicators of local polymorphonuclear cell function, 235
lipid crystal significance in patient with isolated monoarthritis, (CC) 183
- Synovial lining cells in chronic arthritis, (E) 433
- Synovitis
interleukin-1-induced blocked by interleukin-1 receptor antagonist, (A2) 114
intra-articular steroid for knee synovitis: to rest or not to rest, (A2) 81
maedi-visna virus-associated, immunohistological investigation in sheep, (A2) 5
in polymyalgia rheumatica: an immunogenetic study, (L) 718
rheumatoid, evidence for restricted T-cell receptor beta-chain heterogeneity and clonal expression, (A2) 104
rheumatoid hand, treatment with hydrocortisone using a regional block technique, (A1) 29
ultrasonographic evidence in axial joints in patients with polymyalgia rheumatica, 201
- Systemic lupus erythematosus, 207
adult respiratory distress syndrome in, (L) 647
anti-intrinsic factor antibodies, (A2) 49
anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia, 453
anticardiolipin antibodies and a severe subset, 567
antilactoferrin antibody, 669
association between anti-hnRNP A1 protein antibodies, Raynaud's phenomenon and esophageal dysmotility, (A2) 191
autoantibodies in, (A2) 59
autoantibodies in pet dogs owned by patients, (A1) 4
CD3+CD4-CD8- and CD3+CD4+CD8+ lymphocyte analysis in the peripheral blood of patients with systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease, (A2) 42
CD38+CD8+ T cells are increased in the peripheral blood, (A2) 43
Chinese, renal vein thrombosis in with high titre anticardiolipin antibody, (L) 787
and complete functional C1q-deficiency: a case report, (A2) 195
cytidine deaminase increased spontaneous release by polymorphonuclear neutrophils, 675
cytokine modulation by Tenidap, (A2) 25
detection of circulating form of VCAM-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus and lack of correlation with levels of circulating ICAM-1, (A2) 90
disease activity correlation with C3D measurements by ELISA, (A2) 59
elevated soluble CD23 representing disease activity, (A2) 91
and fungal HSP 90, (A2) 46
inadequate production of progesterone in women, 247
isotype switch in the generation of human monoclonal anti-DNA antibodies, (A2) 49
malignancy association: an analysis of 150 patients under long term review, (A2) 215
Pneumocystis carinii pneumonia following immunosuppressive therapy, (L) 643
prevalence of diagnosed in whites and Indian Asian immigrants in Leicester city, UK, 679
protein S, C4B-binding levels and lupus anticoagulant, (A2) 51
relationships between serum C3 levels, with anti-dDNA binding activity and fluorescent antinuclear antibody titers, (A2) 182
serologic association with cardiac abnormalities in adults, (A2) 56
seronegative, 619
soluble thrombomodulin: marker of vascular endothelial injury, (A2) 90
synovial fluid analysis from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout, (A2) 219
transverse myelitis in: two cases with magnetic resonance imaging, 555
treponemal infection coexisting with, 345
in Turkey: a survival study, (A2) 200
type III procollagen peptide levels, (A2) 227
urine neopterin as indicator of disease activity - comparison with ESR and C3 degradation products, (A2) 56
VH gene usage in human/human hybridoma derived monoclonal antibodies, (A2) 215
- Systemic rheumatoid vasculitis, muscular involvement, (L) 355
- Systemic sclerosis
alpha interferon-2a (Roferon-A) in treatment of diffuse cutaneous systemic sclerosis: a pilot study, 683
bone turnover markers, (A2) 216
capillary microscopy of the oral mucosa, (A2) 188
endothelial cell changes in uninvolved skin, (A2) 198
endothelin-1 serum levels, (A2) 13
heat distribution pattern and nailfold capillary damage, (A2) 54
HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome, 609
IgM anticardiolipin antibodies and vasculitis in patients with severe digital ischaemia requiring amputation, (A2) 50
Lp (a) increased levels, (A2) 17
neutral endopeptidase levels in, (A2) 13
oesophageal dysfunction in: scintigraphic study with 99m technetium labelled meal in 159 patients, 6(A1)
osteoporosis in: preliminary considerations, (A2) 139
overlap syndrome with rheumatoid arthritis, (A2) 54
papular mucinosis (scleromyxoedema) complicating: clinical features and electron microscope observations, 779
pilot study with oral iloprost, a prostacyclin analogue, (A2) 55
prostacyclin-thromboxane imbalance in: a possible role in endothelial damage, (A2) 15
rapid resynthesis of antiprotease-1-antibodies and complement after plasma exchange, (A2) 50
and rheumatoid arthritis, clinical and immunological parallels, (A2) 183
spontaneous neutrophil activation, (L) 856
type III procollagen peptide levels, (A2) 227
- Systemic vasculitis: a study of 88 patients, (A2) 60
- SZPALSKI M, HAYEZ JP. Objective functional assessment of tenoxicam (TILCOTIL) in acute low back pain. A double blind placebo controlled study, (A2) 153
- SZÜTS I, WEISZ M, BÉLY M, FEDOR J, GIDÓFALVY E, MERÉTEY K, PIROSKA E, ROJKOVICH B, RÓNA K, VOGT F. Our experience on occurrence of drug hypersensitivity in patients with Sjögren's syndrome, (A2) 127
- Tgamadelta cells and their subsets in blood and synovial fluid from patients with rheumatoid arthritis, 527
- T lymphocyte
functions in rheumatoid arthritis, (A2) 209
synovial rheumatoid, polyclonal origin, 55
- T rheumatoid rosettes, (A2) 232
- T-cell
clone PCR analysis in synovial fluid before and after culture in IL-2, (A2) 39
proliferation and interferon gamma production inhibition by minocycline after stimulation with anti-CD3 monoclonal antibodies, (A2) 41

- subset abnormalities in Behçet's disease, (A2) 185
- T-cell receptor
gamma-delta positive lymphocytes in synovial membrane, 59
and rheumatic disease: approaches to repertoire analysis, 3
usage of synovial lymphocytes from a patient with reactive arthritis, (A2) 40
- TAAL E, RASKER JJ, WIEGMAN O, SEYDEL ER. Health status, self-efficacy, social support and adherence with health guidelines in patients with rheumatoid arthritis, (A2) 148
- TACCARI E See Ricci V; Spadaro A
- TAEAMN H See Blanche P
- TAHA AS, STURROCK RD, RUSSELL RI
Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - influence of age, smoking, ulceration and *Helicobacter pylori*, (A1) 27
Health assessment questionnaire as predictor of non-steroidal peptic ulceration, (A1) 27
- TAKEDA A See Yoshida A
- TANKA D See Kurth G
- TANNER SB See Gendi N
- TAVARES V See Branco JC
- TAYLOR G See Weiss JB
- TAYLOR HG. Transdermal fungal implantation causing an infectious arthritis, (L) 715
- TAYLOR J See D'Cruz D
- TAYLOR PC, WILLIAMS DG, MAINI RN. Serological and pathological features of rheumatoid arthritis transferred to severe combined immunodeficient (SCID) mice, (A2) 6
- TAYLOR PC See also Plater-Zyberk C
- Teaching, rheumatology, test/inform/retest: useful technique in, 49
- TEALE D See McAlindon TE
- TEBBS VM See Haanen HCM; Sanz Frutos P
- Temperature control, abnormal, suggesting sympathetic dysfunction in the shoulder skin of patients with frozen shoulder, 539
- TEN WOLDE S, BREEDVELD FC, DE VRIES RRP, D'AMARO J, RUBENSTEIN P, SCHREUDER I, CLAAS FHJ, VAN ROOD JJ. Noninherited maternal HLA antigens (NIMA) influence occurrence of rheumatoid arthritis. A new approach to study HLA and disease association, (A2) 84
- Tenascin in normal synovial tissue: variations in osteoarthritis, (A2) 201
- Tendon rupture, tophaceous pyrophosphate deposition with, 421
- Tenidap
and cytokine effects on fibroblast proliferation, (A2) 25
in vitro investigation of the free radical scavenging effects of tenidap, a new anti-inflammatory drug, (A1) 28
modulation of acute phase proteins, (A2) 175
modulation of cytokines in systemic lupus erythematosus, (A2) 25
and naproxen effects on production of proinflammatory cytokines, (A2) 175
new antirheumatic agent, inhibition of acute phase protein production, (A2) 257
- TENNANT A, BADLEY EM. Rheumatic disease and disability: who sees the specialist, (A2) 75
- TENNANT A, MCKENNA S, HUNT S. Audit in rheumatology: the challenge of outcome and quality of life, (A2) 77
- TENNENT G See Peps MB
- Tenoxicam
in 124 osteoarthritic patients. Efficacy and tolerability, (A2) 153
in acute low back pain: an open comparative study versus diclofenac, (A2) 155
in maxillo-facial surgery: an open comparative trial versus diclofenac sodium following single parenteral administration, (A2) 154
objective functional assessment in acute low back pain. A double blind placebo controlled study, (A2) 153
versus diclofenac (Voltaren) in osteoarthritis of the knee: a Canadian multicenter study, (A2) 155
versus ketoprofen (Flexen): a double-blind study in the treatment of active rheumatoid arthritis, (A2) 156
versus naproxen in osteoarthritis: a double-blind multicenter study following long term administration (6 months), (A2) 154
- TEOH LS See White R
- TERRACINA S See Sorgi ML
- Test/inform/retest: useful technique in undergraduate rheumatology teaching, 49
- Thalassaemia minor, frequency and features of rheumatic findings: a blind controlled study, 197
- THAMSBORG G See Pødenphant J
- THEBUD-LASSAK R, BERNARD I, HEININGER K. Therapy of inflammatory rheumatic joint diseases with acetaminophen and indomethacin, (A2) 176
- THEBUD-LASSAK R See also Bernard I; Heininger K
- Therapy seminar, 137
- THOMAS AL See Jenkins EA
- THOMAS JT See Hoyland JA
- THOMAS R See O'Neill T
- THOMPSON P, DE SILVA L, ROLAND L, BASKARHAN V, EBRAHIM S. Singh index in postmenopausal women at risk of fracture, (A2) 66
- THOMPSON PW, SPECTOR TD, JAMES IT, HENDERSON E, HART DJ. Urinary collagen crosslinks reflect the radiographic severity of knee osteoarthritis, 759
- THOMPSON PW See also James IT; Kirwan JR; Wedderburn LR
- THOMSON W, PAYTON T, OLLIER WER, SYMMONS DPM, BARRETT EM, SILMAN AJ. Frequency of DR4 and DR1 in newly diagnosed cases of rheumatoid arthritis and inflammatory arthritis found in a population survey, (A2) 84
- THORNE SA See Stevens CR
- THORSBY E See de Vries N
- Thrombomodulin, soluble: marker of vascular endothelial injury in vasculitis and systemic lupus erythematosus, (A2) 90
- Thyroid antibodies and hypothyroidism in polymyalgia rheumatica, (L) 214
- Tiaprofenic acid
effects on plasminogen activators and inhibitors in human OA and RA synovium, (S1) 19
(Surgam SR[®]) in the long term treatment of active rheumatoid arthritis, (A2) 152
- TICEHURST H, MCKENNA F. Articular indices in rheumatoid arthritis - the Trafford index correlates with the acute phase response, (A2) 76
- TIKLY M See Pole KD
- TILANUS MGJ See de Vries N
- TINAHONES F See Collantes E
- TINDALL EA, ROTH H, McMAHON G, FLEISCHMANN RM, APRIL PA, BOCKOW G. Comparative, randomized parallel group, endoscopy study of effects of nabumetone, ibuprofen and combination of ibuprofen and misoprostol in osteoarthritic patients, (A2) 165
- TITARELLI E See Cervini C
- TNFalpha
IL-6 production and superoxide generation in Behçet's disease, (A2) 214
pivotal role in rheumatoid arthritis, 293
- TOBIN M See Crowley JJ
- TODD I See Hemsley AG
- TOIVANEN A See Laheesmaa R; Mäki-Ikola O
- TOIVANEN P See Laheesmaa R; Mäki-Ikola O
- Tolerability of Brufen Retard, (A2) 231
- Tolfenamic acid (Gantil) in rheumatoid arthritis: effect on the immunologic profile, (A2) 174
- TOLOSA-VILELLA C See Simeon-Aznar CP
- TOMURA S See Hay EM
- Tong Bi Ling for the treatment of rheumatoid disease: an observation of 52 cases, (A2) 125
- TOOKE A See O'Neill T
- Tophaceous pyrophosphate deposition with extensor tendon rupture, 421
- TORMA O See Kurth G
- TORTORELLI E See Scagliusi P
- Total body irradiation failure in polymyositis: report of three cases, (L) 282
- Total hip and knee replacement bring long term overall benefit in osteoarthritis and rheumatoid arthritis, (A2) 78
- TRACEY A, MCKENNA F. Difficulties with drug containers and domestic containers in elderly and patients with rheumatoid arthritis, (A2) 145
- TRACEY A See also Hayes JH
- Transdermal fungal implantation causing an infectious arthritis, (L) 715
- Transforming growth factor-beta, interleukin 1beta and tumour necrosis factor alpha effects on the induction of cartilage resorption by ATP, (A2) 22
- Transverse myelitis in systemic lupus erythematosus: two cases with magnetic resonance imaging, 555
- Trap activity and vitronectin receptor immunostaining in synovium, (A1) 11
- TRATKIEWICZ J, KIRKHAM B. Polymerase chain reaction technique amplification of synovial compartment cytokine mRNA, (A2) 23
- Treponemal infection coexisting with systemic lupus erythematosus, 345
- TRIGER DR See Peel NFA
- TRNAVSKÝ K See Podrážký V
- TROTTE F See Canazza S; Govoni M; La Corte R
- L-Tryptophan associated eosinophilia myalgia syndrome course and treatment with cyclosporin A, (A2) 218
- TSAI C-Y See Yu C-L
- TSAPAS G See Boura P
- TÜZÜN H See Hamuryudan V
- TÜZÜN Y See Hamuryudan V
- TUGWELL P. New disease modifying agents, (A2) 240
- TULIP GR, ABRAHAM DJ, SUMMER H, OLSEN I. Activation-induced changes in expression of murine CD2 receptor gene, (A2) 196
- TULLO A See John SL
- Tumour necrosis factor alpha

- and extracellular ATP interact in stimulating the production of prostaglandin E by human articular chondrocytes, (A2) 22
- interleukin 1 β and transforming growth factor- β effects on the induction of cartilage resorption by ATP, (A2) 22
- localisation in cranial arteritis, (A2) 24
- promoter, genetic variation, (A2) 23
- Tumour necrosis factor and platelet activating factor involvement in pathogenesis of joint inflammation in rabbits, (A2) 24
- Tumour necrosis factor receptors
- increased expression on cells isolated from rheumatoid arthritis synovial joints, (A2) 211
 - soluble, are increased in the sera and synovial fluids of patients with rheumatic diseases, (A2) 211
- TUNCER S, SEÇKİN B, ARAŞIL TK. Extraarticular manifestations of rheumatoid arthritis in Turkey based on analysis of 110 cases, (A2) 224
- TUNN E *See* Emery P
- TURAL C *See* Juncá J
- TURGAY M *See* Kinikli G
- TURK Z, BAROVIĆ J, VAJD F, FLIS I. Magnetotherapy in lumbar syndrome, (A2) 116
- TURK Z, GAZIĆ M. Effects of back school in chronic low back pain patients, (A2) 147
- TURK Z *See also* Krajnc I
- TURNER M *See* Corcoran AE
- Type I collagen metabolism in rheumatoid arthritis. Effects of pulse treatment with methylprednisolone, (A2) 129
- Type III procollagen peptide levels in patients with systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis, (A2) 227
- UGUCCIONI M *See* Meliconi R
- UK SCLERODERMA STUDY GROUP *See* Brennan P
- UK SYSTEMIC SCLEROSIS STUDY GROUP *See* Stevens W
- Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica, 201
- Ultrasonography
- in the evaluation of hip involvement in rheumatoid arthritis, (A2) 225
 - of the subtalar and midtarsal joints, (A2) 135
- Undergraduate curriculum, guidelines on in UK, 409
- UNSWORTH A *See* Russell P
- Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases, 747
- Urate crystal phagocytosis in synovial fluid obtained from asymptomatic knees of patients with gout, (A2) 20
- Urate deposition: scintigraphy and magnetic resonance imaging, (A2) 135
- Uric acid, synovial and gouty arthropathy, (L) 791
- Urinary collagen cross links
- increased levels in females with rheumatoid arthritis, (A2) 27
 - reflect the radiographic severity of knee osteoarthritis, 759
- Urinary D-glucuronic acid in rheumatoid arthritis, (A2) 115
- Urine neopterin as indicator of disease activity in patients with systemic lupus erythematosus - comparison with ESR and C3 degradation products, (A2) 56
- Urticarial vasculitis, autoantibodies in, (A2) 59
- VADA P *See* Pruzanski W
- VAIANI G *See* Pellerin I
- VAJD F *See* Turk Z
- VALCKENAERE I *See* Pourcel J
- VALDONOCI R *See* Govoni M
- VALENTINI M, CANNIZZARO R, BORTOLUSSI R, SOZZI M, FRACASSO A, FORNASARIG M. Misoprostol vs ranitidine in prevention of NSAID gastroduodenal mucosal injury in cancer patients, (A2) 181
- Validation of electronic method for measuring joint tenderness in rheumatoid arthritis, (A2) 76
- Validity of surrogate markers in rheumatic disease and the role of APPs in inflammation, (A2) 256
- VAN ALBADA-KUIPERS GA *See* van der Heide A
- VAN DE PUTTE L *See* Haagsma C; Kerstens P; Laan R; van Riel P
- VAN DE PUTTE LBA *See* Barrera P; de Vries N; Laan RFJM; van den Hoogen FHJ; van der Heijde DMFM; Wijnands MJH
- VAN DEN BRINK HR, BLANKENSTEIN MA, KOPPESSCHAAR HPF, BUIJSMA JWJ. Influence of disease activity steroidhormone levels in peripheral blood of patients with rheumatoid arthritis, (A2) 28
- VAN DEN BRINK HR, VAN WIJK MJG, BUIJSMA JWJ. Steroid hormone influence on proliferation of peripheral blood mononuclear cell in patients with rheumatoid arthritis, 663
- VAN DEN HOOGEN FHJ, BOERBOOMS AMT, FAST JH, VAN DE PUTTE LBA. High prevalence of mitral valve lesions in anti-RNP-positive connective tissue disease patients, (A2) 57
- VAN DEN HOOGEN FHJ, BOERBOOMS AMT, VERHEIJEN R, VAN VENROOIJ WJ, VAN DE PUTTE LBA. Rapid resynthesis of antipolysomerase-1 antibodies and complement after plasma exchange in a patient with systemic sclerosis, (A2) 50
- VAN DEN HOOGEN FHJ *See also* Boerbooms AMT
- VAN DER HEIDE A, JACOBS JWJ, VAN ALBADA-KUIPERS GA, BUIJSMA JWJ. Influence of psychological and social factors on self-reported functional status in early stage rheumatoid arthritis, (A2) 206
- VAN DER HEIJDE DMFM, VAN RIEL PLCM, VAN LEEUWEN MA, VAN'T HOF MA, VAN RIJSWIJK MH, VAN DE PUTTE LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients, 519
- VAN DER LINDEN SJ, BAKKER C. Cost effectiveness of rheumatology, (A2) 248
- VAN DER LINDEN SJ *See also* Blaauw AAM; Schlapbach P
- VAN DER LINDEN SM *See* Beyeler Ch
- VAN DER MEER JWM *See* Barrera P
- VAN DER SLUIS FA *See* Janssen M
- VAN DER WIELEN JGB *See* Janssen M
- VAN ERNING L *See* Laan R
- VAN ERNING LJTHO *See* Laan RFJM
- VAN HAERINGEN NJ *See* Markusse HM
- VAN HEEREVELD HAEM *See* Boerbooms AMT
- VAN LAARHOVEN J *See* Laan R
- VAN LEEUWEN M *See* van Riel P
- VAN LEEUWEN MA *See* van der Heijde DMFM; van Rijswijk MH; Wijnands MJH
- VAN RIEL P, HAAGSMA C, PREVOT M, VAN DE PUTTE L. Long term prospective study of sulphasalazine in rheumatoid arthritis, (A2) 83
- VAN RIEL P, WJNANDS M, VAN 'T HOF M, VAN LEEUWEN M, VAN DE PUTTE L. Risk factors for the discontinuation of second-line antirheumatic drugs in rheumatoid arthritis: a prospective analysis, (A2) 207
- VAN RIEL P *See also* Haagsma C; Laan R
- VAN RIEL PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis, (E) 793
- VAN RIEL PLCM *See also* Laan RFJM; van der Heijde DMFM; Wijnands MJH
- VAN RIJSWIJK MH, VAN LEEUWEN MA, LIMBURG PC. Correlation between acute phase protein production, clinical measures of disease activity and progression of radiological damage in early rheumatoid arthritis. Analysis of the global and individual value for prognostic purposes, (A2) 256
- VAN RIJSWIJK MH *See also* van der Heijde DMFM; Wijnands MJH
- VAN ROOD JJ *See* Ten Wolde S
- VAN 'T HOF M *See* van Riel P
- VAN 'T HOF MA *See* van der Heijde DMFM; Wijnands MJH
- VAN VENROOIJ WJ. Antigens, (A2) 253
- VAN VENROOIJ WJ *See also* van den Hoogen FHJ
- VAN WIJK MJG *See* Van Den Brink HR
- VAN ZEBEN D, HAZES JMW, BREEDVELD FC, ZWINDERMAN AH. How should we define the medium-term outcome of rheumatoid arthritis, (A2) 144
- VAN ZEBEN D, HAZES JMW, ZWINDERMAN AH, BREEDVELD FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow-up study, (A2) 220
- VANCHEESWARAN R *See* Magoulas; Stevens W
- VANDENBROUCKE JP *See* Jansen M; Janssen M
- VANDERSTRAETEN G *See* Haanen HCM
- VANEDEN W *See* Wilbrink B
- VANNEUVILLE B *See* De Keyser F
- VANROY JLM *See* Lefeber F; Wilbrink B
- VARGA J, MATSUOKA LY, HASHIMOTO K, DI LEONARDO M, JIMINEZ SA. Papular mucinosis (scleromyxoedema) complicating diffuse systemic sclerosis: clinical features and electron microscope observations, 779
- Variations amongst rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs, 477
- Vascular cell adhesion molecule-1, cell populations expressing in normal and inflamed synovium, (A2) 10
- Vasculature assessment and angiogenesis in the synovial lining of human rheumatoid knees, (A2) 9
- Vasculitis
- anti-neutrophil cytoplasmic antibodies, (A2) 255
 - and lupus nephritis risk factors, West Indian race, U1-RNP and Sm antibodies, (A2) 58
 - soluble thrombomodulin: marker of vascular endothelial injury, (A2) 90
- VASEY FB, GERMAIN BF, ESPINOZA IR. Double-blind, randomized comparison of nabumetone and naproxen in rheumatoid arthritis, (A2) 165
- VAZ C, BRITO I, MAIA C, DIAS A, LOPES VAZ A, VELOSO T. Osteoporose dans la maladie de Crohn, (A2) 141
- Vaz C *See also* Pinto MJ; Quevedo V
- VÁZQUEZ JJ *See* Muñoz-Fernández S
- VCAM-1, detection of circulating form: raised levels in rheumatoid arthritis and systemic lupus erythematosus and lack of correlation with levels of circulating ICAM-1, (A2) 90

- VEALE D. Psoriatic arthritis, DIP or not DIP, that is the question, (L) 430
- VEALE D, FITZGERALD O. Immunolocalisation of adhesion molecules in synovium and skin in psoriatic arthritis, (A2) 89
- VEALE D, ROGERS S, BARNES L, BRESNIHAN B, FITZGERALD O. Clinical subsets in psoriatic arthritis: is there a need to re-classify, (A2) 92
- VECCHIO P, ADEBAJO AO, HAZLEMAN BL, CAVE M, KING V. Laser treatment of rotator cuff tendinitis, (A2) 61
- VECCHIO P, HAZLEMAN BL. Suprascapular nerve block in lesions of rotator cuff, (A1) 23
- VECCHIO P, RODDY J, HAZLEMAN BL. Follow-up of a community survey of shoulder disorders in the elderly, (A1) 23
- VECCHIO PC, EMMERSON BT. Gout due to renal disease, 63
- VELDHUIZEN JP. See Lafeber F
- VELOSO T. See Vaz C
- VENABLES P, BROOKES S. Retroviruses, potential aetiological agents in autoimmune rheumatic disease, 841
- VENABLES PJW. See Brookes SM
- VENDRELL J. See Cañete JD
- VENN G, NIETZELD JJ, DUTTS AJ, BRENNAN F, ARNER E, COVINGTON M, HARDINGHAM T. Synovial fluid IL-6 is raised in early experimental osteoarthritis, (A2) 214
- VERBRUGEN G. See De Clercq L; De Keyser F
- VERDONK MJ. See Landewé RBM
- VERDONK MJA. See Kloppenburg M
- VERHEIJEN R. See van den Hoogen FHJ
- VERHEYEN G. See Driessens M
- VERNON S. See Regan M
- VERREUSSEL RLP. See Landewé RBM
- VERSTRAETE K. See De Clercq L
- Vertebral fracture prevalence in females with rheumatoid arthritis, (A2) 94
- VEYS EM. See De Clercq L; De Keyser F; Mielants H
- VH gene usage in human/human hybridoma derived monoclonal antibodies from SLE patients, (A2) 215
- VIGNON E. See David MJ
- VIGUSHIN DM, PEPPY MB, HAWKINS PN. *In vivo* turnover studies of radioiodinated C-reactive protein in man, (A2) 100
- VILARDELL M. See Fernandez-Cortijo J; Lima J
- VILJOEN D. See Beighton P
- VILLAGGIO B. See Cutolo M
- VINER N. See Gordon C
- VIOQUE J. See Ruiz MT
- Viruses and rheumatic disease, (L) 716
- VISSER GJ, PETERS L, RASKER JJ. Rheumatologists and their patients who seek alternative care: an agreement to disagree, 485
- Vitronectin receptor immunostaining and trap activity in synovium, (A1) 11
- VIVANCOS J, BOSCH X, GRAU JM, COCA A, FONT J. Development of Hodgkin's disease in the course of primary Sjögren's syndrome, 561
- VLA-integrins in osteoarthrotic cartilage, (A2) 11
- VLOTES PW. See Haanen HCM
- VOGL T. See Kamilli I
- VOGT F. See Szüts I
- Von Willebrand factor
exercise induces rise in rheumatoid arthritis, (A2) 110
high antigen levels associated with increased mortality in connective tissue disease, (L) 211
- VOUDRIS C. See Vougiouka O
- VOUGIOUKA O, SCARDOUSOU A, VOUDRIS C, DIAMADIS V, SINANIOTIS C. Isolated angitis of the central nervous system, (A2) 232
- VREUGDENHIL G. Rheumatoid arthritis, possible downregulating effects of increased iron stores on erythropoietin responsiveness, (L) 212
- VYSE T. So AKL. Sulphasalazine induced autoimmune syndrome, 115
- WADE AG, FLETCHER DM, KILL DC. General practice comparison of nabumetone and indomethacin in the treatment of osteoarthritis, (A2) 168
- WADE J. See Atkins CJ
- WALDMANN H. See Watts RA
- WALKER D. See Foster H
- WALKER DJ. Rheumatology/general practitioner interface. Proceedings of meeting held between general practitioners and rheumatologists, (L) 209
- WALKER DJ. See also Deighton CM; McDonagh J
- WALKER M. See Lau CS
- WALKER P. See Kaminsky P
- WALL DA. See Smith PL
- WALLACH D. See Cope AP
- WALLER A, JACOBS R, WRIGHT L, BUTLER MG, DOWD GSE, SCOTT DL. Extent of cellular proliferation rheumatoid synovium and pannus, (A2) 17
- WALPORT MJ, ISENBERG DA. Research priorities in rheumatology, (E) 505
- WALPORT MJ, OLLIER WER, SILMAN AJ. Immunogenetics of rheumatoid arthritis and the Arthritis and Rheumatism Council's National Repository, 701
- WALPORT MJ. See also Beynon HLC; Fong KY; Hohler T; Lunardi C; Mackworth-Young CG
- WALSH DA, MAPP PI, WHARTON J, POLAK JM, BLAKE DR. Aminopeptidase M in normal and diseased human synovium, (A2) 18
- WANG S-R. See Yu C-L
- WARD RL. See Smith GM
- WARDLE EN. Adult respiratory distress syndrome in systemic lupus erythematosus, (L) 647
- WARDROPPER A. See McKenna F
- WARING R. See Emery P; Murphy EA
- WASIL M, HALLIWELL B, HUTCHISON DCS, BAUM H. Alpha-1- antiproteinase in patients with rheumatoid arthritis: is all API in these patients functionally active, (A1) 10
- WATKISS S. See Hussain W
- WATSON A, WINROW VR, RAGNO S, MASCAGNI P, BLAKE DR. Haem oxygenase (HO-1) in synovial fluid cells, (A2) 19
- WATT I. See Axford JS; Jevtic V; Rozman B
- WATT N. See Anderson A
- WATTS RA
Mastocytosis and osteoporosis, (L) 715
Meningococcal infection: diagnostic and therapeutic pitfalls, (L) 428
- WATTS RA, ISAACS JD, HALE G, HAZLEMAN BL, WALDMANN H. Treatment of rheumatoid arthritis with humanised anti- lymphocyte antibody Campath-1H, (A2) 103
- WEBB C. See Samanta A
- WEBLEY M. See Chakravarty K
- WEDDERBURN LR, KWAN JTC, THOMPSON PW, RUDGE SR. Juvenile chronic arthritis and Wegener's granulomatosis, 121
- Wegener's granulomatosis
electrophysiological study of peripheral nerve function, (A2) 83
and juvenile chronic arthritis, 121
long-term observations of patients. Prevention of relapses based on antineutrophil cytoplasmic antibody titre, (A2) 192
- Weight status and dietary knowledge in the rheumatology out-patient clinic, (A1) 14
- WEILL BJ. See Menkes CJ
- WEINER ES. See Loose LD
- WEISS JB, TAYLOR G. Endothelial cell stimulating angiogenesis factor (ESAF) in patients with ankylosing spondylitis, (A2) 15
- WEISS JB. See also Jones PB
- WEISZ M. See Szüts I
- WELD A. See Russell P
- WELLCOME SM. See Mason JC
- WELSH G. See Donnelly S
- WELSH KI. See Stephens CO; Whyte J
- WESELOH G. See Herrmann J
- West Indian race, U1-RNP and Sm antibodies: possible risk factors for lupus nephritis and vasculitis, (A2) 58
- WESTACOTT CI. See Dularay B
- WESTWOOD D. See Gerova Z
- WEUSTEN BLAM, JACOBS JWJ, BIJLSMA JWJ. Corticosteroid pulse therapy complications in rheumatoid arthritis, (A2) 125
- WEYAND CM. See Roche NE
- WHARTON J. See Walsh DA
- WHELAN A. See Callaghan M
- Whiplash injuries, (E) 579
- Whipple's disease - a differential diagnostic challenge, (A2) 232
- WHITE R, RASKIN JB, JASZEWSKI R, TEOH LS, SUE SO. Misoprostol and ranitidine in prevention of NSAID-induced gastric and duodenal ulcer disease: a multicenter trial, (A2) 180
- WHITTAKER T. See Phelan M
- WHYTE J, HARVEY GR, STEPHENS CO, BRIGGS DC, BLACK C, WELSH KI, HOUGH D, MADDISON PJ, MCHUGH N. Familial clustering of anti-topoisomerase-I antibodies, (A2) 87
- WICKHAM C. See Croft P
- WIEGMAN O. See Taal E
- WIGAND R. See Kaltwasser JP
- WINANDS M. See van Riel P
- WINANDS MJH, VAN 'T HOF MA, VAN LEEUWEN MA, VAN RUSWIJK MH, VAN DE PUTTE LBA, VAN RIEL PLCM. Long-term second-line treatment: prospective drug survival study, 253
- WILBRINK B, HOLEWIJN M, VANROY JLAM, DENOTTER W, BIJLSMA JWJ, VANEDEN W. Cytokines released by heat shock protein-activated rheumatoid synovial fluid mononuclear cells suppress cartilage proteoglycan synthesis, (A2) 114
- WILKINS RJ. See Poole ES
- WILKINSON LS, EDWARDS JCW, POSTON RN, HASKARD DO. Cell populations expressing vascular cell adhesion molecule-1 in normal and inflamed synovium, (A2) 10
- WILKINSON LS. See also Worrall JG
- WILKINSON M, DOHERTY SM, PURDIE DW. North Humberside osteoporosis screening project - one year review of acceptance of hormone

- replacement therapy (HRT) and its cost to a general practice, (A1) 19
- WILL R *See* Pitsillides AA
- WILL RK, BARNES J, CASPERSZ C, HALL N, MADDISON P, BUTTAR R. Proteoglycan synthesis is induced by azapropanone and inhibited by indomethacin in patients with osteoarthritis of the knee, (A2) 201
- WILL RK, RING EFJ, CLARKE AK, MADDISON PJ. Infrared thermography: what is its place in rheumatology in the 1990s, 337
- WILLIAMS BD. Immunology of inflammatory arthritis, 131
- WILLIAMS D *See* Atkins CJ
- WILLIAMS DG *See* Adebajo AO: Taylor PC
- WILLIAMS DM *See* Kaul A
- WILLIAMS GH, RIGBY AS, PAPAGEORGIOU AC. Back to front, examining research priorities in rheumatology, 193
- WILLIAMS P *See* Gallivan S
- WILLIAMS RB, EDMONDS SE, CARR AJ, BLAKE DR, GHATEI M, BLOOM SR, COX NL. Exercise causes a rise in plasma endothelin concentration in patients with rheumatoid arthritis, (A2) 16
- WILLIAMS RB *See also* Farrell A
- WILLIAMS RO *See* Adebajo AO
- WILLOUGHBY DA *See* Da Silva JAP: Moore AR
- WILSON AG, DI GIOVINE FS, DUFF GW. Genetic variation in the tumour necrosis factor alpha promoter, (A2) 23
- WILSON S *See* Samanta A
- WILTSHIRE P *See* Hall GM
- WINFIELD J *See* Gallivan S
- WINKLES J *See* Janssen BA
- WINROW VR *See* Watson A
- WINSKA-WILOCH H *See* Kalsi J: Longhurst C
- WYNARD PG *See* Asmar G
- WIRTZ P *See* Herrmann J
- WISNIEWSKI J *See* D'Cruz DP
- WOJTAHA D *See* McCormick JN
- WOLLHEIM F *See* Brennan P
- WOO P. Paediatric rheumatology, 627
- WOO P *See also* Edelsten C
- WOOD A, MCCRAE FC, HULL RG. Rheumatological disability, difference from other types, (A1) 14
- WOOD A *See also* Jenkins EA
- WOODS EM, GEIS GS. Antiarthritis efficacy of arthrotec in rheumatoid arthritis patients: subgroup analysis of the effects of disease duration and functional capacity, (A2) 179
- WOOLF AD. European rheumatology - a need for greater understanding, (E) 217
- WOOLF AD *See also* Deodhar AA
- WORDSWORTH BP
- ARC family material repository, 207
- Genetic mapping in connective tissue disorders, (E) 147
- Some applications of the new genetics to the investigation of the rheumatic diseases, (A2) 104
- WORDSWORTH BP *See also* Bowness P: MacLeod D: Pile KD: Pole KD
- WORKMAN E, SMITH M, NASH P, HAZLEMAN B, HUNTER J. Use of elemental diet and subsequent food reintroduction in rheumatoid arthritis, (A2) 80
- WORRALL JG, WILKINSON LS, BAYLISS MT, EDWARDS JCW. Synovial expression of the chondroitin sulphate proteoglycans decorin and biglycan, (A2) 68
- WORRALL JG, WILKINSON LS, PITSILLIDES AA, EDWARDS JCW. Hyaluronan synthase distribution in synovium, (A1) 11
- WOUTERS M *See* Reginster JY
- WRIGHT L *See* Waller A
- WRIGHT RF *See* Rotherham JR
- WRIGHT V. Academic rheumatology and the Arthritis and Rheumatism Council, (E) 650
- WRIGHT V, HELLIWELL PS. Education, undergraduate in musculoskeletal diseases, 279
- WRIGHT V *See* Dearlove SM: Helliwell PS
- WU CH *See* Lan JL
- WYNN PARRY CB *See* James IM
- WYNN-JONES C *See* Matthey DL
- Xanthine oxidase plasma activity increases on exercise of a chronically inflamed knee joint, (A2) 220
- YALÇIN P *See* Kinikli G
- YALIMAN A *See* Oral A
- YANNI G *See* Doherty E: Farahat MNMR
- YAOUB RAZA M *See* Gontar IP
- YARWOOD H *See* Mason JC
- YAZICI H *See* Hamuryudan V: Imeryüz N
- YLI-KERTTILA U *See* Mäki-Ikola O
- YOSHIDA A, MOROZUMI K, TAKEDA A, KOYAMA K, SUGITO K, OIKAWA T, FUJIMAMI T. Clinicopathological findings of bucillamine-induced nephropathy in patients with rheumatoid arthritis, (A2) 134
- YOUNG A *See* Bond A: Gallivan S
- YOUNG DY *See* Simon LS
- YOUNG PJ *See* Kirwan JR
- YOUSUF ALI S, BIRD L. Sequence of subchondral bone changes which may lead to degenerative joint disease in the knee, (A2) 120
- YOUSUF ALI S, SCOTCHFORD CA. Histomorphologic analysis of Cuboid microcrystallin human articular cartilage, (A2) 71
- YU C-L, TSAI C-Y, SUN K-H, CHEN Y-S, LIN W-M, LIAO T-S, CHEN K-H, WANG S-R. Increased spontaneous release of cytidine deaminase by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus, 675
- YURDAKUL S *See* Hamuryudan V: Imeryüz N
- ZACHER J *See* Saal JG
- ZAHARIOUDAKI E *See* Boura P
- ZALCBERG M *See* Florent Ch
- ZAPHIROPOULOS GC *See* Farrell AJ
- ZARCO P *See* Gutierrez S
- ZBOROVSKY AB M *See* Gontar IP
- ZHANG Z *See* Asmar G
- ZIEBLAND S *See* Fitzpatrick R: Mowat A
- ZIELIŃSKA M *See* Fenrych W
- ZIELIŃSKI A *See* Atkins CJ
- ZIMMERMANN-GÓRSKA I *See* Fenrych W
- ZÖLLNER N *See* Gresser U: Kamilli I
- ZÖLLNER N *See* Rauh G
- ZONCA M *See* Croft PR
- ZOPPINI A *See* De Castro S
- ZORZIN LR, DAINOTTO F, LUZIATELLI S, MARINI M, POLITO R. Clinical study of older age onset rheumatoid arthritis with comparison to an early onset group, (A2) 216
- ZUKOVSKIS K. Ankylosing spondylitis assessment, (L) 143
- ZLNAY D *See* Drličková V
- ZWINDERMAN AH *See* Jansen M: Janssen M: van Zeben D